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Abstract

ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a late‐onset and rapidly progressive neurodegenerative
disease in humans, which is characterised by the degeneration and loss of motor neurons,
eventually leading to paralysis and death. A similar disease phenotype can occur in dogs and
is induced in transgenic mutant superoxide dismutase 1 (SOD1) mouse models. The
mechanisms underlying neurodegeneration and disease progression are unknown, with
evidence for the involvement of a wide range of cellular mechanisms. These include
microglial activation, neuroinflammation, and aberrant release and uptake of toxic proteins
such as mutant SOD1. P2X7, a purinergic receptor expressed in a range of central nervous
system cells, is involved in inflammatory signalling pathways and is up‐regulated during ALS.
Given this, the work presented in this thesis aimed to further examine P2X7 in the context
of neurodegeneration, and investigate whether this receptor plays a role in ALS progression.
The primary aims of this thesis were to: examine P2X7‐mediated responses in murine EOC13
microglia (Chapter 2); examine the therapeutic efficacy of the P2X7 antagonist Brilliant
Blue G (BBG) on disease progression in the transgenic SOD1G93A ALS mouse model (Chapter
3); determine whether P2X7 is involved in SOD1 release from murine NSC‐34 motor neurons
and, if so, the mechanisms involved, the characteristics of the material released, and
whether the released SOD1 is internalised by NSC‐34 motor neurons or EOC13 microglia
(Chapter 4); and examine the functional effects of recently identified single nucleotide
polymorphisms (SNPs) in the canine P2RX7 gene (Chapter 5).
In Chapter 2, ATP‐induced reactive oxygen species (ROS) formation, nitric oxide (NO)
formation, death and phagocytosis in EOC13 microglia were investigated using flow
cytometric measurements of dichlorofluorescein, benzotriazole, Annexin‐V binding and
xxii

Abstract
yellow green bead uptake, respectively. A role for P2X7 in microglial proliferation was
investigated using a 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT)
assay. P2X7 activation on EOC13 microglia was shown to induce ROS formation, NO
formation, and cell death. P2X7‐mediated ROS formation was not dependent on Ca2+ influx
or K+ efflux. Furthermore, the ROS scavenger N‐acetyl‐L‐cysteine inhibited P2X7‐induced
death of EOC13 microglia, suggesting a role for ROS in this process. In contrast, a role for
P2X7 in proliferation or phagocytosis was not established in these cells. Lastly, the
expression of functional P2X7 on primary murine microglia was confirmed using
immunoblotting and ATP‐induced ethidium+ uptake assays. Collectively, these data suggest
that P2X7 is capable of mediating neuroinflammatory responses in EOC13 microglia, similar
to those observed during ALS progression, and that similar mechanisms may operate in vivo.
In Chapter 3, to investigate the therapeutic efficacy of P2X7 blockade on ALS progression,
SOD1G93A mice were treated with the P2X7 antagonist BBG three times per week, from pre‐
onset of clinical disease (62‐64 days of age) until end‐stage. BBG treatment reduced body
weight loss and prolonged survival in female, but not male, SOD1G93A mice. Furthermore,
treatment had no effect on ALS score or motor coordination in either sex, as assessed using
the ALS Therapy Development Institute neurological scoring system and rotarod
performance, respectively. At end‐stage, microgliosis and motor neuron loss, lumbar spinal
cord P2X7 and SOD1 protein, serum monocyte chemoattractant protein‐1, splenocyte
immunophenotypes and P2X7 expression in livers and spleens were assessed by
immunohistochemistry, immunoblotting, enzyme‐linked immunosorbent assays (ELISAs),
flow cytometry and quantitative real‐time PCR, respectively. However, BBG treatment was
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found to have no effect on any of these parameters. Collectively, these data suggest that
P2X7 has a partial role in ALS progression. However, additional research is required.
In Chapter 4, the expression of functional P2X7 in NSC‐34 motor neurons was demonstrated
using immunoblotting and ATP‐induced ethidium+ uptake assays. SOD1 release from
transfected NSC‐34 cells was assessed by immunoblotting pelletable fractions (20,000 x g
for 30 min) of conditioned media from these cells. Mutant SOD1G93A‐EGFP (mSOD1) and
EGFP were confirmed to be passively released from mSOD1‐ and EGFP‐transfected NSC‐34
motor neurons. Incubation of mSOD1‐transfected cells with ATP was found to enhance
mSOD1 release, and this could be completely inhibited by pre‐incubation with the P2X7
antagonist AZ10606120. However, ATP also induced EGFP release from EGFP‐transfected
cells, indicating that P2X7‐mediated SOD1 release is not specific for this protein.
Microscopic observations and measurements of lactate dehydrogenase suggested that
P2X7‐mediated mSOD1 release occurred independently of cell death. Furthermore, confocal
microscopy indicated that P2X7‐mediated mSOD1 release coincided with membrane
blebbing, while differential centrifugation and transmission electron microscopy indicated
that the material released was structurally heterogeneous. Flow cytometric measurements
indicated that both passively and ATP‐induced released mSOD1 could associate with naïve
EOC13 and NSC‐34 cells. Furthermore, confocal microscopy demonstrated that the ATP‐
induced released mSOD1 could be internalised by EOC13 or NSC‐34 cells; this coincided with
tumour necrosis factor‐α release and endoplasmic reticulum stress, respectively, as
assessed by ELISA and fluorescent measurements of x‐box binding protein 1 splicing. These
data suggest that P2X7 activation mediates mutant SOD1 release from motor neurons,
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which, when present extracellularly, may initiate molecular cascades leading to motor
neuron death.
In Chapter 5, to investigate the effects of recently identified SNPs in the canine P2RX7 gene,
these SNPs (F103L, R270C, R365Q, L440F and P452S) were introduced into a cloned English
springer spaniel P2X7 plasmid by site‐directed mutagenesis, and then heterologously
expressed in human embryonic kidney (HEK)‐293 cells. P2X7 function, total expression, cell‐
surface expression and channel activity in transfected HEK‐293 cells were then investigated
by ATP‐induced ethidium+ uptake assays, immunoblotting, immunocytochemistry and
electrophysiology, respectively. Of the above mutations, R270C was determined to be a
loss‐of‐function mutation, with minimal pore‐forming and channel activities despite cell‐
surface expression. In contrast, P452S had no effect on canine P2X7 function, while F103L
and R365Q were identified as potential partial loss‐of‐function mutations, and L440F as a
potential gain‐of‐function mutation. These data suggest that canine P2X7 SNPs can alter
receptor function, and that SNPs should be considered if dogs are used as models of human
diseases potentially involving P2X7, such as ALS.
Overall, this thesis demonstrated that EOC13 microglia and NSC‐34 motor neurons express
functional P2X7, and that P2X7 activation on these cells induced responses that could
potentially mediate neuroinflammation and disease progression in ALS. However, inhibition
of P2X7 in vivo had limited beneficial effects, consistent with ALS being complex, multi‐
systemic and multi‐factorial in nature. While data from this thesis suggests that P2X7 alone
is unlikely to mediate ALS progression, this receptor may act in concert with other signalling
pathways to mediate motor neuron degeneration. Thus, further work is required to
establish whether P2X7 represents a viable therapeutic target for treatment of ALS.
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1.2

Amyotrophic lateral sclerosis: a motor neuron disease

1.2.1 Clinical features and disease course
Amyotrophic lateral sclerosis (ALS) is the most common form of adult‐onset motor neuron
disease, and is characterised by the degeneration and death of both upper and lower motor
neurons (Boillee et al., 2006a). Degeneration of these cells leads to progressive spasticity,
muscle weakness and muscle atrophy. This results in progressive difficulties in moving limbs,
swallowing, speaking and breathing, and culminates in paralysis and death, generally within
3‐5 years from clinical onset (Al‐Chalabi et al., 2012).
ALS is a heterogeneous disorder, with varied regions of onset, contributions of upper and
lower motor neuron deficits, and rates of progression between individuals (Ravits and La
Spada, 2009). Despite these differences, the majority of cases are defined by a focal onset of
motor neuron degeneration, followed by an outward spreading of pathology to
interconnected neurons or adjacent regions (Ravits et al., 2007). However, there is also
evidence that the onset of degeneration may be multifocal in some cases, with local
propagation of pathology spreading from these sites (Sekiguchi et al., 2014). While the
neuroanatomic propagation of motor neuron degeneration is considered a distinct clinical
characteristic of ALS (reviewed in Ravits, 2014), the molecular basis for this spread of
pathology is unknown. Given this clinical course, it is likely that the mechanisms
underpinning ALS progression mediate or facilitate the spread of disease between cells.
1.2.2 Incidence, risk factors and available therapeutics
ALS has an incidence of approximately 2‐3 people per 100,000 per year, with a slightly
higher incidence in men compared to women in Caucasian populations (Logroscino et al.,
3
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2010). The overall population‐based lifetime risk of developing this disease is 1:350 and
1:400 for men and women, respectively (Kiernan et al., 2011). Major reproducible risk
factors for ALS development include family history and age, with onset most commonly
occurring between the ages of 45‐65 (Kiernan et al., 2011).
While a number of pharmacological treatments are currently under investigation (reviewed
in Harikrishnareddy et al., 2015), the only clinically approved ALS therapeutic available is
Riluzole. However, this drug is only able to extend median survival by 2‐3 months, and its
efficacy is dependent upon the site of disease onset (Bensimon et al., 1994). Furthermore,
despite being approved for clinical use in 1995, the exact mechanisms of action of this drug
remain elusive (Cifra et al., 2013). Given the limited therapeutic effects of Riluzole, it is clear
that novel therapeutics capable of interfering with disease processes and improving disease
outcomes are required. Further research into the pathogenic mechanisms underlying ALS
development and progression will assist with this goal.
1.3

Aetiology, pathogenesis and progression of amyotrophic lateral sclerosis

1.3.1 Overview
The aetiology and pathogenic mechanisms underlying the progression of ALS are poorly
understood. Complicating matters is the multi‐factorial and multi‐systemic nature of this
disease, with studies of ALS patients and animal and cell culture models implicating a wide
range of cellular mechanisms, many of which could potentially explain the observed regional
spread of pathology (see Section 1.2.1). These mechanisms include protein aggregation,
dysfunctional protein degradation, defective axonal transport, endoplasmic reticulum and
oxidative stress, aberrant secretion and uptake of toxic proteins, glial activation, and
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neuroinflammation (see Harikrishnareddy et al., 2015). However, it is likely that multiple
mechanisms operate in concert to mediate motor neuron degeneration. Some of these
pathophysiological processes and their interactions will be discussed below. In addition, the
involvement of genetic factors in disease pathogenesis will be discussed.
1.3.2 Genetic factors
While most cases of ALS are sporadic, with no obvious genetic or hereditary component,
approximately 10% of cases are familial or heritable in nature (Harikrishnareddy et al.,
2015). However, both sporadic and familial forms of ALS share the same profile of
pathological and clinical features, suggesting the involvement of similar disease mechanisms
(Al‐Chalabi et al., 2012). Furthermore, there is increasing evidence that genes associated
with familial ALS are also involved in sporadic disease (Al‐Chalabi et al., 2012). Thus, while
the majority of ALS research tends to focus on familial ALS and the involvement of gene
mutations in disease processes, it is hoped that any mechanistic or therapeutic
breakthroughs will be translatable to all forms of the disease.
Over 125 potential ALS‐related genes have been identified based on genome‐wide
association and other studies, a complete list of which can be found on the ALS online
genetics database (http://alsod.iop.kcl.ac.uk/; Abel et al., 2013). Some of the major genes
with mutations linked to familial ALS are shown in Table 1.1, with genes that are also
associated with sporadic disease indicated. These ALS‐associated genes have a wide range
of normal functions, including in DNA and/or RNA processing, and protein transport,
trafficking and degradation. This further highlights the multi‐factorial nature of this disease.
Of these genes, Cu2+, Zn2+ superoxide dismutase 1 (SOD1) was the first in which mutations
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were found to be associated with ALS, accounting for approximately 20% of familial cases
(2% of all cases) (Rosen et al., 1993). This protein is one of the most widely researched and
will form the basis of further discussion.
Table 1.1 Genes with mutations linked to familial amyotrophic lateral sclerosis.

Gene

Product

Normal function

sALS

DNA/RNA processing

Inheritance
mode1
AD

ANG

Angiogenin

ATXN2

Ataxin 2

DNA/RNA processing

AD

Yes

C9orf72

Chromosome 9 open reading
frame 72

‐

AD

Yes

Coiled‐coil‐helix‐coiled‐coil‐helix
domain containing 10

‐

‐

Yes

D‐amino‐acid oxidase

Serine metabolism

‐

No

Dynactin

Axonal transport and
vesicle trafficking

‐

No

FIG4

SAC domain‐containing protein

Phosphoinositide
phosphatase activity

AD

Yes

FUS

Fused in sarcoma

DNA/RNA processing

AD, AR, DN

Yes

Heterogeneous nuclear
ribonucleoprotein A1

DNA/RNA processing

‐

Yes

Matrin 3

DNA/RNA processing

AD

Yes

NEFH

Neurofilament heavy chain

Cytoskeletal network

AD

Yes

OPTN

Optineurin

Post‐golgi trafficking

AD, AR

Yes

Peripherin

Cytoskeletal network

‐

Yes

Cu , Zn superoxide dismutase 1

Antioxidant

AD, AR, DN

Yes

Sequestosome 1

Protein degradation

‐

Yes

TAF15 RNA polymerase II, TATA
box binding protein‐associated
factor

DNA/RNA processing

AD, AR

No

TARDBP

TAR DNA binding protein

DNA/RNA processing

AD, AR

Yes

UBQLN2

Ubiquilin 2

Protein degradation

SD

Yes

VAPB

Vesicle‐associated membrane
protein‐associated protein B

Axonal transport and
vesicle trafficking

AD

No

VCP

Valosin‐containing protein

Protein degradation

AD

No

CHCHD10
DAO
DCTN1

HNRNPA1
MATR3

PRPH
SOD1
SQSTM1
TAF15

2+

2+

Yes

1

AD, autosomal dominant; AR, autosomal recessive; DN, de novo; sALS, sporadic amyotrophic lateral sclerosis.
(‐) refers to currently unknown information. Adapted from ALSoD database (http://alsod.iop.kcl.ac.uk/; Abel et
al., 2013) and Al‐Chalabi et al. (2012).
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1.3.2.1 Superoxide dismutase 1
SOD1 is a cytosolic, ubiquitously expressed 32 kDa homodimeric enzyme, the normal
biological function of which is to dismutate (or convert) damaging superoxide radicals
produced during respiration and other biological processes into hydrogen peroxide or
oxygen. Over 180 SOD1 mutations have been identified in ALS patients to date, the majority
of which are point mutations spread over the length of the gene (http://alsod.iop.kcl.ac.uk/;
Abel et al., 2013). These mutations result in SOD1 proteins that differ greatly in enzymatic
activity, stability, folding, turnover and metal ion affinities (Kaur et al., 2016; Shaw and
Valentine, 2007). Characteristics of some of the most common SOD1 mutations are listed in
Table 1.2. To further study the role of SOD1 in ALS, rats and mice over‐expressing mutated
forms of human or murine SOD1 have been developed. These transgenic animals display
progressive motor neuron degeneration which mirrors that of the human disease, and are
thus widely used as experimental ALS models (Islam et al., 2014; Turner and Talbot, 2008).
Of note, missense mutations in the SOD1 gene have also been linked to canine degenerative
myelopathy, a naturally occurring ALS‐like disease in dogs (Nardone et al., 2016), further
implicating mutant SOD1 in ALS.
Table 1.2 The most common superoxide dismutase 1 mutations implicated in familial amyotrophic lateral
sclerosis (ALS).

Mutation
(exon)1
A4V (1)
G37R (2)
H46R (2)
G85R (4)
D90A (4)
G93A (4)

Inheritance
mode2
AD
AD
AD
AD
AD, AR
AD

Aggregation
propensity3
High
Moderate
Low
High
High
High

Enzyme
activity4
Reduced
Active
Reduced
Inactive
Active
Active

Progression5
Rapid, aggressive
Slow
Slow
Moderate
Rapid
Rapid

Mouse
model6
Yes*
Yes
Yes
Yes
Yes
Yes

1

Over 180 SOD1 mutations have been associated with ALS to date (http://alsod.iop.kcl.ac.uk/; Abel et al.,
2013). This table summarises the features of six of these mutants. 2AD, autosomal dominant; AR, autosomal
recessive; Gros‐Louis et al. (2006). 3Prudencio et al. (2009) and Karch and Borchelt (2010). 4Saccon et al.
(2013). 5Prudencio et al. (2009). 6Turner and Talbot (2008). *A double transgenic SOD1A4V/SOD1WT mouse
model is available.
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Initially, mutations in SOD1 were thought to cause disease due to a loss of dismutase
activity. However, rodents expressing dismutase‐active SOD1 mutants (Gurney et al., 1994;
Howland et al., 2002; Wong et al., 1995) develop a disease with similar symptoms to those
of rodents expressing dismutase‐inactive mutants and human ALS patients (Bruijn et al.,
1997; Jonsson et al., 2004; Nagai et al., 2001; Ripps et al., 1995). Furthermore, mice
completely lacking SOD1 develop normally, with no motor neuron degeneration (Reaume et
al., 1996). Given this, it is widely accepted that SOD1‐mediated ALS development occurs
independently of dismutase activity, and that mutant SOD1 is directly responsible for
causing motor neuron death, possibly through a toxic gain of function. However, the
primary cytotoxicity of mutant SOD1 is at present unknown. Further complicating this, a role
for misfolded wild type (WT) SOD1 in ALS has recently emerged (reviewed in Kabashi et al.,
2007; Rotunno and Bosco, 2013), which may implicate shared SOD1‐mediated pathogenic
pathways in familial and sporadic ALS. Of note, conformation‐specific antibodies raised
against mutant or structurally disrupted SOD1 species or peptides, which are reactive for
misfolded but not native WT SOD1, react with human post‐mortem sporadic ALS spinal cord
tissues (Bosco et al., 2010; Forsberg et al., 2010; Pokrishevsky et al., 2012). Moreover, WT
SOD1 immunopurified from sporadic ALS tissues has similar toxic effects in vitro as that of
recombinant ALS‐linked mutant SOD1 (Bosco et al., 2010). Possible mechanisms of SOD1‐
mediated ALS development will be discussed.
1.3.3 Protein misfolding and aggregation
Protein misfolding and aggregation is a common feature of a range of neurodegenerative
diseases, including ALS, and Alzheimer’s, Parkinson’s and Huntington’s diseases (Mulligan
and Chakrabartty, 2013). A feature shared by all ALS‐associated SOD1 mutants is the higher
8
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propensity to misfold and aggregate compared to WT SOD1. In a study of over 30 ALS‐
associated SOD1 mutants, all mutations were reported to increase the inherent aggregation
propensity of the protein in culture (Prudencio et al., 2009). Furthermore, an inverse
correlation between ALS disease duration and the propensity of different forms of mutant
SOD1 to aggregate has been reported (Wang et al., 2008). While protein misfolding is the
most likely mediator of aggregate formation, the mechanism by which these diverse SOD1
mutations lead to protein misfolding remains unclear. Shedding light on this, recent studies
have identified aggregation prone sequence segments in SOD1, which may interact to
modulate the aggregation of mutant proteins (Ivanova et al., 2014; Karch and Borchelt,
2010). These interactions were found in a number of SOD1 mutants, suggesting that
mutations may destabilise normal protein structure, making these residues more accessible
to solvent. However, it is likely that additional factors are involved in triggering SOD1
misfolding (see Mulligan and Chakrabartty, 2013).
In addition to mutant forms of SOD1, WT SOD1 has also been demonstrated to have a
propensity to misfold and aggregate under certain conditions. Aggregation of WT SOD1 has
been reported following oxidation, removal of metal co‐factors and as a result of defects in
post‐translational modification and/or aberrant covalent modifications (Beckman et al.,
2001; Bredesen et al., 1997; Kabashi et al., 2007). This suggests that WT SOD1 may be able
to adopt a toxic conformation similar to that of familial ALS‐linked SOD1 mutants.
Progressive aggregation of proteins leads to the development of cytoplasmic proteinaceous
deposits, known as inclusion bodies, the presence of which are a pathological hallmark of
ALS. A number of proteins have been found within these inclusions, most commonly
transactivation response DNA‐binding protein (TDP‐43), but also SOD1 and fused in
9
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sarcoma/translocated in liposarcoma protein (FUS/TLS) in cases of SOD1 and FUS mutations,
respectively (Bento‐Abreu et al., 2010). However, SOD1 is the only one of these specific to
ALS, with TDP‐43‐ and FUS‐containing inclusions also found in other disorders, including
Alzheimer’s disease and frontotemporal dementia (King et al., 2012; Wilson et al., 2011).
The formation of SOD1‐rich inclusions in spinal cords is thought to be an early pathological
event of SOD1‐linked familial ALS, based on human post‐mortem histopathological and ALS
mouse model studies (Bruijn et al., 1997; Bruijn et al., 1998; Jonsson et al., 2004; Shibata et
al., 1996; Watanabe et al., 2001). In addition, the presence of SOD1‐containing inclusions in
post‐mortem human spinal cords has also been reported for sporadic ALS patients
(Matsumoto et al., 1996; Shibata et al., 1996; Shibata et al., 1994), further supporting a role
for WT SOD1 in sporadic disease (reviewed in Chattopadhyay and Valentine, 2009).
Evidence for the involvement of misfolded SOD1 in ALS progression is supported by a
number of immunisation studies. Active immunisation strategies involving vaccination of
transgenic SOD1 mice with recombinant mutant SOD1 protein, non‐metallated WT SOD1
protein and SOD1 peptides have all been reported to delay disease onset and prolong
survival (Liu et al., 2012; Takeuchi et al., 2010; Urushitani et al., 2007). In addition, passive
immunisation studies involving intracerebroventricular infusion of anti‐mutant or anti‐
misfolded SOD1 antibodies have also been reported to extend the lifespan of transgenic
SOD1 mice (Gros‐Louis et al., 2010; Urushitani et al., 2007).
While it is well established that protein misfolding and aggregation are important features
of ALS pathogenesis, the identity of the toxic SOD1 species and the mechanism by which it
potentially mediates motor neuron death is currently unknown. A study of detergent‐
insoluble and disulfide cross‐linked SOD1 aggregates in transgenic SOD1 mice over time
10
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found that mutant SOD1 aggregates were primarily present in the later stages of the disease
(Karch et al., 2009). This indicates that large insoluble aggregates are not the initiating
cytotoxic factor, but that smaller or soluble SOD1 species may be initially involved.
Regardless, given that protein aggregation appears to be a stochastic process (Abdolvahabi
et al., 2016; Hortschansky et al., 2005; Stefani and Dobson, 2003), protein aggregation alone
is unlikely to explain the regional spread of pathology largely observed in human ALS
patients (see Section 1.2.1). Recent evidence suggests that misfolded SOD1 is capable of
spreading between cells in a prion‐like fashion (discussed in Section 1.3.5), which may
explain this spread. In addition, it has been proposed that SOD1 aggregates may exert
toxicity via inhibition of the proteasome, decreasing chaperone activity, disruption of axonal
transport and/or disruption of organelle activity (particularly the golgi, endoplasmic
reticulum and mitochondria) (see Boillee et al., 2006a).
1.3.4 Endoplasmic reticulum stress
The endoplasmic reticulum (ER) is a cellular organelle responsible for the native folding,
post‐translational modification and trafficking of a number of transmembrane and secretory
proteins. Disruptions to the normal functions of this organelle, such as in the case of an
accumulation of unfolded or misfolded proteins, results in ER stress. This triggers two
adaptive pathways, intended to reduce the burden of unfolded proteins: the unfolded
protein response (UPR), which refolds misfolded proteins, and ER‐associated degradation,
which exports misfolded proteins from the ER to the ubiquitin proteasome system for
degradation. Severe or prolonged ER stress can promote the activation of pro‐apoptotic
pathways, providing a potential link between ER stress and ALS progression (reviewed in
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Bunton‐Stasyshyn et al., 2015; Karademir et al., 2015; Walker and Atkin, 2011; Xu et al.,
2005).
Elements of the UPR have been observed in spinal motor neurons from mutant SOD1
transgenic rodents (Atkin et al., 2006; Atkin et al., 2008; Kikuchi et al., 2006; Saxena et al.,
2009) and post‐mortem sporadic ALS patients (Atkin et al., 2008; Ilieva et al., 2007).
Furthermore, induced pluripotent stem cell‐derived motor neurons from familial ALS
patients also show evidence of these responses (Kiskinis et al., 2014). In SOD1 mice, the UPR
appears to be up‐regulated early, before the onset of clinical symptoms (Atkin et al., 2008).
In SOD1 mice with a loss‐of‐function mutation in pancreatic ER kinase, a component of the
UPR, clinical and molecular disease onset is accelerated and lifespan shortened compared to
SOD1 mice without this mutation (Wang et al., 2011). Supporting this, pharmacological
inhibition of protein‐disulfide isomerase, another UPR component, increased the number of
inclusions in cells transfected with SOD1 mutants (Atkin et al., 2006). In contrast, treatment
of SOD1 mice with the drug guanabenz, which enhances the unfolded protein response,
delayed disease onset and prolonged survival (Jiang et al., 2014; Wang et al., 2014).
Collectively, this suggests that the UPR may be protective in ALS, but becomes overwhelmed
or dysfunctional during disease progression.
Mutant SOD1 has been reported to accumulate in the ER during ALS (Kikuchi et al., 2006),
which could potentially lead to the initiation of ER stress responses. However, more recent
evidence suggests that mutant SOD1 can directly activate ER stress by interacting with
cytoplasmic ER‐Golgi transport proteins or proteins involved in ER‐associated degradation
(reviewed by Bunton‐Stasyshyn et al., 2015; Karademir et al., 2015; Walker and Atkin, 2011).
In one study, interaction of mutant SOD1 with Derlin‐1, a component of the ER‐associated
12
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degradation pathway, triggered ER stress, leading to the activation of apoptosis pathways
(Nishitoh et al., 2008). In this study, siRNA knock‐down of Derlin‐1 reduced SOD1‐induced
ER stress and motor neuron death. Thus, mutant or misfolded SOD1 may play a role in ALS
progression by mediating dysfunction of the ER‐associated degradation pathway and
consequently ER stress.
1.3.5 SOD1 transmission
While SOD1 is generally considered a cytosolic protein, there is evidence that this protein
can be secreted into the extracellular environment by neuronal cells. Once present
extracellularly, misfolded or aggregated SOD1 can be internalised by neighbouring cells,
where it acts as a template to seed further misfolding. In this way, misfolded SOD1 may
contribute to disease progression by acting as a transmissible toxic factor. Given that
misfolded WT SOD1 is detected in sporadic ALS, similar mechanisms may also operate in
sporadic disease. This "prion‐like" spread of protein misfolding may explain the regional
spread of pathology discussed in Section 1.2.1. The idea of disease‐related proteins
pathologically propagating from cell to cell is also receiving attention in other
neurodegenerative diseases, including the proteins alpha‐synuclein and amyloid‐beta in
Parkinson's and Alzheimer's diseases, respectively (reviewed in Brundin et al., 2010;
Polymenidou and Cleveland, 2011; Zeineddine and Yerbury, 2015). However, the following
discussion will focus on the role of SOD1 propagation in ALS progression.
1.3.5.1 Evidence for SOD1 release
WT and mutant SOD1 are present in conditioned media of transgenic SOD1 mouse spinal
cord cultures (Urushitani et al., 2006) and in the cerebrospinal fluid of ALS patients
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(Zetterstrom et al., 2011), suggesting that SOD1 is released in vivo. Supporting this,
misfolded or aggregated forms of SOD1 (both WT and mutant) are released from neuronal
cells in culture, in both an active manner in association with exosomes or passively from
dead or dying cells (Gomes et al., 2007; Grad et al., 2014). In addition, mutant SOD1
associates with chaperone‐like proteins called chromogranins in cultured cells and spinal
cord tissue, which may also act to facilitate the release of this protein (Urushitani et al.,
2006). However, the mechanism by which SOD1 is released in vivo is not completely
understood. It is possible that these mechanism act in concert to promote SOD1 release and
disease propagation.
1.3.5.2 Evidence for SOD1 uptake and seeding of aggregation
Misfolded and aggregated recombinant WT and mutant SOD1 fibrils have been shown to
seed aggregation of each other and themselves in in vitro cell‐free systems (Chia et al.,
2010; Grad et al., 2011). In addition, spinal cord homogenates from end‐stage SOD1
transgenic mice similarly specifically seed misfolding of WT or mutant SOD1 protein (Chia et
al., 2010). However, for propagation of misfolding in vivo, extracellular misfolded or
aggregated proteins would need to be internalised by living cells and gain access to the
cytosolic compartment. In fact, evidence of uptake of exogenously applied misfolded or
aggregated WT or mutant SOD1, derived recombinantly or from conditioned media, into
cultured neuronal or glial cells has been demonstrated in a number of recent studies
(Franco et al., 2013; Furukawa et al., 2013; Grad et al., 2014; Meissner et al., 2010; Munch
et al., 2011; Roberts et al., 2013; Sundaramoorthy et al., 2013). In these studies, SOD1
uptake occurred in a time‐dependent manner and was followed by localisation of SOD1 to
the cytosol. However, the mechanisms by which SOD1 was able to access this compartment
14
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are not completely understood (see Zeineddine and Yerbury, 2015). Once internalised,
aggregated mutant SOD1 was shown to accumulate in cytosolic inclusions (Sundaramoorthy
et al., 2013) and be capable of seeding aggregation of natively folded WT or mutant SOD1
(Furukawa et al., 2013; Grad et al., 2014; Munch et al., 2011). This led to the initiation of
neurodegenerative pathways similar to those observed in ALS (see Section 4.1.2),
supporting a role for SOD1 misfolding in disease progression.
1.3.5.3 Evidence of transmission in vivo
In addition to the above, there is also in vivo evidence for the spread of ALS pathology,
potentially through a toxic SOD1 species. In one study, injection of spinal cord homogenates
from symptomatic SOD1G93A transgenic mice into the spinal cords of genetically vulnerable
newborn mice expressing low amounts of an alternate SOD1 mutant (SOD1G85R) induced an
ALS‐like disease not normally observed in these animals (Ayers et al., 2014). This was
characterised by the presence of SOD1G85R‐containing inclusion bodies throughout the spinal
cord, brainstem and thalamus. When tissues from these mice (i.e. "second passage
homogenates") were used to inoculate new SOD1G85R mice, an early onset of clinical disease
was observed, again with abundant SOD1G85R inclusion‐like pathology (Ayers et al., 2014). In
a more recent study, this same group injected spinal cord homogenates from symptomatic
SOD1G93A transgenic mice into the sciatic nerve of adult, rather than newborn, SOD1G85R
mice (Ayers et al., 2016). These mice also developed an ALS‐like disease, which in this case
was characterised by a spreading of SOD1G85R‐containing inclusion pathology akin to that of
the human disease. Interestingly, in the earlier study, injection of spinal cord homogenates
from human WT SOD1 transgenic mice induced an ALS like disease with abundant SOD1G85R
inclusion‐like pathology in one out of three inoculated SOD1G85R mice (Ayers et al., 2014),
15
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supporting a role for WT SOD1 in sporadic ALS propagation. Collectively, these two studies
support a role for the propagation of misfolded proteins, potentially via a prion‐like
transmission of misfolded SOD1, in disease progression in ALS. However, future work is
required to identify whether a misfolded SOD1 species is the toxic transmissible particle.
1.3.6 Glia and neuroinflammation
ALS was originally thought to be a cell‐autonomous disease, that is, a disease intrinsic to
motor neurons alone. However, increasing evidence suggests that ALS is non‐cell‐
autonomous in nature, and that cell types other than motor neurons play key roles in
disease progression (see Ilieva et al., 2009). Neuroinflammation, which is a pathological
hallmark of ALS characterised in part by the presence of activated microglia, is thought to be
involved. Microglia are capable of producing both neuroprotective or pro‐inflammatory
factors, and the interplay between these, in concert with other disease mechanisms, may
contribute to the degeneration of motor neurons in ALS. While the following discussion will
focus largely on the role of microglia, there is also evidence for the involvement of other cell
types, such as activated astrocytes and infiltrating lymphocytes, in neuroinflammatory
processes (see Henkel et al., 2009; Ilieva et al., 2009).
1.3.6.1 Microglia
Microglia are the resident innate immune cells of the CNS, which play important roles in
immune surveillance and in mediating neuroinflammation (Nimmerjahn et al., 2005). These
versatile cells are constantly active, spending time scanning the extracellular space of the
CNS (Hanisch and Kettenmann, 2007; Henkel et al., 2009). When performing this role
microglia generally possess a ramified morphology, characterised by a small cell body
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covered by a number of fine branched processes that allow for sampling of the surrounding
environment (Bruijn et al., 2004; Ransohoff and Perry, 2009). In response to brain injury or
immunological stimuli, these cells become activated and undergo dramatic morphological
and functional changes (Henkel et al., 2009). These changes can be either neuroprotective
or neurotoxic in nature, and are highly dependent on the context of their activation
(Hanisch and Kettenmann, 2007). Activated microglia phagocytose debris and peptides,
present antigens, and produce a number of factors including reactive oxygen species (ROS),
nitric oxide (NO), pro‐ and anti‐inflammatory cytokines, prostaglandins and growth factors
(Block and Hong, 2005; Hanisch and Kettenmann, 2007; Henkel et al., 2009). Based on their
actions, microglia are generally classified on a spectrum ranging from an M1‐like neurotoxic
to an M2‐like neuroprotective phenotype. These extremes are characterised by the release
of ROS and pro‐inflammatory cytokines, or trophic and anti‐inflammatory factors,
respectively (Evans et al., 2013).
1.3.6.2 Microglia and ALS
Despite the important roles of microglia in maintaining a healthy CNS, chronic activation and
proliferation of these cells is associated with the pathogenesis of a range of
neurodegenerative diseases, including ALS (Monif et al., 2010). Microglial activation and
proliferation is widespread in regions of motor neuron loss in the brain and spinal cord of
human ALS patients' post‐mortem and in mutant SOD1 transgenic mice (Almer et al., 1999;
Hall et al., 1998; Henkel et al., 2004; Kawamata et al., 1992). Observations of SOD1 mice at
different stages of disease suggest that microglial activation begins at or before the onset of
clinical disease, with the number of activated cells increasing with disease progression
(Alexianu et al., 2001; Boillee et al., 2006b; Hall et al., 1998). In humans, post‐mortem
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studies suggest that the degree of microglial activation at end‐stage correlates with the
severity of the disease (Brettschneider et al., 2012). In addition to post‐mortem studies,
evidence of widespread in vivo microglial activation in humans has also been observed
during disease using positron emission tomography scanning (Turner et al., 2004; Zurcher et
al., 2015). In these studies, radiotracers specific for activated microglia identified microglial
activation in ALS patients, but not healthy controls. In future, this technique may be useful
for investigating microglial activation in asymptomatic individuals possessing SOD1
mutations, to determine if and at what stage chronic microglial activation can be observed.
While these studies had small sample sizes, together with the above‐mentioned post‐
mortem and murine studies, they highlight the active role of microglia in ALS, the activation
of which is clearly not just an end‐stage result.
A role for microglial activation in ALS has also been supported using the tetracycline
derivative minocycline, which is able to inhibit microglial activation in addition to and
independent of its antimicrobial activities (Yrjanheikki et al., 1999). In SOD1 mice, treatment
with minocycline at pre‐symptomatic stages potently increased survival (Kriz et al., 2002;
Van Den Bosch et al., 2002; Zhu et al., 2002), possibly through selective inhibition of M1‐like
neurotoxic, but not M2‐like neuroprotective, microglial factors during the progressive phase
of disease (Kobayashi et al., 2013). However, treatment beginning after the onset of clinical
symptoms did not prolong survival in SOD1 mice or human ALS patients (Gordon et al.,
2007; Keller et al., 2011). This suggests that microglial activation may not drive disease
progression, or that it is too extensive after disease onset to be targeted effectively with this
drug. Alternatively, given that Riluzole antagonised the neuroprotective actions of three
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potential therapeutic agents in vitro, including minocycline (Yanez et al., 2014), it is possible
that Riluzole was a confounding factor in human clinical trials.
1.3.6.3 Role for SOD1 in microglial activation and neurotoxicity
Mutant SOD1‐mediated damage within microglial cells is a key determinant of ALS
progression. Selective partial mutant SOD1 gene excision from microglia/macrophages or
transfer of bone marrow to produce WT donor‐derived microglia significantly extended
survival of mutant SOD1 transgenic mice, but had no effect on disease onset (Beers et al.,
2006; Boillee et al., 2006b; Wang et al., 2009). This suggests that SOD1 expression in
microglia and the resulting microglial activation are important determinants of disease
progression following onset. However, partial or more complete ablation of proliferating
microglia from SOD1 mice beginning before symptomatic disease onset has been reported
to have no effect on motor neuron degeneration or lead to accelerated disease progression,
respectively (Audet et al., 2012; Gowing et al., 2008). This suggests that microglia may have
a protective role during the early stages of disease, despite mutant SOD1 expression.
Indeed, in SOD1 mice, microglia with an M2‐like neuroprotective phenotype have been
shown to be predominant during the early stages of disease, while the M1‐like neurotoxic
phenotype appears predominant during the rapidly progressive stages of disease (Henkel et
al., 2009; Murdock et al., 2015; Tang and Le, 2016). It is possible that the expression and/or
internalisation of mutant or misfolded WT SOD1 within microglia promotes conversion from
an M2‐ to an M1‐like phenotype during ALS (see Section 1.3.5.2).
In vitro evidence suggests that mutant SOD1‐expressing microglia are toxic to motor
neurons. Untreated or lipopolysaccharide‐activated microglia derived from mutant SOD1
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mice are more neurotoxic and less neuroprotective than similarly treated WT microglia
derived from non‐transgenic littermates (Beers et al., 2006; Sargsyan et al., 2011; Weydt et
al., 2004; Xiao et al., 2007; Zhao et al., 2004). This was due to increased release of tumour
necrosis factor (TNF)‐α, NO and superoxide, and decreased insulin‐like growth factor‐1 and
cell adhesion molecule release. Similarly, over‐expression of mutant SOD1 in the microglial
cell line BV‐2 results in greater toll‐like receptor (TLR) 2‐stimulated TNF‐α and ROS release
compared to that from similarly treated BV‐2 microglia over‐expressing WT SOD1 (Liu et al.,
2009b). In a more recent study, microglia were isolated from mutant SOD1 mice at disease
onset and at end‐stage, and co‐cultured with motor neurons (Liao et al., 2012). In this study,
cells isolated at disease onset were neuroprotective and enhanced motor neuron survival,
while those isolated at end‐stage were toxic to motor neurons. Collectively, this suggests
that mutant SOD1 expression in microglia, while initially not harmful, may promote the
adoption of a neurotoxic phenotype as disease progresses.
In addition to mutant SOD1 expression, the presence of extracellular SOD1 may also
contribute to microglia‐mediated neuroinflammation and disease progression. Extracellular
mutant SOD1 has been demonstrated to morphologically and functionally activate microglia
(Meissner et al., 2010; Urushitani et al., 2006), possibly via a CD14/TLR‐dependent pathway
(Zhao et al., 2010). Extracellular SOD1‐mediated activation was characterised by pro‐
inflammatory responses typical of M1‐like neurotoxic microglia. This included the release of
the pro‐inflammatory cytokines TNF‐α and interleukin (IL)‐1β, release of superoxide, and
increases in inducible NO synthase, NADPH oxidase 2 and cyclooxygenase‐2 (COX‐2) mRNA
expression (Meissner et al., 2010; Roberts et al., 2013; Urushitani et al., 2006; Zhao et al.,
2010). Addition of extracellular mutant SOD1 to microglia and motor neuron co‐cultures
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resulted in motor neuron injury, while addition of the same preparation to motor neuron
cultures alone did not (Zhao et al., 2010). Thus, extracellular mutant SOD1 is able to mediate
motor neuron injury through the activation of microglia.
Collectively, this suggests that microglia can become chronically activated in response to
mutant SOD1 expression and/or stimulation by extracellular SOD1 (possibly in conjunction
with other extracellular factors). These activated cells produce large amounts of pro‐
inflammatory mediators, such as TNF‐α, NO and ROS, leading to a self‐propelling cycle of
motor neuron death and microglial activation (Figure 1.2). In this way, neuroinflammation,
mediated at least in part by microglia, may contribute to disease progression in ALS. Further
investigations are needed to better elucidate the mechanisms by which SOD1 activates
microglia and the identity of the microglia‐derived toxic or inflammatory factors which
contribute to motor neuron death.
1.4

The P2X7 receptor

P2X7 is a purinergic receptor which has been shown to play important roles in inflammation,
immunity, afferent signalling, bone homeostasis, neurological function and neoplasia
(Sluyter and Stokes, 2011; Surprenant and North, 2009). This receptor has additionally been
reported to be up‐regulated in diseases characterised by the presence of chronically
activated microglia (Monif et al., 2010), raising questions of a possible role for P2X7 in
mediating inappropriate microglial responses in CNS disorders. This receptor and evidence
for its involvement in ALS progression will be discussed below (Sections 1.4 and 1.5).

21

Cha
Ch
aptteerr 1 ‐ Litteerra
ap
attu
urree re
revviieew
w

Fiiggu
urre
e 1.
1.2
2 Mi
Micro
ogglliaall aaccttivvaattiio
on
n ca
can
n pe
perrp
pe
ettu
uaate a se
ellff‐p
prro
op
pe
ellliin
ngg ccyyccle o
off mo
motto
orr ne
neu
uro
on
n da
dam
magge
ma
e aan
nd
d de
deaatth
h. In
amy
myo
ottrop
ph
hicc lateerraal scclero
e osiis (A
ALSS)), ev
eviid
deen
nccee ssu
uggggeesstss th
thaatt mo
motto
orr ne
neu
urro
on
n da
dam
maggee/dea
ma
e th
h,, th
thee releeaassee o
off
exttrraaccellulaarr SO
ex
OD
D1
1 fro
f om
m ne
neu
urro
on
ns aan
nd
d//o
orr the accccu
um
mu
mulaattion off muttaan
ntt supe
pero
oxxiid
dee dis
d sm
m
mu
utasse
e 1 (SSO
OD1
OD
1) wit
w th
hin
m cro
mi
oggliaa leeaad
dss to
o mic
m crro
oggliiaal ac
actiivvaatio
on
n. Accttivvaatte
ed
d miccroglia co
con
nttrib
bu
uttee to
o the rraap
pid prro
oggrreesssio
on
no
of th
thee disseeaase
byy pr
pro
od
du
uccing
ng laarrggee quant
n ittieess o
of d
deelleeteriio
ou
uss faacctto
ors in an unre
eggu
ulaated ma
man
nn
neerr, wh
whicch
h ind
ndu
uccee th
hee de
deaatth
ho
off
surrrro
su
ou
un
nd
ding mo
motto
orr neu
eurons. Th
Thu
uss, a se
selff‐pro
p opellin
ngg cy
cyclee of
of mo
motto
orr ne
neu
uron dea
e th
h an
and
d mic
m crro
oggliaal aaccttivvaattio
on
ensu
ue
ess.. FFigu
guree aad
daap
ptteed
d ffrro
om
m Bl
B ock an
and
d Ho
Hon
ngg (2
20
00
05
5)). R
RO
OSS,, re
reaacctivvee oxyyggeen
n sp
speeccieess; N
NO
O,
O nit
n trricc oxid
dee.

1.4
4 1 SSttrru
4.1
uccttu
urree a
an
nd fu
fun
nc
ncttio
on
Adeenos
Ad
osine
ne‐‐5
5’‐ttrriip
ph
ho
osph
phaatte
e ((A
ATTP)
P and ot
oth
heerr nu
nucleeo
otid
dees, as
as we
welll as nuc
ucleo
eosside
dess, aree
im
mp
mpo
orttaant
n ex
exttrraacceelllulaar siggn
nallling
ng m
mo
oleeccu
uleess tth
hat
at op
oper
e at
a e th
thrro
ou
ugh
gh a co
com
mp
mplleexx pu
purrine
nerrggic
siggn
naalllin
ng n
neettw
workk (B
wo
Burrn
Bu
nsstto
occkk,, 197
972
2;; 20
2006
06)). Th
Thiiss ne
nettw
worrkk iss co
wo
compo
posseed
d of
of a num
umb
mbeer o
off
membr
me
braan
nee rreecceep
ptto
orss aan
nd
d ec
ectto
oeen
nzym
ymes
es, whic
h ch inc
nclu
ud
deess P2
P2X
X7
7 (Ye
Yeggu
uttkkin
n,, 20
200
008
8)). P2
P2X
X7 is
enc
nco
od
ded
ed by
by th
thee P
P2
2R
RX
X7 ge
X7
gen
nee and
nd be
belo
on
nggss to the P2
P2X
X faam
mi
milyy of
o tr
trimer
e icc liggaand
nd‐‐ggaatteed
d caatio
on
n
cha
han
nn
nels
e s,, of whic
h ch th
theere
e ar
aree seevveen
n d
disttiin
ncctt me
memb
beerrss (P
(P2
2X
X1
1‐‐7
7)) (C
(Co
odd
ddo
ou et
et al.
a ., 20
2011
11;
Kacczzm
Ka
marreekk‐‐H
ma
Háje
á ek et
et al.., 2
20
01
12
2). cD
DN
NA clo
on
nin
ngg of
of hu
um
man
ma
n,, ra
ratt,, mo
mou
usee, do
dogg, and
nd R
Rh
heessu
us

22
22

Cha
Ch
aptteerr 1 ‐ Litteerra
ap
attu
urree re
revviieew
w

maca
ma
caq
qu
uee P2
P2X
X7,
7 aan
nd
d ot
o he
herr P2
P2X fa
fam
m
milyy me
membe
berrss, ha
havvee con
onttrribu
butte
ed
d to
o the
he elu
uccid
daattiio
on
n o
off
strru
st
uccttu
uraal an
and
d fu
un
nccttio
ona
nal prop
opeerrtties
es of
of th
theese reece
cep
ptto
orss (Br
Braad
dleeyy eett aal.,, 2
20
01
11
1; Ch
Cheesssseell et
et al
a .,
199
998
8;; Ra
Rasssseendr
dreen
n et
et al.
a ., 19
1997
97;; Ro
Rom
ma
man
n et
et al
a ., 200
009
9;; Sur
urp
prreen
nant
nt et al
al.,, 19
199
96
6)..
Of the
Of
he P
P2
2X
X faam
milyy, th
mi
thee P
P2
2X
X7
7m
mo
on
nom
om
meerric su
ub
bu
un
nitt iss th
thee llaarrggeesstt, wi
with a leeng
ngtth
h of
of 59
595
5 amin
no
o
acid
c ds fo
forr th
thee hu
human,
n raatt,, mou
oussee,, do
dogg,, an
and
d Rhe
hessu
uss ma
maccaaqu
quee re
recceept
po
orrss (B
(Braadle
d ey eet al., 20
2011
11;
Cheesssseell et al
Ch
al., 19
199
98;
8 Ra
Rasssseen
nd
dren
en et
et al.
a ., 199
997
7;; Ro
Roma
man et
et al.., 20
20
00
09
9;; SSu
urrp
prreen
nan
antt et
et al.., 199
996
6)).
Eac
ach
h su
sub
bun
uniit iss ch
chaarraacctteeriisseed
d by re
elaattiivveely sho
horrtt an
and
d llo
on
ngg in
nttrraacceellu
ular amin
no
o an
nd
d ccaarb
box
oxyyl
term
te
min
mi
nii, reespe
peccttive
velyy, as we
well aass tw
two
wo hy
hydr
dro
op
ph
ho
ob
biicc me
mem
mbrane
mb
ne‐‐ssp
paan
nni
n ng se
seggm
ment
me
nts
(ttrraan
nssm
membr
me
braan
nee do
domain
ns) se
sep
paaraatteed by a lo
ong
ng gly
g yccos
osyylaateed
d ex
extracceellu
ullaarr A
ATTP
P‐‐b
bin
nd
din
ngg
dom
oma
maiin
n (Figgu
uree 1.3
3aa)..

Fiiggu
urre
e 1.3
3 Th
The
e sttrru
uccttu
ure
e of
of a si
sin
nggle
e P2
P2X
X7
7 su
sub
bu
un
niit an
nd
d tth
he
e triim
me
eriic arrrraan
ngge
em
men
nt fo
forrm
meed
d be
bettw
ween
en m
mu
ulltip
ple
sub
su
bunit
n tss. (a
(a) Ea
Eacch
h su
sub
bu
un
nit is pr
preed
dicteed
d to
to po
posssesss a sh
sho
ort an
and
d lon
ongg in
nttraceellu
ulaarr NH
NH2 and CO
COO
OH teerrm
min
nu
uss,
reessp
pe
eccttivveely,, tw
w
wo
o me
mem
mbrraan
mb
nee‐sp
pannin
ngg se
seggm
meenttss (TTM
M
M1
1 an
and
d TM
TM2) an
and
d an
an exttrraacceellula
u arr AT
ATP
P‐bin
nd
diin
ngg lo
oo
op
p.. The
lo
on
ngg CO
COO
OH tteerrm
min
nu
uss has be
beeen
n ssh
ho
ow
wn
n to
to plaayy an esssseen
nttiaal ro
ole in
n poree fo
form
maattio
on
n an
and
d receepto
orr trraafffiicckkin
ngg. (b
b)
Thre
ee
e in
nd
divvid
dual P2X7
X7 su
sub
bu
un
nitts cco
om
mb
bin
nee to fo
orm a ttrrim
mericc liggaan
me
nd‐ggaatteed
d caattion ch
haan
nn
ne
ell w
wh
hicch
h,, upon
on aaccttivvaattion
byy ex
exttraacceelllu
ullaar AT
ATP
P,, allows
ws tth
he
e flu
f uxx of
o ca
catio
on
nss. Fi
F gureess ad
adaap
ptteed
d ffrro
om
m Le
Len
ne
errtz et
et aall. (201
011
1) an
and
d SSchwa
warrzz et
et al.
(2
20
00
09
9)).

23
23

Chapter 1 ‐ Literature review

To form a functional receptor, three P2X7 subunits are thought to associate, with three ATP
molecules binding between subunits of the trimeric complex (Jarvis and Khakh, 2009)
(Figure 1.3b). The trimeric structures of human and Rhesus macaque P2X7 are supported by
atomic computer modelling (Bradley et al., 2011; Jiang et al., 2013; Roger et al., 2010),
based on the crystal structure of the related zebrafish P2X4 receptor (Gonzales et al., 2009;
Kawate et al., 2009). To the best of our knowledge, similar modelling experiments have not
been carried out for rodent or canine P2X7. However, the structures of rodent and canine
P2X7 are likely to be similar to that of primate P2X7, as these receptors share 80–85%
sequence identity to human P2X7 (Bradley et al., 2011; Donnelly‐Roberts et al., 2009;
Roman et al., 2009; Surprenant et al., 1996). Furthermore, the study of native rat P2X7
complexes supports the trimeric arrangement of rodent P2X7 (Nicke, 2008). More recently,
the crystal structure of the zebrafish P2X4 receptor in complex with ATP has been reported
(Hattori and Gouaux, 2012). This agonist‐bound structure provides new insights into the
mechanism of P2X activation and may be useful for the development of new
pharmacological agents.
Compared to other P2X receptors, P2X7 requires much higher ATP concentrations for
activation, with a characteristic half maximal effective concentration (EC50) of 100‐300 μM
(Donnelly‐Roberts et al., 2009; Surprenant et al., 1996; Young et al., 2007). Activation of
P2X7 by extracellular ATP results in the passage of small cations, including Ca2+, Na+, and K+,
across the plasma membrane (Chessell et al., 1998; Rassendren et al., 1997; Surprenant et
al., 1996). However, prolonged ATP stimulation leads to the formation of a larger reversible
pore, which allows for the uptake of organic ions including ethidium+ and YO‐PRO‐12+
(Chessell et al., 1998; Rassendren et al., 1997; Steinberg and Silverstein, 1987; Surprenant et
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al., 1996). The identity of the pore formed following ATP stimulation is controversial, with
evidence for both a widening of the P2X7 channel itself or opening of a second molecule
such as the hemi‐channel pannexin (see Rokic and Stojilkovic, 2013). Finally, it should be
noted that P2X7 can also be activated by synthetic ATP analogues such as 2,3‐O‐(4‐
benzoylbenzoyl)‐ATP (BzATP) (Surprenant et al., 1996).
Activation of P2X7 by ATP results in a number of cell‐specific downstream signalling events,
many of which were established or are supported by rodent models of disease (Section
1.4.5). These downstream signalling events are dependent on a variety of factors, including
cell type, extracellular conditions, and the concentration of extracellular ATP (Burnstock,
2007). The presence of ectonucleotidases, which degrade ATP and other nucleotides,
regulate the concentration and duration of availability of P2 receptor agonists in the
extracellular space (Yegutkin, 2008). Thus, P2X7 is possibly only activated after injury,
infection, or in tumour microenvironments when the concentration of ATP increases locally
or when ectonucleotidases are downregulated (Lenertz et al., 2011). Alternatively, it is
possible that currently unknown allosteric modulators might act on P2X7 in vivo to decrease
its Km for ATP, thus allowing the activation of P2X7 at lower nucleotide concentrations.
There is also emerging evidence that P2X7 activation stimulates ATP release, further
complicating the study of the ATP/P2X7 signalling axis. P2X7‐mediated ATP release has been
observed from human embryonic kidney (HEK)‐293 cells transfected with rat or human P2X7
(Pellegatti et al., 2005), from astrocytes during Ca2+ signal transmission (Suadicani et al.,
2006), from osteoclasts undergoing fusion (Pellegatti et al., 2011) and in culture (Brandao‐
Burch et al., 2012), and from melanoma cells after γ‐irradiation (Ohshima et al., 2010).
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1.4.2 Distribution
P2X7 is widely distributed throughout the mammalian body (see Burnstock and Knight,
2004). This receptor was originally thought to be restricted to cells of the hematopoietic
lineages; this includes macrophages, dendritic cells, monocytes, lymphocytes, and
erythrocytes, as well as osteoclasts, mast cells, and eosinophils. However, it is now evident
that P2X7 is present on cells from other lineages, including osteoblasts, fibroblasts,
endothelial cells, and epithelial cells. Furthermore, P2X7 is present on cells in the central
and peripheral nervous systems, including microglia, astrocytes, oligodendrocytes, and
Schwann cells (Sperlagh et al., 2006). In addition, there are reports of the presence of P2X7
on some populations of neurons, including those from the spinal cord, cerebellum,
hypothalamus, and substantia nigra (see Lenertz et al., 2011; Wiley et al., 2011).
Although P2X7 has been identified on a number of cell types, less is known about the
relative distribution of P2X7 between different cell types within whole tissues. Recently,
transgenic P2X7 reporter mice expressing enhanced green fluorescent protein downstream
of the P2RX7 promoter have been generated (Engel et al., 2012; Garcia‐Huerta et al., 2012;
Jimenez‐Pacheco et al., 2013), which is an important step toward addressing the distribution
of P2X7 in vivo. For example, these mice have been used to localise P2X7 expression in the
CNS after prolonged seizures, with P2X7 identified to be up‐regulated on neurons, but not
up‐regulated on microglia or astrocytes, in the hippocampus and neocortex (Engel et al.,
2012; Jimenez‐Pacheco et al., 2013). Although the P2X7 expression on microglia and
astrocytes was weak in these studies, P2X7 expression in these cell types is well established
from immunohistochemical studies (see Verkhratsky et al., 2012). In addition, transgenic
P2X7 green fluorescent protein reporter mice have been used to localise P2X7 on cells from
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the cerebral cortex and pons of newborn mice (Engel et al., 2012; Garcia‐Huerta et al.,
2012). P2X7 expression was also demonstrated in peritoneal macrophages and the spleen,
validating the reliability of these mice (Garcia‐Huerta et al., 2012).
1.4.3 Variants
P2X7 mediates a diverse array of responses and has been suggested to have important roles
in health and disease (see Sections 1.4.5 and 1.4.6). Thus, particular attention has been
drawn to the identification of and understanding of the importance and contributions of
P2X7 variants. The two main causes of P2X7 variants, P2X7 single nucleotide polymorphisms
(SNPs) and splice isoforms, will be discussed below.
1.4.3.1 Single nucleotide polymorphisms
The human P2RX7 gene is highly polymorphic, with over 3000 SNPs reported in the National
Center for Biotechnology Information (NCBI) SNP database (www.ncbi.nlm.nih.gov
/sites/entrez, accessed March 5, 2016). However, the majority of these SNPs are intronic,
with approximately 300 non‐synonymous (or missense) SNPs reported. Of these missense
SNPs, a small number have been investigated to date that lead to altered human P2X7
function. A loss‐of‐function effect has been reported for SNPs V76A, R117W, G150R, E186K,
L191P, R276H, R307Q, T357S, E496A, and I568N (Gu et al., 2004; Gu et al., 2001; Roger et
al., 2010; Shemon et al., 2006; Stokes et al., 2010; Wiley et al., 2003). In addition, a gain‐of‐
function effect has been reported for three SNPs: H155Y, H270R, and A348T (Cabrini et al.,
2005; Stokes et al., 2010). Investigations into the underlying mechanisms behind the loss‐ or
gain‐of‐function effect of individual SNPs have revealed differences depending on the site of
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the mutations (see Jiang et al., 2013). However, the underlying mechanisms behind many of
these SNPs have not been established.
A number of SNPs have similarly been reported in the murine P2RX7 gene, with a survey of
the NCBI SNP database revealing over 1600 SNPs (accessed March 5, 2016). The majority of
these are intronic, with 15 missense SNPs reported. Of these, only the P451L SNP has been
characterised. This loss‐of‐function SNP was originally identified based on studies of P2X7
function in T cells from different strains of mice, whereby T cells from BALB/c mice (451P)
had significantly higher sensitivity to ATP than those from C57BL/6 mice (451L) (Adriouch et
al., 2002; Young et al., 2006). In a later study, astrocytes from C57BL/6 mice (with the P451L
mutation) were similarly reported to have attenuated ATP‐induced pannexin‐1 currents,
ATP release, and intracellular Ca2+ waves compared with astrocytes from BALB/c mice
(Suadicani et al., 2009).
In addition to human and mouse P2RX7, missense SNPs have also been identified in the
coding region of other mammalian P2RX7 genes, including that of dogs. From a survey of
the NCBI SNP database (accessed March 5, 2016), four missense SNPs, F103L, P452S, R365Q
and R270C, have been reported in the canine P2RX7 gene. The P452S SNP in the canine
P2RX7 gene is located at the equivalent position as the partial loss of function SNP, P451L,
of the murine P2RX7 gene. However, the functional effects of this and other canine SNPs
remains unknown.
1.4.3.2 Single nucleotide polymorphisms and disease
In the last five years, many studies have investigated the association of SNPs in P2RX7 with a
number of different diseases. In humans, loss‐of‐function SNPs have been linked to
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susceptibility to extrapulmonary tuberculosis infection (Fernando et al., 2007), enhanced
bone mineral density loss in post‐menopausal women (Gartland et al., 2012; Jorgensen et
al., 2012), and an increased risk of age‐related macular degeneration due to reduced
phagocytosis of cellular debris (Gu et al., 2013). Inheritance of E496A has been linked to a
reduced risk of ischemic stroke and ischemic heart disease (Gidlof et al., 2012). The human
gain‐of‐function A348T SNP is protective for Toxoplasmosis gondii infection (Jamieson et al.,
2010) and is found at an increased frequency in Arabic patients with rheumatoid arthritis
(Al‐Shukaili et al., 2011) and patients with major depressive disorder (Lucae et al., 2006). In
mice, the P451L SNP has been associated with reduced neuropathic pain and altered bone
phenotype (Sorge et al., 2012; Syberg et al., 2012). In comparison, it is unknown whether
the reported SNPs in canine P2RX7 are associated with any canine diseases.
1.4.3.3 Splice Isoforms
Alternative splicing is a process that enables one gene to produce multiple protein isoforms.
In humans, nine naturally occurring splice variants have been reported and termed P2X7B to
P2X7J (Cheewatrakoolpong et al., 2005; Feng et al., 2006), with P2X7A referring to the
original full‐length 595 amino acid protein (Rassendren et al., 1997). The splice variants
include truncated variants that have an alternate short C‐terminus (P2X7B, C, E, G and J),
variants that lack exons responsible for coding parts of the extracellular domain (P2X7C–F)
and variants that have additional exons, thought to result in P2X7 protein lacking the first
transmembrane domain (P2X7G and H). In addition, P2X7I codes for a null allele and is a
result of the SNP rs35933842 (Skarratt et al., 2005). These ten variants of human P2X7 differ
in distribution, functional characteristics, and predicted physiologic roles (see Sluyter and
Stokes, 2011). Of these, P2X7B is the best studied and is able to form functional channels
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but not the large pores that are often associated with inflammation and cell death (Adinolfi
et al., 2010). P2X7J is similarly unable to form pores and also displays reduced ligand‐binding
ability and channel function, and oligomerises with P2X7A to form non‐functional P2X7
heterotrimers (Feng et al., 2006).
Three naturally occurring P2X7 splice variants have also been identified in mice, termed
P2X7K, P2X713B and P2X713C (Masin et al., 2012; Nicke et al., 2009). P2X7K results from a
novel exon 1 in the rodent P2RX7 gene, leading to a receptor with an alternate amino‐
terminal and first transmembrane domain (Nicke et al., 2009). In contrast to the human
P2X7 variants mentioned above, P2X7K is a fully functional variant, with an 8‐fold higher
sensitivity to P2X7 agonists, slower deactivation, and increased propensity to form P2X7
pores compared with P2X7A (Nicke et al., 2009). In contrast, P2X713B and P2X713C are
encoded by genes with alternative exon 13s, resulting in truncated or alternate short C‐
termini, respectively (Masin et al., 2012). When expressed in HEK‐293 cells, both variants
displayed low cell surface expression and channel function and no pore formation. This low
cell surface expression of P2X713B was due to inefficient trafficking to the cell surface and,
similar to the human variant P2X7J (Feng et al., 2006), appeared to inhibit the function of
full‐length P2X7 through hetero‐oligomerisation (Masin et al., 2012). Equivalent variants of
human P2X7B‐J are yet to be reported in rodents. Furthermore, the influence of these
variants on P2X7 in vivo or ex vivo in primary cells has not been widely examined, and
remains a potential confounder in preclinical studies in rodents.
Several splice variants have also been identified in cloned canine P2X7 (Roman et al., 2009).
One variant possessed an alternative splice site within exon 13, which would result in a
truncated P2X7 protein with the C‐terminus lacking residues 432‐522. Another variant was
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missing exon 7, resulting in a frame‐shift and introduction of a premature stop codon. If
translated, this latter variant would produce a truncated P2X7 protein consisting of residues
1‐205, and an additional 13 C‐terminal residues.
1.4.4 Pharmacology
There are a number of P2X7 antagonists commercially available, all of which vary in terms of
chemical structure, mode of antagonism, specificity, and species selectivity. The first
generation of compounds available that was capable of antagonising P2X7 were generally
non‐specific, with many also capable of inhibiting other P2X and in some cases P2Y
receptors or other molecules (see Gever et al., 2006). Of these earlier compounds, Brilliant
Blue G (BBG) in particular remains one of the most useful. BBG is generally considered a
specific P2X7 antagonist, blocking rat P2X7 in the nanomolar compared with micromolar
range or not at all for other rat P2X receptors (P2X1, P2X2, P2X3, P2X2/3, P2X4, and P2X1/5)
(Jiang et al., 2000). In the last two decades, a second generation of more specific antagonists
has been developed, largely aided by high‐throughput screening of large chemical libraries
(see Bhattacharya et al., 2011; Friedle et al., 2010; Jiang, 2012). One second generation
P2X7 antagonist is the adamantine amide N‐[2‐([2‐([2‐hydroxyethyl]amino)ethyl]amino)‐5‐
quinolinyl]‐2‐tricyclo[3.3.1.13,7]dec‐1‐ylacetamide

(AZ10606120),

which

has

been

characterised and, like BBG, reported to be a non‐competitive inhibitor of P2X7 (Michel et
al., 2007). The concentration responses of a number of P2X7 antagonists including BBG and
AZ10606120 have been determined at native murine P2X7 (e.g. Bartlett, 2011), which is
useful for their in vivo application. Furthermore, there are a number of additional potential
antagonists identified that have yet to be fully characterised (Donnelly‐Roberts and Jarvis,
2007), which may prove even more specific and potent than those currently available.
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1.4.5 Downstream signalling pathways
A number of cell type‐specific signalling pathways have been associated with P2X7
activation. These include the formation of reactive oxygen and nitrogen species, the release
of various molecules (such as cytokines, enzymes and microparticles), cell death and
proliferation, and phagocytosis. These P2X7 signalling pathways will be discussed below.
1.4.5.1 Reactive oxygen and nitrogen species formation
The generation of reactive oxygen and nitrogen species after ATP activation of P2X7 is well
established in a number of cell types. P2X7‐mediated ROS formation is observed in
macrophages (Lenertz et al., 2009; Moore and MacKenzie, 2009; Pfeiffer et al., 2007),
microglia (Apolloni et al., 2013b; Bartlett, 2011; Parvathenani et al., 2003), submandibular
gland cells (Seil et al., 2008), and erythroid cells (Wang and Sluyter, 2013). P2X7‐mediated
formation of the reactive nitrogen species NO has been observed in macrophages (Marques
da Silva et al., 2008; Sperlagh et al., 1998), monocytes (Lee et al., 2012), microglia (Gendron
et al., 2003; Lai et al., 2013; Li et al., 2013; Skaper et al., 2006) and hippocampal neurons
(Codocedo et al., 2013). The cellular source of P2X7‐mediated ROS remains controversial,
with evidence for the involvement of both NADPH oxidase (Parvathenani et al., 2003) and
mitochondria (Nakahira et al., 2011; Yaron et al., 2015). In contrast, the cellular sources of
P2X7‐mediated NO are less widely investigated, but presumably are generated by one or
more of the three major isoforms of NO synthase (Mattila and Thomas, 2014).
1.4.5.2 Cytokine release
P2X7 activation mediates the release of various cytokines, including pro‐inflammatory IL‐1β,
IL‐18 and TNF‐α. P2X7‐mediated secretion of mature IL‐1β and IL‐18 is well established, and
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is thought to occur in a caspase‐1‐, NLRP3 inflammasome‐dependent manner (Dubyak,
2012). However, the precise mechanisms involved in P2X7‐mediated IL‐1β and IL‐18
secretion remain unknown. Proposed mechanisms include exocytosis of secretory
lysosomes, autophagosomes or autophagolysosomes, release of membrane‐derived
microvesicles or exosomes, and direct release following regulated cell death (see Dubyak,
2012). In addition, P2X7 activation mediates TNF‐α secretion from microglia (D'Ambrosi et
al., 2009; Hide et al., 2000; Masuch et al., 2016; Shieh et al., 2014; Suzuki et al., 2004) and
dentate granule cells (Kim et al., 2011). However, the mechanisms involved in this process
are poorly understood.
1.4.5.3 Enzyme release
P2X7 activation can also induce the release of various enzymes. In monocytes and
macrophages, P2X7 activation induces lysosome secretion of the cysteine proteases
cathepsin B, D, K, L, and S, via a pathway regulated by increased intracellular Ca2+
concentrations (Andrei et al., 2004; Lopez‐Castejon et al., 2010). P2X7 can also mediate the
unconventional export of the tissue repair enzyme transglutaminase‐2 (Adamczyk et al.,
2015), and can stimulate the release of matrix metalloprotease‐9 (Gu and Wiley, 2006).
However, the specific release mechanisms are yet to be determined. Therefore, P2X7 can
regulate several families of proteases, namely caspases (Ferrari et al., 1999), as well as
cathepsins, transglutaminases and matrix metalloproteinases.
1.4.5.4 Microparticle release and plasma membrane blebbing
P2X7 regulates the release of microparticles. These include microvesicles (100 nm ‐ 1 μm)
and exosomes (30 ‐ 80 nm), which are derived from the plasma membrane and intraluminal
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vesicles of endosomal multivesicular bodies, respectively (Qu and Dubyak, 2009; Wiley et
al., 2011). Rapid P2X7‐mediated microvesicle release has been observed in dendritic cells
(Pizzirani et al., 2007), fibroblasts (Solini et al., 1999), erythroleukemia cells (Constantinescu
et al., 2010), monocytes (MacKenzie et al., 2001), macrophages (Graziano et al., 2015;
Gulinelli et al., 2012) and microglia (Bianco et al., 2005; Takenouchi et al., 2015). A range of
molecules have been shown to be present in these released microvesicles, including
cytokines, enzymes, membrane receptors and phospholipids (see Qu and Dubyak, 2009).
Furthermore, there is evidence that microvesicles can "encapsulate" and release small
volumes of cytosolic material (Qu and Dubyak, 2009). P2X7‐mediated exosome release has
similarly been observed in a number of cell types, including dendritic cells (Qu et al., 2009),
macrophages (Qu et al., 2007; Qu et al., 2009) and microglia (Takenouchi et al., 2015).
Proteins, lipids and nucleic acids, including those derived from the cytosolic compartment,
have been found within these structures (see Schneider and Simons, 2013). However, the
mechanisms underlying P2X7‐dependent release of both microvesicles and exosomes are
poorly understood.
In addition to microvesicle release, P2X7 activation can also trigger membrane blebbing, a
reversible process involving the protrusion and retraction of sections of the plasma
membrane at the cell surface (see Qu and Dubyak, 2009). Membrane blebbing can occur
alongside or independently of microvesicle release (Qu and Dubyak, 2009), and has been
observed in macrophages (Pfeiffer et al., 2004; Verhoef et al., 2003), salivary gland epithelial
cells (Hwang et al., 2009), hepatocytes (Gonzales et al., 2007), osteoblasts (Grol et al., 2012;
Panupinthu et al., 2007) and bone marrow mesenchymal stem cells (Noronha‐Matos et al.,
2014). However, the mechanisms by which P2X7 triggers this response, and the biological
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function of membrane blebbing remain unknown. In a recent paper, P2X7‐mediated
membrane blebbing in murine macrophages required activation of anoctamin 6, a
phospholipid scramblase (Ousingsawat et al., 2015). This provides some insight into the
mechanisms by which P2X7 triggers this response.
1.4.5.5 Cell death and proliferation
P2X7 is historically known for its ability to induce apoptotic cell death following activation by
ATP (Chow et al., 1997; Ferrari et al., 1999; Zanovello et al., 1990). A role in cell proliferation
would seem to be at odds with this, but evidence suggests that in certain cell types, namely
T cells and microglia, activation of P2X7 is more likely involved with proliferation than cell
death. This may be due to expression of particular splice variants (Adinolfi et al., 2010). In T
cells, release of autocrine ATP during activation through the T cell receptor activates P2X7
and enhances secretion of the T cell growth factor IL‐2, through stimulation of the nuclear
factor of activated T cells transcription factor (Yip et al., 2009). Baricordi and colleagues
(1996) first suggested a role for P2X7 in mitogen‐induced T cell proliferation. This same
group subsequently went on to show that transfection of cell lines with full‐length P2X7 or a
truncated splice variant of this receptor increased cell proliferation, especially in the
absence of serum (Adinolfi et al., 2005a; Adinolfi et al., 2010; Baricordi et al., 1999). In
microglia, blocking P2X7 pharmacologically or over‐expressing a pore‐mutant (G345Y) to
abolish secondary permeability reduced the proliferative response (Bianco et al., 2006;
Monif et al., 2009). It will be interesting to determine if the trophic effect in microglia is also
due to transcriptional regulation of a growth factor.

35

Chapter 1 ‐ Literature review

1.4.5.6 Phagocytosis
A novel cellular signalling process associated with P2X7 is the regulation of phagocytosis
(Wiley and Gu, 2012), a process by which foreign particles or organisms are taken up into
cells. Transfection of HEK‐293 cells, which are not normally phagocytic, with DNA encoding
P2X7 introduces the ability to take up 1 µm latex beads or fluorescently labelled bacteria
(Gu et al., 2010). Gu and colleagues (2012; 2009; 2010; 2011) propose that P2X7 is acting as
a scavenger receptor. Typically scavenger receptors, such as CD36, recognise modified
lipoproteins (Endemann et al., 1993). Although it is noted that P2X7 has a similar two
transmembrane domain structure to CD36 (Gu et al., 2012; Gu et al., 2011), whether P2X7
can recognise such lipoproteins is not yet known. The ability of P2X7‐expressing cells to take
up particles does not appear to require classic activation of the ion channel by extracellular
ATP. In fact, stimulation of the channel with ATP switches off this phagocytic pathway (Gu et
al., 2010). This suggests that particle uptake does not require classic signalling through the
ion channel or the secondary pore pathway, but may use a novel signalling pathway due to
association of P2X7 with the cytoskeleton (Gu et al., 2009; Gu et al., 2010).
1.4.5.7 Summary
In summary, P2X7 regulates a diverse series of signalling pathways commonly involved in
inflammation. Because these signalling pathways are cell type specific, it is highly likely that
each cell type expressing P2X7 has a different complement of downstream effectors. This
information is critical for understanding the role of P2X7 in disease and the potential for this
receptor as a therapeutic target.
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1.4.6 In health and disease
P2X7 has been associated with a number of diseases, in addition to those associated with
SNPs (Section 1.4.3.2). These include CNS disorders, such as ALS (Yiangou et al., 2006) (see
Section 1.5), multiple sclerosis (Yiangou et al., 2006), Alzheimer’s disease (Chen et al.,
2014a; Diaz‐Hernandez et al., 2012; Ryu and McLarnon, 2008), Huntington’s disease (Diaz‐
Hernandez et al., 2009), Parkinson’s disease (Marcellino et al., 2010), prion disease
(Iwamaru et al., 2012), status epilepticus (Engel et al., 2012; Jimenez‐Pacheco et al., 2013),
brain tumour (Fang et al., 2011; Ryu et al., 2011), cerebral ischemia (Arbeloa et al., 2012;
Chu et al., 2012; Melani et al., 2006) and spinal cord injury (Peng et al., 2009; Wang et al.,
2004b). In addition, P2X7 is implicated in inflammatory and immune diseases, including
rheumatoid arthritis (Portales‐Cervantes et al., 2010), glomerulonephritis (Taylor et al.,
2009), pulmonary fibrosis (Riteau et al., 2010), Sjogren’s syndrome (Lester et al., 2013),
graft‐versus‐host disease (Wilhelm et al., 2010) and inflammatory pain (Chessell et al.,
2005). Furthermore, a role for P2X7 has been suggested in cancer (Adinolfi et al., 2012;
Ghiringhelli et al., 2009) and infectious diseases (Miller et al., 2011a; Miller et al., 2011b).
1.5

Purinergic signalling in amyotrophic lateral sclerosis: a new player?

In the CNS, ATP acting on P2X receptors is important for neurotransmission,
neuromodulation, glial communication, neurite outgrowth and glial cell activation and
proliferation (Burnstock, 2008; Monif et al., 2009). ATP, which is normally present within
cells, is released via both lytic and non‐lytic mechanisms into the extracellular space
following cell activation, stress or cell damage, and constitutes a well‐known neuron‐to‐glia
alarm signal (Apolloni et al., 2009). Microglia are known to express a variety of P2X
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receptors, including P2X7 and P2X4 (Burnstock, 2008; 2015). Moreover, other CNS cells,
including astrocytes and neurons, are also reported to express functional P2X receptors such
as P2X7 (Burnstock, 2015). Collectively, this suggests that purinergic signalling, in particular
P2X7, has a role in the progression of neurodegenerative and neuroinflammatory diseases
such as ALS. Evidence for the involvement of P2X7 in ALS progression will be discussed, and
is summarised in Table 1.3. However, it should be noted that roles for other P2 receptors in
ALS progression, such as P2X4, have also been reported (see Volonte et al., 2015).
Table 1.3 Summary of the major findings implicating P2X7 in amyotrophic lateral sclerosis (ALS)

Year
2006
2008
2009
2010
2013

Finding1
P2X7 immunoreactivity is increased in microglia of human ALS SC
P2X7 immunoreactivity is increased in microglia of rat ALS SC
P2X7 activation on SOD1G93A microglia mediates neurotoxicity
P2X7 activation on SOD1G93A astrocytes mediates neurotoxicity
P2X7 activation on motor neurons mediates cell death

2013
2013
2013
2013
2014
2015

P2X7 activation on SOD1G93A microglia mediates ROS formation
P2X7 activation on SOD1G93A microglia up‐regulates microRNAs
P2X7 knock‐out exacerbates disease progression in SOD1G93A mice

2016

Microglial microRNA‐125b expression mediates neurotoxicity

P2X7 antagonism improves disease outcomes in SOD1G93A mice
Ectonucleotidases are down‐regulated in microglia during ALS

Reference
Yiangou et al.
Casanovas et al.
D'Ambrosi et al.
Gandelman et al.
Gandelman et al.;
Franco et al.
Apolloni et al. [b]
Parisi et al.
Apolloni et al. [a]
Cervetto et al.
Apolloni et al.
Butovsky et al.;
Volonte et al.
Parisi et al.

1

ROS, reactive oxygen species; SC, spinal cord. Adapted from (Volonte et al., 2015).

1.5.1 P2X7 expression in microglia in ALS
As previously discussed (Section 1.3.6), the sustained activation of glial cells, including
microglia, is a major component of ALS. Emerging evidence suggests that P2X7 may play a
role in this sustained activation, as well as in microglia‐mediated neurotoxicity. Initially,
early work found a significantly higher density of active P2X7‐immunoreactive microglial
cells in human post‐mortem sporadic ALS spinal cords compared to control spinal cords
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(Yiangou et al., 2006). Although only nine ALS samples were used for this
immunocytochemical analysis, this up‐regulation was found for all nine specimens. Similarly,
a higher density of P2X7‐positive microglial cells was reported in SOD1G93A transgenic rats at
an advanced stage of the disease compared to WT controls (Casanovas et al., 2008).
In 2009, D'Ambrosi et al. examined P2X receptors in immortalised and primary microglia
obtained from SOD1G93A mice and WT mice (D'Ambrosi et al., 2009). P2X7 mRNA and
protein were both found to be up‐regulated in SOD1G93A microglia compared to WT
microglia. By employing semiquantitative RT‐PCR, immunoblot, and biotin‐pulldown
analysis, higher amounts of P2X7 were found in total cell extracts, as well as on the cell
surface of SOD1G93A microglia. In addition, this study found a down‐regulation in
ectonucleotidase activity in mutant microglia, indirectly suggesting that P2 receptor
activation, including that of P2X7, may be potentiated in these cells. Consistent with this,
more recent studies have found that the microglia‐specific and dominant cellular
ectonucleotidase CD39 is down‐regulated at both the mRNA and protein levels in microglia
obtained from ALS mice and humans post‐mortem (Butovsky et al., 2015; Volonte et al.,
2015). In the study by D'Ambrosi et al., treatment of SOD1G93A microglia with the potent
P2X7 agonist BzATP induced morphological changes, and enhanced TNF‐α and COX‐2
production compared to WT microglia (D'Ambrosi et al., 2009), suggesting potentiation of
P2X7. Moreover, conditioned medium from BzATP‐treated SOD1G93A microglia induced the
death of two neuronal cell lines. These changes and the associated neurotoxicity were each
inhibited by the P2X7 antagonist BBG. However, studies with neutralising antibodies
excluded TNF‐α as the neurotoxic factor, while a neurotoxic role for COX‐2 was not

39

Chapter 1 ‐ Literature review

investigated further (D'Ambrosi et al., 2009), despite also being up‐regulated in human ALS
spinal cords (Yiangou et al., 2006).
In a more recent study, NADPH oxidase 2, the main ROS‐producing enzyme, and its
signalling pathways were examined in microglia derived from SOD1G93A mice and SOD1G93A
mice lacking P2X7 (Apolloni et al., 2013b). In SOD1G93A microglia, BzATP stimulation of P2X7
enhanced NADPH oxidase 2 activity, leading to increased ROS formation. These responses
were absent in microglia derived from SOD1G93A mice lacking P2X7 or in those from
SOD1G93A mice which had been treated with the P2X7 antagonists BBG, 1‐(2,3‐
dichlorophenyl)‐N‐[[2‐(2‐pyridinyloxy)phenyl]methyl]‐1H‐tetrazol‐5‐amine (A839977) or 3‐
[[5‐(2,3‐dichlorophenyl)‐1H‐tetrazol‐1‐yl]methyl]pyridine (A438079), further supporting a
neurotoxic role for P2X7 in ALS.
In a parallel study to that described above, BzATP stimulation of P2X7 in primary SOD1G93A
murine microglia was found to up‐regulate the expression of inflammatory microRNAs,
small non‐coding RNAs important for regulating gene expression at the post‐transcriptional
level (Parisi et al., 2013). This dysregulation contributed to an ALS phenotype in microglia. In
particular, up‐regulation of microRNA‐125b led to increased TNF‐α via negative modulation
of the signal transducer and activator of transcription 3 pathway (Parisi et al., 2013).
Furthermore, microRNA‐125b negatively regulated the expression of A20, which encodes an
ubiquitin‐editing enzyme with known anti‐inflammatory functions, in part involving
termination of the inflammatory nuclear factor kappa B (NF‐κB) pathway (Parisi et al., 2016).
In this way, microRNA‐125b mediated increased mRNA expression of TNF‐α and NADPH
oxidase 2, transcriptional targets of NF‐κB, leading to increased ROS production.
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The neurotoxic effects of microRNA‐125b were also demonstrated in a cell culture system.
While significant cell death was observed in primary motor neuron cultures incubated with
conditioned media from BzATP‐stimulated SOD1G93A microglia, increased survival was
observed in cultures incubated with conditioned media from BzATP‐stimulated SOD1G93A
microglia in which microRNA‐125b had been inhibited (Parisi et al., 2016). This increased
survival was dependent on A20 expression, suggesting that the BzATP‐induced neurotoxic
actions of microglia were mediated through the negative modulation of A20 by microRNA‐
125b. This is supported by observations of end‐stage SOD1G93A mouse spinal cord tissues, in
which microRNA‐125b mRNA is significantly up‐regulated and A20 protein is strongly down‐
regulated compared to WT mice, consistent with the up‐regulation of P2X7 in human ALS
spinal cords (Yiangou et al., 2006).
In addition to microRNA‐125b, microRNA‐155 was also up‐regulated during BzATP
stimulation of P2X7 in primary SOD1G93A murine microglia (Parisi et al., 2013). Furthermore,
mRNA expression of microRNA‐155 is up‐regulated in post‐mortem familial and sporadic
human ALS spinal cords (Butovsky et al., 2015). Similar to observations with microRNA‐125b
in culture (Parisi et al., 2016), genetic ablation of microRNA‐155 extended the survival of
SOD1G93A mice (Butovsky et al., 2015). This further implicates microRNAs in disease
progression in ALS, the dysregulation of which may be potentiated by P2X7 activation.
A neurotoxic role for P2X7 in microglia is further supported by studies using cells from
normal mice or rats (e.g. Parvathenani et al., 2003; Skaper et al., 2006). In these studies, co‐
culture of P2X7‐activated microglia with neurons induced neuronal cell death. Nevertheless,
the identity of the neurotoxic factor released from these microglia following P2X7
activation, and whether this factor differs to that released from SOD1 microglia, remains to
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be determined. Moreover, it remains to be determined if the increased P2X7 expression in
SOD1 microglia directly correlates with increased P2X7 channel/pore function.
1.5.2 P2X7 expression in astrocytes in ALS
In addition to microglia, a role for P2X7 in other non‐neuronal cells such as astrocytes has
also been suggested in ALS. Although evidence for increased P2X7 expression in astrocytes
in ALS is lacking, P2X7 astrocyte expression, which is normally low in healthy brains, is up‐
regulated following injury or in response to pro‐inflammatory events (Franke et al., 2004;
Narcisse et al., 2005). Co‐cultures of ATP or BzATP‐treated rat non‐transgenic astrocytes
with non‐transgenic neurons induced neurotoxicity, and this process could be impaired by
pre‐incubation of astrocytes with BBG, the ATP‐degrading enzyme apyrase or modulators of
oxidative and nitrative stress (Gandelman et al., 2010). In a similar manner, the
neurotoxicity of rat SOD1G93A astrocytes towards co‐cultured non‐transgenic neurons could
be impaired by pre‐incubation of astrocytes with BBG or with the ATP‐degrading enzyme
apyrase, suggesting that P2X7 was basally activated in these SOD1G93A astrocytes
(Gandelman et al., 2010). As with the studies of D'Ambrosi et al. (2009) and Parisi et al.
(2016) with SOD1G93A microglia, the neurotoxic signal from SOD1G93A astrocytes was not
identified. It was also not determined whether this neurotoxic signal was due to the release
of a soluble factor or due to cell‐to‐cell contact.
1.5.3 P2X7 expression in motor neurons in ALS
Recently, a potential role for P2X7 activation on motor neurons in directly inducing cell
death was reported. Cultured motor neurons isolated from embryonic non‐transgenic rat
spinal cord were found to express P2X7, and stimulation of these cells with low
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concentrations of ATP or BzATP led to death via a peroxynitrite/FAS‐dependent pathway
(Gandelman et al., 2013). Three P2X7 antagonists, including BBG, were preventative,
suggesting that these effects were mediated by P2X7 activation. Of note, higher
concentrations of ATP were found to be protective, and the authors suggest that this was
due to the breakdown of ATP to adenosine and subsequent activation of adenosine
receptors. In a parallel study, nitrated 90‐kDa heat‐shock protein induced motor neuron
death, by P2X7‐dependent activation of the FAS pathway (Franco et al., 2013). Collectively,
these studies suggest a direct role for P2X7 in mediating motor neuron death through
oxidative stress‐related pathways. While neither of these studies investigated motor
neurons from ALS models, they do suggest that direct activation of P2X7 on motor neurons,
in concert with P2X7 activation on glial cells, may contribute to neurodegeneration in ALS. It
will be interesting in future to investigate whether P2X7 induces death via a similar pathway
in motor neurons isolated from SOD1 transgenic rodents, and the contribution of this to the
overall cellular degeneration observed in ALS.
1.5.4 P2X7 expression in vivo in ALS
While the majority of in vitro work suggests that P2X7 activation on CNS cells is deleterious
in ALS, current in vivo evidence suggests a more complex dual role for this receptor. This is
highlighted by one study, in which disease onset and progression was investigated in
SOD1G93A mice encoding P2X7 and in SOD1G93A mice lacking the P2RX7 gene. In SOD1G93A
mice lacking the P2RX7 gene, females, but not males, had an extended lifespan compared to
SOD1G93A mice encoding P2X7 (Apolloni et al., 2013a). However, these double transgenic
mice also had anticipated onset and accelerated disease progression, characterised by
increased astrocytosis, microgliosis and motor neuron loss, and the induction of pro‐
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inflammatory markers such as NADPH oxidase 2, compared to mice carrying the SOD1G93A
transgene alone. This suggests that constitutive deletion of P2X7 is detrimental in ALS, but
that this receptor may be neuroprotective during the early stages of the disease. Consistent
with this, pharmacological inhibition of P2X7 with BBG at late pre‐onset or onset of clinical
symptoms, but not at asymptomatic stages, improved disease outcomes in SOD1G93A mice
(Apolloni et al., 2014; Cervetto et al., 2013).
It is possible that this potential dual role of P2X7 corresponds to the timing at which
microglia switch from an M2‐like neuroprotective to an M1‐like neurotoxic phenotype (see
Section 1.3.6.3). In this way, P2X7 may become an important modulator of microglial‐
mediated toxicity. However, if so, it is unclear whether P2X7 may be causative or a
consequence of this phenotypic switch, or how ALS‐related genes such as SOD1 may be
involved. Recently, high affinity radio‐labelled P2X7 antagonists have been synthesised as a
means of imaging neuroinflammation by positron emission tomography (Gao et al., 2015;
Janssen et al., 2014; Lord et al., 2015). This may shed light on the timing at which P2X7
becomes neurotoxic.
1.5.5 Overview
It is becoming increasingly evident that purinergic signalling plays an instrumental role in
neurodegeneration in ALS. Modification of the purinergic signalling network in microglia,
astrocytes and motor neurons due to expression of mutant SOD1 appears to contribute to
the ALS phenotype. It is hypothesised that ATP and SOD1 released from dying motor
neurons in the early stages of the disease activate P2X7 on surrounding microglia, astrocytes
and motor neurons, which may be more susceptible to these signals due to endogenous
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1.6

Summary and research aims

ALS affects thousands of people world‐wide. With no effective therapies currently available,
it is clear that the development of new therapeutics capable of slowing disease progression,
and reducing disability and mortality are vital. Recent research has implicated purinergic
signalling, in particular the P2X7 receptor, in the progression of ALS. However, additional
research is clearly required to further confirm this involvement, using both in vitro and in
vivo systems, as well as to expand this research to incorporate different SOD1 mutations
and other fALS genes. This will be important in determining whether P2X7 represents a
viable therapeutic target for the treatment of this devastating disease.
This project aims to further investigate the roles of P2X7 in ALS, through utilisation of the
microglial cell line, EOC13, the motor neuron‐like cell line, NSC‐34, and human SOD1G93A
transgenic mice. In addition, given that dogs naturally suffer from an ALS‐like disease
(Nardone et al., 2016), canine P2X7 will be investigated to allow for future investigations
into the role of P2X7 in this disease. Specifically, this project aims to:
1. Examine P2X7‐mediated responses in murine EOC13 microglia, in particular, to
investigate the role of P2X7 in mediating ROS formation, NO formation, proliferation,
phagocytosis and cell death;
2. Examine the therapeutic efficacy of the P2X7 antagonist BBG, beginning at pre‐onset
of clinical disease, on disease progression in SOD1G93A transgenic mice;
3. Determine whether P2X7 is involved in SOD1 release from murine NSC‐34 motor
neurons and, if so, the mechanisms involved, the characteristics of the material
released, and whether the released SOD1 is internalised by NSC‐34 motor neurons or
EOC13 microglia and;
4. Examine the functional effects of recently identified SNPs in the canine P2RX7 gene,
following the heterologous expression of canine P2X7 mutants in HEK‐293 cells.
These aims will be addressed in Chapters 2‐5, respectively.
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2.1

Background

2.1.1 Chronic microglial activation and neurodegeneration
Microglia have important roles in the maintenance of a healthy central nervous system
(CNS) (Hanisch and Kettenmann, 2007). However, chronic activation of these cells is
implicated in the pathogenesis and progression of a number of neurodegenerative diseases,
including amyotrophic lateral sclerosis (ALS) (Monif et al., 2010). When activated, microglia
are capable of undergoing proliferation, attaining phagocytic activity and producing a
number of inflammatory or cytotoxic factors, including reactive oxygen species (ROS), nitric
oxide (NO) and pro‐inflammatory cytokines (Hanisch and Kettenmann, 2007). In this way,
prolonged or excessive microglial activation can be highly toxic to neurons.
2.1.2 Role for P2X7 in mediating microglial responses
While the mechanisms behind chronic microglial activation in ALS are unknown, evidence
suggests a role for P2X7 (see Section 1.5.1). Microglia are well known to express functional
P2X7 (Monif et al., 2010). Activation of P2X7 by extracellular ATP leads to the passage of
small cations across the plasma membrane, including Ca2+ and K+, as well as organic cations,
such as the fluorescent dyes ethidium+ and YO‐PRO‐12+ (Jarvis and Khakh, 2009). P2X7
activation on microglia has been reported to induce a number of downstream signalling
events, including the formation of reactive oxygen and nitrogen species (Hewinson and
Mackenzie, 2007), and either cell proliferation or death (Adinolfi et al., 2005b; Monif et al.,
2010). In murine macrophages, P2X7‐induced cell death is mediated by ROS formation
(Noguchi et al., 2008), although this has yet to be reported in microglia. Conversely, in the
absence of ATP (and serum) P2X7 has been implicated as a scavenger receptor in monocytes
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and macrophages to facilitate phagocytosis (Wiley and Gu, 2012). In microglia, P2X7
activation attenuates phagocytosis (Fang et al., 2009), which may suggest that P2X7 has a
similar role in phagocytosis in these cells. However, whether P2X7 acts as a scavenger
receptor in the absence of ATP in microglia has not been reported.
2.1.3 Aims
Recent work has identified the presence of P2X7 on the murine EOC13 microglia cell line,
which, following activation by extracellular ATP, mediates organic cation uptake, ROS
formation and cell death (Bartlett, 2011). Given the potential role for P2X7 in mediating
inappropriate microglial responses in ALS, and following on from this previous study, the
study outlined in this chapter aimed to further investigate P2X7‐mediated responses in
EOC13 cells. In particular, this study aimed to further investigate P2X7‐mediated ROS
formation and cell death, and determine whether ROS formation is involved in P2X7‐
mediated cell death in this cell line. In addition, this study aimed to investigate whether
P2X7 mediates NO formation, proliferation and phagocytosis in EOC13 microglia. Lastly, this
study aimed to confirm P2X7 expression in primary murine microglia, to allow for future
investigation of murine P2X7 in vivo.
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2.2

Methods

2.2.1 Reagents and antibodies
DMEM, DMEM/F12 and OPTI‐MEM reduced serum medium, GlutaMAX, Penicillin‐
Streptomycin, Lipofectamine 2000, normal horse serum (NHS), 0.05% trypsin, 0.25% trypsin‐
EDTA, YO‐PRO‐1 iodide solution, 2’,7’‐dichlorodihydrofluorescein diacetate (H2DCFDA), 2’,7’‐
difluorofluorescein diacetate (DAF‐FM DA) and SuperSignal West Pico Chemiluminescent
Substrate were from ThermoFisher Scientific (Waltham, MA). Foetal bovine serum (FBS)
(heat‐inactivated before use) was from Bovogen Biologicals (East Keilor, Australia). Papain
was from Worthington Biochemical Corporation (Lakewood, NJ) and 13 mm glass coverslips
were from ProSciTech (Kirwan, Australia). The restriction endonucleases HindIII and XbaI
were from New England Biolabs (Whitby, Canada). ATP, BzATP, ethidium bromide, dimethyl
sulfoxide (DMSO), poly‐D‐lysine (PDL) hydrobromide, glycerol gelatin, paraformaldehyde
(PFA), ampicillin sodium salt, 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide
(MTT) and casein (heat‐denatured before use; HDC) were from Sigma‐Aldrich (St. Louis,
MO). The P2X7 antagonist AZ10606120 was from Tocris Bioscience (Ellisville, MO). Protease
inhibitor cocktail tablets (complete, Mini, EDTA‐free) and Annexin‐V‐Fluorescein were from
Roche Diagnostics (Penzberg, Germany). Diploma full‐cream milk powder was from Fonterra
(Mount Waverley, Australia). The viability dye 7‐aminoactinomycin D (7AAD) and the ROS
scavenger N‐acetyl‐L‐cysteine (NAC) were from Enzo Life Sciences (Plymouth Meeting, PA).
The broad‐spectrum ROS inhibitor diphenyleneiodonium (DPI) was from Cayman Chemical
(Ann Arbor, MI). Phenyl‐methyl‐sulfonyl‐fluoride (PMSF), n‐dodecyl β‐D‐maltoside, ethylene
glycol tetraacetic acid (EGTA) and bovine serum albumin (BSA) were from Amresco (Solon,
OH). Fluoresbrite 1.00 μm yellow green (YG) carboxylate microspheres were from
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Polysciences (Warrington, PA). All other reagent grade chemicals and salts were from Sigma‐
Aldrich or Amresco. The antibodies (Abs) used and their respective companies are listed in
Table 2.1.
Table 2.1 Antibodies used in Chapter 2 to investigate P2X7 expression and function in murine microglia

Antibody target1

Conjugate

CD11b
IgG2b isotype control
Rat IgG
P2X7, extracellular epitope
P2X7, middle region epitope
P2X7, middle region epitope
P2X7, N‐terminal epitope
Rabbit IgG

‐
‐
DyLight 488
‐
‐
‐
‐
Peroxidase

Host species1
(clonality)
Rat (mAb [M1/70])
Rat (mAb [eB149])
Donkey (pAb)
Rabbit (pAb)
Rabbit (pAb)
Rabbit (pAb)
Rabbit (pAb)
Goat (pAb)

Company2
(catalogue number)
Abcam (ab8878)
eBioscience (14‐4031)
Jackson (712‐485‐150)
Alomone Labs (APR‐008)
Aviva (ARP35517)
Aviva (ARP35112)
Aviva (ARP35518)
Rockland (611‐103‐122)

1

Ig, immunoglobulin; mAb, monoclonal antibody; pAb, polyclonal antibody. 2Abcam, Cambridge, United
Kingdom; Alomone Labs, Jerusalem, Israel; Aviva Systems Biology, San Diego, CA; eBioscience, San Diego, CA;
Jackson ImmunoResearch, West Grove, PA; Rockland Immunochemicals, Gilbertsville, PA.

2.2.2 Cell lines
Human embryonic kidney (HEK)‐293 and murine microglial EOC13 cells were from the
American Type Culture Collection (Manassas, VA). Murine lymphoblast LADMAC cells,
originally obtained from the American Type Culture Collection, were kindly provided by Iain
Campbell (University of Sydney, Sydney, Australia). HEK‐293 cells were maintained in
DMEM/F12 medium supplemented with 10% FBS, 2 mM GlutaMAX, 100 U/mL penicillin,
and 100 μg/mL streptomycin (complete culture medium) at 37°C/5% CO2. Murine microglial
EOC13 cells were maintained in DMEM/F12 supplemented with 10% FBS, 2 mM GlutaMAX,
and 20% LADMAC conditioned medium (complete DMEM medium) at 37°C/5% CO2.
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2.2.3

ROS formation assay

EOC13 cells in complete DMEM medium were plated into 24‐well plates (5 × 104 cells/
0.5 mL/ well) and incubated at 37°C/5% CO2 overnight. Cells were then incubated with
complete DMEM or NaCl medium (140 mM NaCl, 5 mM NaOH, 5 mM KCl, 10 mM HEPES,
and 5 mM glucose, pH 7.4) containing 5 or 10 μM H2DCFDA (0.5 mL/well; as indicated) at
37°C/5% CO2, protected from light for 30 min. The medium was removed, and cells were
further incubated in complete DMEM or NaCl medium (containing 1 mM CaCl2) in the
absence or presence of 2 mM ATP at 37°C/5% CO2 for 15 min. Incubations were stopped by
the addition of an equal volume of ice‐cold MgCl2 medium. Cells were harvested using
0.05% trypsin (5 min, 37°C) and were washed once with NaCl medium. Events were
collected using a LSR II flow cytometer (BD Biosciences, San Diego, CA) (excitation 488 nm,
emission collected at 515/20 nm) and the mean fluorescence intensity (MFI) of relative
dichlorofluorescein (DCF) determined using FlowJo software (Tree Star, Ashland, OR).
In some experiments, ATP‐induced ROS formation was assessed in KCl medium (150 mM
KCl, 5 mM glucose, and 10 mM HEPES, pH 7.4), in NaCl medium in the absence of 1 mM
CaCl2 or in NaCl medium in the presence of 100 μM EGTA. As free Ca2+ lowers the
concentration of ATP4− (North, 2002), cells incubated in the absence of 1 mM Ca2+ were
incubated with 1.4 mM ATP to provide equimolar ATP4− concentrations (575 μM), as
calculated using the Bound and Determined Program (Marks and Maxfield, 1991). In other
experiments, cells were pre‐incubated in the absence or presence of AZ10606120, NAC, or
DPI (as indicated) for 15, 30, and 30 min, respectively, prior to ATP addition. Before
harvesting, cells were visualised by differential interference contrast (DIC) imaging using an
Eclipse TE2000 inverted microscope (Nikon, Tokyo, Japan) to examine cell morphology. DIC
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images were captured using Image‐Pro AMS (Version 6.1) (Media Cybernetics, Rockville,
MD).
2.2.4 Fluorescent cation dye uptake assay
P2X7‐induced pore formation was assessed using a cation uptake assay. Cells were
harvested by mechanical scraping, washed in NaCl medium (300 x g for 5 min), resuspended
in NaCl medium, and equilibrated at 37°C for 5 min (1 × 105 cells/ 1 mL/ tube). For plate‐
based assays, cells in complete DMEM medium were plated into 24‐well plates (5 × 104
cells/ 0.5 mL/ well) and incubated at 37°C/5% CO2 overnight. Adherent cells were then
washed in NaCl medium, and equilibrated in NaCl medium at 37°C for 15 min. Suspended or
adherent cells were then incubated with 25 μM ethidium+ (or 1 μM YO‐PRO‐12+ where
indicated) in the absence or presence of the P2X7 agonists ATP or BzATP (as indicated) for
5 min. In some experiments, ATP‐induced cation uptake was assessed with cells suspended
in KCl medium, or in NaCl medium containing 1 mM CaCl2 or 100 μM EGTA. In other
experiments, cells were pre‐incubated in the absence or presence of the P2X7 antagonist
AZ10606120 or the ROS scavenger NAC (as indicated) for 15 and 30 min, respectively, prior
to cation dye and ATP addition. Incubations with nucleotides were stopped by the addition
of an equal volume of ice‐cold NaCl medium containing 20 mM MgCl2 (MgCl2 medium). This
was followed by centrifugation (300 x g for 5 min) for suspended cells. For adherent cells,
cells were harvested using 0.05% or 0.25% trypsin (5 min, 37°C), prior to centrifugation.
Cells were washed once with NaCl medium and events collected using a LSR II flow
cytometer (BD Biosciences) (excitation 488 nm, emission collected with 575/26 and 515/20
band‐pass filters for ethidium+ and YO‐PRO‐12+, respectively). The MFI of relative cation
uptake was determined using FlowJo software.
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2.2.5 Cell death assay
EOC13 cells in complete DMEM medium were plated into 24‐well plates (5 × 104 cells/
0.5 mL/ well) and incubated at 37°C/5% CO2 overnight. Cells were then incubated with filter
sterile 2 mM ATP at 37°C/5% CO2 for 24 h. In some experiments, cells were pre‐incubated in
the absence or presence of filter sterile 40 mM NAC for 30 min prior to ATP addition. In
other experiments, cells were pre‐incubated in the absence or presence of 40 mM NAC for
90 min, with 2 mM ATP added in the final 15‐60 min, and then the medium replaced and
cells incubated at 37°C/5% CO2 for a further 24 h. Following the 24 h incubations, cells were
harvested from wells using 0.05% trypsin (5 min, 37°C) and washed once with Annexin‐V
binding medium (NaCl medium containing 5 mM CaCl2). Cells were then incubated with
Annexin‐V binding medium containing Annexin‐V‐Fluorescein and 7AAD at room
temperature protected from light for 15 min. Events were collected using a LSR II flow
cytometer (BD Biosciences) (excitation 488 nm, emission collected with 515/20 and 695/40
band‐pass filters for Annexin‐V‐Fluorescein and 7AAD, respectively). The percentage of
Annexin‐V+/7AAD−, Annexin‐V−/7AAD+, and Annexin‐V+/7AAD+ cells was determined using
quadrant markers in FlowJo software. In some experiments, cells prior to harvesting were
visualised by DIC imaging to examine cell morphology, and DIC images captured as outlined
in Section 2.2.3.
2.2.6 NO formation assay
EOC13 cells in complete DMEM medium were plated into 24‐well plates (5 × 104 cells/
0.5 mL/ well) and incubated at 37°C/5% CO2 overnight. Cells were then incubated with NaCl
medium containing 10 μM DAF‐FM DA (0.5 mL/well) at 37°C/5% CO2, protected from light
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for 30 min. The medium was removed, and the cells were washed once. Cells were then pre‐
incubated with NaCl medium in the absence or presence of 10 μM AZ10606120 at 37°C/5%
CO2 for 15 min. Following this, cells were further incubated in the absence or presence of
1.4 mM ATP for 15 min. Incubations were stopped by the addition of an equal volume of ice‐
cold MgCl2 medium. Cells were harvested using 0.05% trypsin (5 min, 37°C) and were
washed once with NaCl medium. Events were collected using a LSR II flow cytometer (BD
Biosciences) (excitation 488 nm, emission collected at 515/20 nm) and the MFI of relative
benzotriazole derivative determined using FlowJo software.
2.2.7 Cell proliferation assay
EOC13 cells in complete DMEM medium were plated into 96‐well plates (1 × 103 ‐ 5 x 105
cells/ 0.1 mL/ well) and incubated at 37°C/5% CO2 overnight to allow time to adhere. The
following day, cells were washed with phosphate‐buffered saline (PBS) and the medium
replaced with DMEM/F12 supplemented with 2 mM GlutaMAX in the absence or presence
of 10 μM AZ10606120 and absence or presence of 10% FBS and/or 20% LADMAC
conditioned medium as a source of colony‐stimulating factor‐1 (CSF‐1) (as indicated). Cells
were then incubated at 37°C/5% CO2 for an additional 24‐72 h. After incubations, MTT
assays were performed to determine the relative number of metabolically active cells.
Briefly, MTT (5 mg/mL in water, 10 μL/ well) was added to wells and incubated at 37°C
protected from light for 4 h. HCl (0.01 M) containing 10% SDS (solubilisation solution) was
then added to wells (100 μL) and plates incubated at 37°C/5% CO2 overnight to dissolve the
produced formazan. The following day, absorbance values of wells were recorded with a
SpectraMax Plus 384 Microplate Reader and SoftMax Pro software (Molecular Devices,
Silicon Valley, CA) (550‐690 nm).
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2.2.8 Phagocytosis assay
Cells in complete DMEM medium were plated into 12‐well plates (9.5 × 104 cells/ 1 mL/
well) and incubated at 37°C/5% CO2 overnight. Cells were then washed in NaCl medium, and
equilibrated in ice‐cold or warmed NaCl medium containing 0.1 mM CaCl2 at 4°C on ice or at
37°C for 15 min. Cells were incubated in the absence or presence of YG beads (5 μL/mL) for
5 min. In some experiments, cells were pre‐incubated in the absence or presence of the
P2X7 agonists ATP or BzATP (as indicated) for 15 min, prior to bead addition. Incubations
were stopped by the addition of an equal volume of ice‐cold MgCl2 medium. Cells were
washed with ice‐cold NaCl medium and then harvested using 0.05% trypsin (5 min, 37°C),
and centrifugation (300 x g for 5 min). Cells were washed once with ice‐cold NaCl medium
and then events were collected using a LSR II flow cytometer (BD Biosciences) (excitation
488 nm, emission collected with 515/20 band‐pass filter). The MFI of YG beads was
determined using FlowJo software.
2.2.9 Primary microglia
2.2.9.1 Cultures
Mixed glial cultures were prepared with the approval (AE11/29) of the Animal Ethics
Committee of the University of Wollongong (Wollongong, Australia), as previously described
(McCarthy and de Vellis, 1980; Milner and Ffrench‐Constant, 1994). Briefly, postnatal
forebrain (days 1‐2) from 3‐6 C57Bl/6J mice were stripped of meninges, finely chopped, and
dissociated in papain at 37°C for 1 h. Cells were then washed with DMEM medium
supplemented with 10% FBS, 100 U/mL penicillin and 10 μg/mL streptomycin (complete
medium). Cells were cultured in complete medium for 7‐10 days on PDL‐coated culture
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flasks at 37°C/5% CO2. After establishment of the astrocyte monolayer, flasks were shaken
at 37°C for 3 h to detach microglia and obtain enriched microglia cultures.
2.2.9.2 Cell morphology
Detached microglia were plated into 24‐well plates (1.5 mL/ well), and incubated at 37°C/5%
CO2 overnight to allow time to adhere. The following day, cell morphology was examined
using an Eclipse TE2000 inverted microscope (Nikon). DIC images were captured using
Image‐Pro AMS (Version 6.1) (Media Cybernetics).
2.2.9.3 Purity
Detached microglia were plated into 24‐well PDL‐coated plates containing sterile 13 mm
glass coverslips (1.5 mL/ well), and incubated at 37°C/5% CO2 overnight to allow time to
adhere. The following day, cells were fixed with 4% PFA in PBS at room temperature for
15 min and then washed three times with PBS over 10 min. Cells were incubated with
permeabilisation solution (PBS containing 0.1% DMSO, 2% NHS, and 0.1% Triton X‐100) at
room temperature for 10 min and washed three times with PBS. Cells were then blocked
with 20% NHS in PBS at room temperature for 20 min. Cells were incubated at 4°C overnight
with either rat anti‐CD11b or rat IgG2b isotype control monoclonal antibody (mAb) (1.3 μg/
250 μL/ well) in PBS containing 1% BSA, 0.2% NHS and 0.05% NaN3 to assess the proportion
of CD11b+ cells. The next day, cells were washed as above, and incubated for 1 h at room
temperature with DyLight 488‐conjugated donkey anti‐rat IgG Ab (1 μg/ 250 μL) in PBS
containing 0.2% NHS. Cells were washed as above and then the coverslips mounted onto
slides with 50% (v/v) glycerol gelatin in PBS. Coverslips were sealed with nail varnish. Cells
were visualised using a DM IBRE inverted microscope and TCS SP confocal imaging system
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(Leica, Mannheim, Germany) (excitation 488 nm, emission collected at 520‐550 nm). Images
were captured using Leica Confocal Software.
2.2.9.4 Cell viability
To determine the harvest method which would result in the highest percentage of viable
cells for flow cytometric analyses, detached microglia were plated in uncoated or PDL‐
coated 24‐well plates (1.5 mL/ well), and incubated at 37°C/5% CO2 overnight to allow time
to adhere. The following day, cells were washed, harvested as indicated and analysed by
flow cytometry using a LSR II flow cytometer (BD Biosciences). Cell viability was assessed
using FlowJo software as the percentage of cells gated by forward and side scatter.
2.2.10 Plasmid purification
pcDNA3.1 expression vectors containing rat P2X4, mouse P2X7 and human P2X7 cDNAs
were kindly provided by Leanne Stokes (University of Sydney, Sydney, Australia). Chemically
competent JM109 Escherichia coli cells (Promega, Madison, WI) were transformed with the
P2X‐containing plasmids using heat shock (42°C), as per the manufacturer’s instructions.
Transformed cells were then spread onto lysogeny broth (LB) agar plates containing
100 μg/mL ampicillin, and incubated at 37°C/5% CO2 overnight. The next day, overnight
starter cultures derived from single transformed bacterial colonies were prepared in sterile
LB containing 100 μg/mL ampicillin. Plasmid DNA was then purified from bacterial cells using
the Wizard Plus SV Miniprep DNA Purification System (Promega), as per the manufacturer’s
instructions. The concentration and quality (260/280 ratio) of DNA within samples was
assessed using a NanoDrop 2000c dual‐mode UV‐Vis Spectrophotometer (ThermoFisher
Scientific). To confirm purification of plasmid DNA, the samples were digested with HindIII
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and Xba1, enzymes with single corresponding restriction sites in the expected plasmids
(determined using EnzymeX V3.1; Nucleobytes, Aalsmeer, The Netherlands). Digestions
were carried out at 37°C for 1 h. Digested products (0.5 μg/well) were separated on a 1%
agarose gel in Tris‐acetate‐EDTA (TAE) buffer (40 mM Tris, 20 mM acetic acid, and 1 mM
ethylenediaminetetraacetic acid disodium salt) and visualised with ethidium bromide
staining.
2.2.11 Cell transfections
HEK‐293 cells in complete culture medium (0.25 ‐ 0.5 x 106 cells/mL) were incubated
overnight at 37°C/5% CO2. Cells were then incubated in complete culture medium
containing 2 μg plasmid DNA and Lipofectamine 2000 (diluted in OPTI‐MEM Reduced Serum
Medium) for 24 h at 37°C/5% CO2. The medium was then replaced, and the cells incubated
for a further 24 h at 37°C/5% CO2. To confirm transfection, cells were harvested by
mechanical scraping and ATP‐induced ethidium+ uptake into suspended cells assessed (as
outlined in Section 2.2.4).
2.2.12 Immunoblotting
Cells were washed three times with PBS (300 × g for 5 min) and lysed (1 x 106 ‐ 1 x 107
cells/mL) over 60 min in ice‐cold lysis buffer (50 mM BisTris, 750 mM 6‐aminohexanoic acid,
1% n‐dodecyl β‐D‐maltoside, 1 mM PMSF, and protease inhibitor cocktail, pH 7.0). Cells
were sheared by passing ten times through a 21 G needle and stored at −20°C un l needed.
Cells were then thawed and cleared (16,000 × g at 4°C for 10 min). Supernatants (50 or
20 μg protein/lane) were separated under reducing conditions (5% β‐mercaptoethanol)
using 4‐20% Tris‐Glycine (NuSep, Bogart, GA) or Any kD Mini‐PROTEAN TGX Stain‐Free Gels
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(Bio‐Rad, Hercules, CA) for HEK‐293 or microglia cell lysates, respectively. Before
immunoblotting, equal protein loading was confirmed by visualising stain‐free gels with a
Bio‐Rad Criterion Stain Free Imager and Image Lab software. Proteins were then transferred
to nitrocellulose membranes using a Trans‐Blot Turbo Transfer System (all Bio‐Rad). For
HEK‐293, membranes were blocked at 4°C overnight with Tris‐buffered saline (250 mM NaCl
and 50 mM Tris, pH 7.5) containing 0.2% Tween‐20 and 5% milk powder. The following day,
nitrocellulose membranes were incubated at room temperature for 2 h with anti‐P2X7 Abs
(1:500) in Tris‐buffered saline containing 0.2% Tween‐20 and 5% milk powder. For microglia,
membranes were blocked at room temperature for 1 h with HDC, and then incubated at 4°C
overnight with an anti‐P2X7 pAb in HDC. Membranes were then washed three times over
30 min with Tris‐buffered saline containing 0.2% Tween‐20 or PBS containing 0.1% Triton X‐
100 for HEK‐293 or microglia membranes, respectively. Membranes were incubated at room
temperature for 1 h with peroxidise‐conjugated anti‐IgG Ab (1:1000) in Tris‐buffered saline
containing 0.2% Tween‐20 and 5% milk powder or HDC for HEK‐293 or microglia
membranes, respectively, and then washed as above. P2X7 was visualised using
chemiluminescent substrate and Amersham Hyperfilm ECL (GE Healthcare, Little Chalfont,
Buckinghamshire, UK). Films were processed using GBX Developer and Replenisher, and GBX
Fixer and Replenisher as per the manufacturer’s instructions (Kodak Australasia,
Collingwood, Australia). Images of films were collected using a GS‐800 Calibrated
Densitometer (Bio‐Rad).
2.2.13 Data presentation and statistical analyses
Data is presented as the mean ± SD. Differences between multiple treatments were
compared by ANOVA paired with Tukey’s HSD post‐tests. For single comparisons, unpaired
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student’s t‐tests were performed. The software package Prism 5 for Windows (Version 5.01)
(GraphPad Software, San Diego, CA) was used for these statistical analyses, with differences
considered significant for P < 0.05. Concentration response curves were fitted using Prism 5
and assuming a variable slope, with normalised response curves selected to obtain the best
fit. Estimates of half maximal effective concentration (EC50) values were obtained from
individual fits of these plots.
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2.3

Results

2.3.1 P2X7 activation induces ROS formation in murine EOC13 microglia
2.3.1.1 Optimising the ROS assay
P2X7 activation is well known to result in ROS formation in a number of cell types (Kim et
al., 2007; Parvathenani et al., 2003). Using the ROS‐sensitive probe carboxy‐H2DCFDA in
culture medium, our group has shown that ATP induces ROS formation in EOC13 cells
(Bartlett, 2011). Since P2X7 is a ligand‐gated cation channel (Jarvis and Khakh, 2009), the
possible roles for cation fluxes in this process were next investigated. To investigate cation
fluxes, the ROS formation assay, previously carried out in culture medium (Bartlett, 2011),
was first assessed in NaCl medium. As extracellular Ca2+ has been reported to be important
for P2X7‐induced ROS formation in a number of cell types (Fontanils et al., 2010; Kim et al.,
2007; Suh et al., 2001), and the original studies were conducted in culture medium which
contains 1 mM Ca2+ (Bartlett, 2011), assays with NaCl medium were initially conducted in
the presence of 1 mM Ca2+.
In both culture and NaCl medium, 2 mM ATP induced ROS formation in EOC13 cells loaded
with 5 μM DCF, with greater ATP‐induced ROS formation detected in cells in NaCl medium
compared to culture medium (Figure 2.1a). To see if a higher signal could be obtained in
NaCl medium, ATP‐induced ROS formation was next investigated in cells loaded with 5 or
10 μM DCF. ATP‐induced ROS formation was detected in cells loaded with 5 or 10 μM DCF,
with significantly greater ATP‐induced ROS formation detected in 10 μM DCF‐loaded cells
(Figure 2.1b). However, lower signals were detected compared to the pilot experiment
(Figure 2.1a), indicating inter‐assay variability.
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Figure 2.1 P2X7 activation induces ROS formation in EOC13 microglia. Adherent EOC13 cells in (a) DMEM/F12
medium, (a‐c) NaCl medium containing 1 mM Ca2+ or (d) NaCl medium containing 1 mM Ca2+ (pre‐incubated in
the absence (control) or presence of 10 μM AZ10606120 at 37°C for 15 min) were loaded with (a‐c) 5 or (b‐d)
10 μM DCF for 30 min. (a‐d) Cells were then incubated in the absence (basal) or presence of 2 mM ATP at 37°C
for 15 min. Incubations were stopped by the addition of MgCl2 medium. (a‐d) Cells were firstly gated on
forward (FSC) and side (SSC) scatter to exclude debris and doublets, and then (a,b,d) the mean fluorescence
intensities (MFI) of DCF (ROS formation) determined by flow cytometry. Results shown as (a) n = 1, (b,d) means
± SD, n = 3; ∗∗∗P < 0.001 compared to corresponding basal; †††P < 0.001 compared to corresponding ATP or (c)
dot plots showing the percentage of cells within the FSC and SSC gates (single viable cells) of the total number
of events.

DCF at higher concentrations has been found to affect the viability of some cell types (Bin
Wang and Ronald Sluyter, personal communication). Thus, the viability of EOC13 cells
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following incubation with 10 μM DCF was assessed by flow cytometry. The percentage of
viable cells, gated by forward and side scatter, was similar between cells treated with 5 or
10 μM DCF (Figure 2.1c), consistent with no change in toxicity. Thus, cells were loaded with
10 μM DCF in future ROS experiments.
To confirm that the observed 2 mM ATP‐induced ROS formation in EOC13 cells in Ca2+‐
containing NaCl medium was mediated by P2X7, cells were pre‐incubated with the P2X7
antagonist AZ10606120. Again, incubation with 2 mM ATP induced significant ROS formation
in EOC13 cells compared to cells incubated in the absence of ATP (Figure 2.1d). Pre‐
incubation of cells with 10 μM AZ10606120 resulted in complete inhibition of ATP‐induced
ROS formation, confirming that this process is mediated by P2X7 activation. Furthermore,
AZ10606120 did not significantly alter the basal ROS formation (Figure 2.1d) or the
percentage of viable cells, as assessed by forward and side scatter (control basal, 59 ± 4%;
AZ10606120 basal, 59 ± 3%; control ATP, 54 ± 2%; AZ10606120 ATP, 57 ± 2; P > 0.05, n = 3).
2.3.1.2 Calcium influx is not required for P2X7‐mediated ROS formation in EOC13 microglia
To determine if Ca2+ influx is required for P2X7‐mediated ROS formation in EOC13 cells, ATP‐
induced ROS formation in the absence and presence of Ca2+ was investigated. For this
comparison, equivalent amounts of ATP4− (575 μM), the presumed agonist of P2X7, were
used by adding 1.4 or 2 mM ATP to NaCl medium nominally free of Ca2+ or containing 1 mM
Ca2+, respectively. ATP induced significant ROS formation in both the absence and presence
of 1 mM Ca2+ compared to corresponding cells in the absence of ATP (Figure 2.2a). ATP‐
induced ROS formation was significantly higher in cells incubated in the absence of Ca2+
compared to those incubated in the presence of Ca2+. In contrast, ATP‐induced ethidium+
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uptake (P2X7 function) was similar in cells incubated in the absence or presence of Ca2+
(Figure 2.2a), indicating that the differences in ATP‐induced ROS formation were not due to
altered P2X7 function.

Figure 2.2 Calcium influx is not required for P2X7‐mediated ROS formation in EOC13 microglia. (Left panels)
Adherent DCF‐loaded EOC13 cells or (right panels) suspended EOC13 cells in (a) NaCl medium in the absence
(control) or presence of 1 mM Ca2+, (b) NaCl medium in the absence (control) or presence of 100 μM EGTA, or
(c) NaCl medium (pre‐incubated in the absence (control) or presence of 10 μM AZ10606120 at 37°C for 15 min)
were (a–c) incubated in the absence (basal) or presence of 575 μM ATP4− (2 or 1.4 mM ATP as explained in
Section 2.2.3) at 37°C for (left panels) 15 min or (right panels) 5 min in the presence of 25 μM ethidium+. (a–c)
Incubations were stopped by the addition of MgCl2 medium. Mean fluorescence intensities (MFI) of (left
panels) DCF (ROS formation) or (right panels) ethidium+ uptake (pore formation) were determined by flow
cytometry and results shown as means ± SD, n = 3; ∗∗∗P < 0.001 or ∗∗P < 0.01 compared to corresponding basal;
†††
P < 0.001 compared to corresponding ATP.
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NaCl medium contains nominal amounts of Ca2+. Thus, to further exclude a role for Ca2+ in
P2X7‐mediated ROS formation in EOC13 cells, ATP‐induced ROS formation was investigated
in the absence and presence of the Ca2+ chelator EGTA. Incubation with 1.4 mM ATP
induced significant but similar amounts of ROS formation in both the absence and presence
of 100 μM EGTA compared to similarly treated cells in the absence of ATP (Figure 2.2b).
Again, ATP‐induced ethidium+ uptake was similar in cells incubated in the absence or
presence of EGTA (Figure 2.2b).
Finally, to confirm that the ATP‐induced ROS formation in the absence of Ca2+ was mediated
by P2X7, cells were pre‐incubated with AZ10606120. Again, incubation with 1.4 mM ATP
induced significant ROS formation in EOC13 cells compared to cells incubated in the absence
of ATP, with pre‐incubation of cells with 10 μM AZ10606120 resulting in complete inhibition
of ATP‐induced ROS formation (Figure 2.2c).
2.3.1.3 Potassium efflux is not required for P2X7‐mediated ROS formation in EOC13
microglia
Next, the role of K+ in P2X7‐induced ROS formation in EOC13 cells was investigated. Both
ROS and K+ efflux have been reported to be involved in interleukin (IL)‐1β release from
monocytes, although whether these downstream processes are linked is controversial
(Muñoz‐Planillo et al., 2013; Yaron et al., 2015). Thus, to determine if K+ efflux is involved in
P2X7‐mediated ROS formation in EOC13 cells, ATP‐induced ROS formation in cells incubated
in either NaCl or KCl medium was compared, the latter of which prevents the loss of
intracellular K+. Incubation with 1.4 mM ATP induced significant ROS formation in both NaCl
and KCl media, with similar amounts of ROS formation in both media (Figure 2.3). Likewise,
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ATP‐induced ethidium+ uptake was similar in NaCl and KCl media (Figure 2.3), indicating that
the inability of high extracellular K+ to impair ATP‐induced ROS formation was not due to
altered P2X7 function.

Figure 2.3 Potassium efflux is not required for P2X7‐mediated ROS formation in EOC13 microglia. (Left panel)
Adherent DCF‐loaded EOC13 cells or (right panel) suspended EOC13 cells in NaCl or KCl medium were
incubated in the absence (basal) or presence of 1.4 mM ATP at 37°C for (left panel) 15 min or (right panel)
5 min in the presence of 25 μM ethidium+. Incubations were stopped by the addition of MgCl2 medium. Mean
fluorescence intensities (MFI) of (left panel) DCF (ROS formation) or (right panel) ethidium+ uptake (pore
formation) were determined by flow cytometry and results shown as means ± SD, n = 3; ∗∗∗P < 0.001 compared
to corresponding basal.

2.3.1.4 The ROS scavenger NAC suppresses ATP‐induced ROS formed in EOC13 microglia
To determine if P2X7‐induced ROS formation could be suppressed, DCF‐loaded cells in NaCl
medium were pre‐incubated in the absence or presence of the ROS scavenger NAC, before
incubation in the absence or presence of ATP. As above (Figure 2.2 and Figure 2.3), 1.4 mM
ATP induced significant ROS formation (Figure 2.4a,b). However, ATP‐induced ROS
formation was similar in cells pre‐incubated with or without 10 mM NAC (Figure 2.4a). In
contrast, pre‐incubation with 20 or 40 mM NAC suppressed ATP‐induced ROS formed by
51 ± 15 and 60 ± 15%, respectively (Figure 2.4a). In another experiment, 40 mM NAC
suppressed ATP‐induced ROS formed by 73.7 ± 0.3% (Figure 2.4b). Basal ROS formation
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(Figure 2.4a,b) and cell viability (as assessed by forward and side scatter) (Figure 2.4c) were
similar between treatments.

Figure 2.4 The ROS scavenger NAC suppresses P2X7‐induced ROS and inhibits pore formation in EOC13
microglia. (Left panels) Adherent DCF‐loaded EOC13 cells or (right panel) suspended EOC13 cells in NaCl
medium were pre‐incubated in the absence (control) or presence of 10‐40 mM NAC (as indicated) at 37°C for
30 min and then in the absence (basal) or presence of 1.4 mM ATP for (left panels) 15 min or (right panel) 5
min in the presence of 25 μM ethidium+. (a‐c) Incubations were stopped by the addition of MgCl2 medium. (a‐c)
Cells were firstly gated on forward (FSC) and side (SSC) scatter to exclude debris and doublets, and then (a and
b) mean fluorescence intensities (MFI) of (left panels) DCF (ROS formation) or (right panel) ethidium+ uptake
(pore formation) were determined by flow cytometry. Results shown as means ± SD, n = 3; ∗∗∗P < 0.001,
∗∗P < 0.01 or ∗P < 0.05 compared to corresponding basal; †††P < 0.001 or ††P < 0.01 compared to corresponding
ATP.
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In addition to NAC suppression of ATP‐induced ROS formation, pre‐incubation of cells with
40 mM NAC inhibited ATP‐induced ethidium+ uptake by 30 ± 2% (Figure 2.4b). Thus, the
inhibitory effect of NAC on P2X7‐induced ROS formation may be partially attributed to
inhibition of P2X7 itself. However, incubation with NAC and ATP or NAC alone, but not ATP
alone, reduced the amount of gated viable cells by 55 ± 12 and 32 ± 12%, respectively, in the
ethidium+ uptake assay (as assessed by forward and side scatter) (Figure 2.4c). This suggests
that the inhibitory action of NAC on ATP‐induced ethidium+ uptake may be a result of
cytotoxicity in this assay.
To confirm that NAC did not induce morphological changes or cause cytotoxicity under the
conditions used for the ROS assay, DIC images of adherent cells were acquired following
incubation in the absence or presence of ATP. Cells incubated in the absence or presence of
NAC (without ATP) displayed discrete cell bodies with long, spindled shaped processes
(Figure 2.5), as previously observed (Walker et al., 1995). Cells incubated in the absence or
presence of NAC (with ATP) also displayed discrete cell bodies, but with retracted and
branched processes (Figure 2.5), typical of ATP causing membrane changes (Qu and Dubyak,
2009). Therefore, in the ROS assay, EOC13 cell morphology was not altered by NAC when
compared to the corresponding treatment.
To further explore P2X7‐induced ROS formation, DCF‐loaded cells were pre‐incubated in the
absence or presence of the broad‐spectrum ROS inhibitor DPI. However, a 30 min
incubation with various concentrations (5‐40 μM) of DPI in the presence of ATP led to high
amounts of cell death (as assessed by forward and side scatter) (Figure 2.6), and thus this
compound was not examined further.
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Figure 2.5 The inhibitory action of the ROS scavenger NAC on ATP‐induced ROS formation is not a result of
cytotoxicity. Adherent DCF‐loaded EOC13 cells in NaCl medium were pre‐incubated in the absence (control) or
presence of 40 mM NAC at 37°C for 30 min and then in the absence (basal) or presence of 1.4 mM ATP for
15 min. Incubations were stopped by the addition of MgCl2 medium. DIC images of cell morphology were
acquired by microscopy. Bars represent 20 μm. Results are representative of two experiments.

Figure 2.6 The broad‐spectrum ROS inhibitor DPI, in the presence of ATP, is cytotoxic to EOC13 microglia.
Adherent DCF‐loaded EOC13 cells in NaCl medium were pre‐incubated in the absence (control) or presence of
5‐40 μM DPI (as indicated) at 37°C for 30 min and then in the absence (basal) or presence of 1.4 mM ATP for
15 min. Incubations were stopped by the addition of MgCl2 medium. Cell viability was assessed by the
percentage of cells within the forward (FSC) and side (SSC) scatter gates of the total number of events (see
Figure 2.1c) for DCF (ROS formation) assays, as determined by flow cytometry. Results shown as n = 1.
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2.3.2 P2X7 activation induces cell death in murine EOC13 microglia, which is mediated by
ROS
2.3.2.1 P2X7 activation induces cell death in EOC13 microglia
P2X7 activation results in the death of various cell types (Adinolfi et al., 2005b; Di Virgilio et
al., 2009), including EOC13 cells (Bartlett, 2011). To confirm that ATP induces the death of
EOC13 microglia, cells in complete DMEM medium were first incubated in the absence or
presence of 2 mM ATP for 24 h, and then the percentage of Annexin‐V+/7AAD−, Annexin‐
V−/7AAD+, and Annexin‐V+/7AAD+ cells examined by flow cytometry (using the gating
strategy outlined; Figure 2.7). Cell death is expressed as the total of dying (Annexin‐
V+/7AAD−) and dead (Annexin‐V−/7AAD+ and Annexin‐V+/7AAD+) cells. Similar to previous
experiments (Bartlett, 2011), incubation with 2 mM ATP resulted in a significantly higher
percentage of total cell death compared to cells incubated in the absence of ATP (Figure
2.7).
2.3.2.2 P2X7‐induced cell death in EOC13 microglia is mediated by ROS
P2X7‐induced death of murine RAW264.7 macrophages is mediated by ROS formation
(Noguchi et al., 2008). Therefore, a role for ROS in P2X7‐induced death of EOC13 microglia
was investigated. EOC13 cells were pre‐incubated in the absence or presence of the ROS
scavenger NAC followed by ATP for 24 h. However, 24 h incubation with 40 mM NAC in the
absence of ATP led to significant amounts of EOC13 cell death (Figure 2.8a).
To reduce the exposure to 40 mM NAC, cells were incubated in the absence or presence of
NAC for 90 min, with ATP added in the final 15‐60 min. The medium was then replaced with
fresh complete DMEM medium and the cells incubated for 24 h. Incubation with 2 mM ATP
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for 30 or 60 min, but not 15 min, resulted in significant cell death compared to cells
incubated in the absence of ATP (Figure 2.8b). In contrast to 24 h incubation with NAC
(Figure 2.8a), 90 min incubation with 40 mM NAC (without ATP) did not induce significant
cell death compared to cells incubated for the same length of time in the absence of both
NAC and ATP (Figure 2.8b). A 60 min pre‐incubation with NAC inhibited cell death induced
by 30 min incubation with ATP by 99 ± 6% (Figure 2.8b). In contrast, a 75 and 30 min pre‐
incubation with NAC, followed by 15 and 60 min ATP treatment, respectively, had no effect
on the percentage of cell death compared to cells incubated for the same time length with
ATP in the absence of NAC (Figure 2.8b).

Figure 2.7 P2X7 activation induces cell death in EOC13 microglia. Adherent EOC13 cells in complete DMEM
medium were incubated in the absence (basal) or presence of 2 mM ATP at 37°C for 24 h. Cells were
harvested, labelled with Annexin‐V‐Fluorescein and 7AAD, and the percentage of Annexin‐V−/7AAD+, Annexin‐
V+/7AAD−, and Annexin‐V+/7AAD+ cells (together representing total cell death) determined by flow cytometry.
Results shown as (left panel) dot plots of one representative set of data demonstrating the quadrant markers
and (right panel) means ± SD, n = 3; ∗∗∗P < 0.001 compared to basal.

To further confirm that incubation with NAC alone did not induce morphological changes or
cause cytotoxicity under the conditions used for the cell death assay, DIC images of
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Figure 2.8 The ROS scavenger NAC inhibits P2X7‐induced cell death in EOC13 microglia. Adherent EOC13 cells
in complete DMEM medium were (a) pre‐incubated in the absence or presence of 40 mM NAC at 37°C for 30
min and then in the absence or presence of 2 mM ATP for 24 h or (b) incubated in the absence or presence of
40 mM NAC at 37°C for 90 min and incubated in the absence or presence of 2 mM ATP for the final 15–60 min
(of the 90 min incubation), and then the medium replaced with fresh complete DMEM medium for 24 h. (a and
b) Cells were harvested, labelled with Annexin‐V‐Fluorescein and 7AAD, and the percentage of Annexin‐
V−/7AAD+, Annexin‐V+/7AAD−, and Annexin‐V+/7AAD+ cells (together representing total cell death) determined
by flow cytometry. (b) Prior to harvesting, DIC images of cell morphology were acquired by microscopy. Bars
represent 20 μm. Wells pre‐incubated with ATP alone had a high amount of non‐adherent cells compared to
the other treatments, but are outside the plane of focus (a and b) Results shown as means ± SD, n = 3, ∗∗∗P <
0.001 compared to (a) basal or (b) corresponding 0 min ATP; †††P < 0.001 compared to (a) NAC or (b)
corresponding ATP in the absence of NAC.
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adherent cells were acquired following the 24 h incubation. As above (Figure 2.5b), cells
incubated in the absence or presence of NAC (without ATP) displayed discrete cell bodies
with long, spindled shaped processes (Figure 2.8b). In addition, cells incubated in the
presence of NAC and ATP displayed a similar morphology to that of cells incubated in the
absence of ATP (Figure 2.8b). In contrast, cells pre‐incubated with ATP alone displayed
rounded and granular cell bodies with no or few processes, characteristic of cell death.
Furthermore, wells pre‐incubated with ATP alone had a high amount of non‐adherent cells
compared to the other treatments (Figure 2.8b). Thus, pre‐incubation with NAC prevented
the morphological changes associated with ATP incubation, but NAC alone had no effect on
cell morphology.
2.3.3 P2X7 activation induces NO formation, but is not involved in proliferation or
phagocytosis in murine EOC13 microglia
To further characterise the function of P2X7 in murine EOC13 microglia, additional events
downstream of P2X7 activation were investigated. This included NO formation, proliferation
and phagocytosis, all of which are microglial responses observed during neuroinflammation
(see Section 2.1).
2.3.3.1 P2X7 activation induces NO formation in EOC13 microglia
P2X7 activation has been shown to be involved in NO formation in macrophages (Sperlagh
et al., 1998) and microglia (Gendron et al., 2003). To determine if P2X7 activation induces
the formation of NO in EOC13 cells, ATP‐induced NO formation was investigated using the
NO sensitive probe DAF‐FM DA. Cells loaded with DAF‐FM DA (which reacts with NO to form
a fluorescent benzotriazole) were incubated in the absence or presence of ATP, and the
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subsequent NO formation analysed by flow cytometry. Incubation with 1.4 mM ATP induced
significant NO formation in EOC13 cells compared to cells incubated in the absence of ATP
(Figure 2.9a). Furthermore, pre‐incubation of cells with 10 μM AZ10606120 inhibited ATP‐
induced NO formation by 82 ± 11% (Figure 2.9b), indicating that this process is mediated by
P2X7 activation. Again, AZ10606120 did not significantly alter the basal NO formation
(Figure 2.9b) or the percentage of viable cells, as assessed by forward and side scatter
(control basal, 55 ± 2%; AZ10606120 basal, 55 ± 1%; control ATP, 55 ± 1%; AZ10606120 ATP,
54 ± 2; P > 0.05, n = 3).

Figure 2.9 P2X7 activation induces NO formation in EOC13 microglia. Adherent DAF‐FM DA‐loaded EOC13
cells in NaCl medium were (a) incubated in the absence (basal) or presence of 1.4 mM ATP at 37°C for 15 min
or (b) pre‐incubated in the absence (control) or presence of 10 μM AZ10606120 at 37°C for 15 min and then in
the absence (basal) or presence of 1.4 mM ATP for 15 min. (a and b) Incubations were stopped by the addition
of MgCl2 medium. Mean fluorescence intensities (MFI) of benzotriazole (NO formation) were determined by
flow cytometry and results shown as means ± SD, n = 3; ∗∗P < 0.01 or ∗∗∗P < 0.001 compared to corresponding
basal; †††P < 0.001 compared to corresponding ATP.

2.3.3.2 P2X7 activation does not promote proliferation in the absence of serum in EOC13
microglia
P2X7 has been shown to promote proliferation in the absence of serum in leukocytes
(Baricordi et al., 1999) and microglia (Bianco et al., 2006; Monif et al., 2009). Furthermore,
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activation and proliferation of microglia is considered a hallmark of disease in a number of
neurodegenerative diseases, including ALS (Lasiene and Yamanaka, 2011). Thus, the
proliferative effect of P2X7 on EOC13 cells was next investigated, using an MTT assay to
determine the relative numbers of metabolically active cells 72 h after plating. Firstly, the
assay was optimised to determine the appropriate number of EOC13 cells to be plated in 96‐
well plates (Figure 2.10a). Very little proliferation was observed after 72 h in wells plated
with 1 x 103 cells. Conversely, cells plated at 5 x 104 cells per well were highly confluent,
with high amounts of cell death after 72 h. In comparison, relatively high amounts of
proliferation were seen between 24 and 72 h in wells plated with 5 x 103 and 1 x 104 cells. As
more proliferation was observed between 24 and 72 h in wells plated with 1 x 104 cells, cells
were plated at this concentration in subsequent experiments.

Figure 2.10 P2X7 activation does not promote proliferation in EOC13 microglia. Adherent EOC13 cells, seeded
at (a) various concentrations (as indicated) or (b) 1 x 104 cells/ well, were incubated in (a) DMEM/F12 medium
in the presence of 10% foetal bovine serum and 20% LADMAC conditioned medium at 37°C for 24‐72 h (as
indicated) or (b) incubated in DMEM/F12 medium in the absence (control) or presence of 10 μM AZ10606120,
and absence (‐) or presence of 10% foetal bovine serum (FBS), 20% LADMAC conditioned medium (CSF‐1) or
both 10% foetal bovine serum and 20% LADMAC conditioned medium (CSF‐1/FBS) at 37°C for 72 h. (a and b)
Cells were then incubated with MTT at 37°C for 4 h and then with solubilisation solution at 37°C overnight.
Absorbances of formazan dye at 550 minus 690 nm (A550‐690)(relative cell number) were determined by
spectrometry and results shown as mean A550‐690 ± SD, n = 3; ***P < 0.001 or **P < 0.01 compared to
corresponding nil (‐). (a) Red arrow indicates chosen plating density for (b).
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Next, adherent EOC13 microglia were incubated in the absence or presence of AZ10606120
and the absence or presence of FBS for 72 h. As EOC13 cells are reported to require CSF‐1
for growth (Walker et al., 1995), cells were also cultured in the absence or presence of
CSF‐1, or in the presence of CSF‐1 and FBS (Figure 2.10b). Incubation of cells with
AZ10606120 had no effect on relative cell number after 72 h for any culture condition,
suggesting that P2X7 is not involved in cell proliferation in EOC13 microglia. However, the
stability of AZ10606120 in culture after 72 h was not assessed. Consistent with the CSF‐1‐
dependency of EOC13 microglia, there was an almost two‐fold increase in the number of
cells present after 72 h cultured in the presence of CSF‐1 (with or without FBS) compared to
cells cultured in the absence of CSF‐1 (with or without FBS) (Figure 2.10b).
2.3.3.3 A role for P2X7 in phagocytosis in EOC13 microglia was not established
There is evidence that P2X7 acts as a scavenger receptor, phagocytosing non‐opsonised
particles, apoptotic cells and bacteria in the absence of serum and extracellular ATP (Wiley
and Gu, 2012). Notably, ATP stimulation of cells reduces or prevents P2X7‐mediated
phagocytosis (Gu et al., 2010). Given that phagocytosis by microglia is suggested to play a
role in neurodegeneration (Neher et al., 2011; Neniskyte et al., 2011), phagocytosis in
EOC13 microglia was next investigated. Firstly, to establish the assay, adherent cells at 4 or
37°C were incubated in the absence or presence of YG beads. Bead uptake in viable cells
(gated by forward and side scatter as per Figure 2.11) was then analysed by flow cytometry.
In EOC13 cells incubated with YG beads, significantly greater fluorescence was observed at
37°C compared to 4°C, or compared to corresponding cells in the absence of YG beads
(Figure 2.11). While some fluorescence was observed from cells incubated with YG beads at
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4°C compared to corresponding cells in the absence of YG beads, this did not reach
statistical significance (Figure 2.11).

Figure 2.11 EOC13 microglia are phagocytic. Adherent EOC13 cells in NaCl medium containing 0.1 mM Ca2+
were incubated in the absence (control) or presence of YG beads at 4 or 37°C for 5 min. Incubations were
stopped by the addition of MgCl2 medium. (left panel) Cells were firstly gated on forward (FSC) and side (SSC)
scatter to exclude debris and doublets and then (right panel) mean fluorescence intensities (MFI) of YG beads
determined by flow cytometry. Results shown as means ± SD, n = 3; ∗∗∗P < 0.001 compared to corresponding
control; †††P < 0.001 compared to corresponding YG Bead.

To examine a role for P2X7 in phagocytosis by EOC13 microglia, the effects of ATP and
BzATP on these cells were investigated. Significant bead uptake was observed in cells pre‐
incubated in the absence or presence of either agonist (Figure 2.12a). Nevertheless, pre‐
incubation of EOC13 cells with ATP, or the more potent P2X7 agonist BzATP, significantly
reduced the basal bead uptake by 27 ± 6 and 36 ± 3%, respectively. However, significant
reductions in viable cells were also observed following treatment with agonists, as assessed
by forward and side scatter (75 ± 9 and 57 ± 2% reductions in basal viability for ATP and
BzATP, respectively; Figure 2.12b). Due to the toxicity of P2X7 agonists in conjunction with
beads, the role of P2X7 in phagocytosis was not further investigated.
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Figure 2.12 YG beads are cytotoxic in the presence of P2X7 agonists in EOC13 microglia. Adherent EOC13
cells in NaCl medium containing 0.1 mM Ca2+ were pre‐incubated in the absence (basal) or presence of 1 mM
ATP or 0.1 mM BzATP at 37°C for 15 min and then in the absence (control) or presence of YG beads at 37°C for
5 min. Incubations were stopped by the addition of MgCl2 medium. (a) The mean fluorescence intensities (MFI)
of YG beads and (b) cell viability, assessed by the percentage of cells within the forward (FSC) and side (SSC)
scatter gates of the total number of events (see Figure 2.1c), were determined by flow cytometry. (a and b)
Results shown as means ± SD, n = 3; ∗∗∗P < 0.001 compared to corresponding control; †††P < 0.001 compared to
corresponding basal.

2.3.4 Primary murine microglia express functional P2X7
2.3.4.1 Assessing the purity and optimal harvest method for primary microglia cultures
Before investigating P2X7 in in vivo murine models, the presence of functional P2X7 on
primary murine microglia was confirmed. Primary microglia were harvested from neonatal
C57Bl/6J mice, and the purity of the resulting microglia cultures assessed by microscopy.
The majority of cells displayed discrete, small cell bodies with long, spindled shaped
processes, characteristic of microglia (Figure 2.13a). Immunocytochemical analyses
confirmed that the majority of cells were positive for the microglial marker CD11b (Figure
2.13b).
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Figure 2.13 Generation and harvesting of primary murine microglia. Adherent primary murine microglia were
(a) visualised by DIC microscopy or (b) fixed with 4% paraformaldehyde, permeabilised, and labelled with anti‐
CD11b or corresponding isotype control, followed by incubation with DyLight 488‐conjugated anti‐IgG. (b)
Slides were analysed by confocal microscopy. (a and b) Bars represent 100 μm. Results are representative of at
least three experiments. (c) Adherent primary murine microglia, plated in the absence or presence of poly‐D‐
lysine (PDL), were harvested by mechanical scraping in culture (C/M) or NaCl medium, dissociation using 0.25%
trypsin followed by mechanical scraping, or dissociation using 0.25% trypsin or 5 mM EDTA alone. Cell viability
was assessed by the percentage of cells within the forward (FSC) and side (SSC) scatter gates of the total
number of events. Results shown as n = 1, with a representative dot plot shown on the left. Red arrow
indicates chosen harvest method.

Microglia grow as adherent cells in culture (Figure 2.13a,b). To determine the harvest
method which would result in the highest percentage of viable cells for flow cytometric
analyses, primary microglia, in culture plates coated with or without PDL, were harvested
using a number of common techniques (as indicated), and analysed by flow cytometry. The
percentage of viable cells was determined as the percentage of cells within the forward and
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side scatter gates of the total number of events (Figure 2.13c). For each harvest technique,
there was no difference in the percentage of gated cells in plates coated with PDL compared
to those without PDL (Figure 2.13c). Nevertheless, mechanical scraping and dissociation
using 5 mM EDTA resulted in the lowest percentage of gated cells, while dissociation using
0.25% trypsin gave the highest percentage of gated cells. Thus, for future investigations,
primary microglia were plated in the absence of PDL and harvested using 0.25% trypsin.
2.3.4.2 The Alomone P2X7 antibody APR‐008 detects P2X7, but not P2X4
Before examining the presence of P2X7 in primary microglia by immunoblotting, the
suitability of a number of commercially available Abs to detect P2X7 were investigated.
Purified human P2X7, mouse P2X7 and rat P2X4 plasmid DNA were used to transiently
transfect HEK‐293 cells. A fluorescent cation uptake assay was then used to confirm cell
transfection. The P2X7 agonist ATP induced ethidium+ uptake into human and mouse P2X7‐
transfected cells, but not mock‐transfected cells (Figure 2.14a). Low amounts of ATP‐
induced ethidium+ uptake were also detected in rat P2X4‐transfected cells (Figure 2.14a).
The Alomone P2X7 Ab APR‐008, which is capable of detecting all P2X7 variants, is
extensively used by our and other groups. (Jalilian et al., 2012b; Masin et al., 2012). During
the course of this study, three new P2X7 Abs became available from AVIVA. Therefore, the
reactivities of these P2X7 Abs were tested by the immunoblotting of separated whole
mock‐, rat P2X4‐, mouse P2X7‐ and human P2X7‐transfected HEK‐293 cell lysates. As
expected, immunoblotting using the Alomone Ab APR‐008 resulted in bands approximately
75 kDa in size for both human and mouse P2X7‐transfected HEK‐293 cell lysates, with no
non‐specific bands present in lysates from mock‐transfected cells or cells transfected with
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rat P2X4 (Figure 2.14b). In contrast, the AVIVA P2X7 Abs ARP35518, ARP35112 and
ARP35517 resulted in a number of non‐specific bands (Figure 2.14b). These bands were
present in rat P2X4‐ and mock‐transfected HEK‐293 cell lysates, in addition to lysates from
cells transfected with human and mouse P2X7. In the case of ARP35112 and ARP35517,
additional bands appeared to be present at 75 KDa in human and mouse P2X7‐transfected
HEK‐293 cell lysates, corresponding to the predicted size of glycosylated P2X7. Given its
specificity for P2X7, the Ab APR‐008 was used for future investigations.

Figure 2.14 The Alomone P2X7 antibody APR‐008 detects P2X7. (a) Mock‐transfected HEK‐293 cells or HEK‐
293 cells expressing rat P2X4 (rP2X4), human P2X7 (hP2X7) or mouse P2X7 (mP2X7) suspended in NaCl
medium, were incubated in the absence (basal) or presence of 1 mM ATP at 37°C for 5 min in the presence of
25 μM ethidium+. Incubations were stopped by the addition of MgCl2 medium. Mean fluorescence intensities
(MFI) of ethidium+ uptake (pore formation) were determined by flow cytometry and results shown as n = 1. (b)
Lysates from mock‐transfected HEK‐293 cells or HEK‐293 cells expressing rP2X4, mP2X7 or hP2X7 were
separated by SDS‐PAGE under reducing conditions, transferred to nitrocellulose membranes, and incubated
with anti‐P2X7 pAbs (as indicated).
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2.3.4.3 Primary murine microglia express functional P2X7
To investigate the presence of total P2X7 protein in primary murine microglia, primary
microglia whole cell lysates were separated and then probed with APR‐008 anti‐P2X7 pAb.
EOC13 cells, which express P2X7 (Bartlett, 2011), were used as a positive control.
Immunoblotting revealed one major protein band of approximately 75 kDa for both
microglia lysates (Figure 2.15a). For EOC13 microglia, an additional band of approximately
110 kDa was also present.
The fluorescent cation uptake assay mentioned above is commonly used in our laboratory
on suspended cells. However, preliminary studies revealed that this assay resulted in low
viabilities of primary microglia when studied in suspension (data not shown). Thus, to
improve the viability of primary microglia, this assay was modified to be performed on
adherent microglia. EOC13 cells were used to develop this modification, as this cell line was
readily available and known to express functional P2X7 (Bartlett, 2011). Incubation of
adherent EOC13 cells with ATP induced significant YO‐PRO‐12+ and ethidium+ uptake into
these cells (Figure 2.15b), similar to previous observations with suspended cells (Bartlett,
2011; Figure 2.2b).
Next, ethidium+ uptake into adherent primary microglia was investigated. ATP induced
ethidium+ uptake into primary microglia in a concentration‐dependent manner, with
maximal ethidium+ uptake at 1 mM ATP and with an EC50 of 160 ± 60 μM (Figure 2.15c). To
show that the observed ATP‐induced ethidium+ uptake into primary microglia was mediated
by P2X7, primary microglia were pre‐incubated with AZ10606120 (Figure 2.15d). ATP at the
EC50 concentration induced significant ethidium+ uptake into these cells, with pre‐incubation
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of cells with 10 μM AZ10606120 completely impairing this 160 μM ATP‐induced ethidium+
uptake (Figure 2.15d). Collectively, these results confirm the presence of functional P2X7 in
primary murine microglia.

Figure 2.15 Primary murine microglia express functional P2X7. (a) EOC13 and primary microglia lysates were
separated by SDS‐PAGE under reducing conditions, transferred to nitrocellulose membranes and incubated
with Alomone anti‐P2X7 pAb. Results are representative of two experiments. Adherent (b) EOC13 cells, (c)
primary microglia or (d) primary microglia pre‐incubated in the absence (control) or presence of 10 μM
AZ10606120 at 37°C for 15 min were (b‐d) incubated in NaCl medium in the absence (basal) or presence of (b)
1 mM, (c) various concentrations (as indicated) or (d) 160 μm ATP at 37°C for 5 min in the presence of (b‐d)
25 μM ethidium+ or (b) 1 μM YO‐PRO‐12+. (b‐d) Incubations were stopped by the addition of MgCl2 medium.
Mean fluorescence intensities (MFI) of (b‐d) ethidium+ or (b) YO‐PRO‐12+ uptake (pore formation) were
determined by flow cytometry and results shown as (b and d) means ± SD, n = 3; ∗∗∗P < 0.001 compared to
corresponding basal; †††P < 0.001 compared to corresponding ATP. (c) The curve is presented as a percentage
of the maximal ethidium+ uptake and expressed as the mean ± SD, n = 3.
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2.4

Discussion

2.4.1 Summary of results
The current study confirmed that P2X7 mediates ROS formation and death of EOC13
microglia. P2X7‐mediated ROS formation was not dependent on Ca2+ influx or K+ efflux.
Furthermore, the study demonstrated that P2X7‐induced cell death is mediated by ROS
under certain conditions in these cells. In addition, activation of P2X7 on EOC13 microglia
induced NO formation, while a role for P2X7 in the proliferation or phagocytic activity of
EOC13 cells was not established. Collectively, this suggests that P2X7 is capable of mediating
neuroinflammatory responses in EOC13 microglia, similar to those observed during ALS
progression. The expression of functional P2X7 on primary murine microglia was also
confirmed in the current study. Thus, future in vivo investigation into the roles of P2X7 in
diseases involving microglia, such as ALS, is warranted.
2.4.2 Role for P2X7 in ROS and NO formation
Similar to previous observations (Bartlett, 2011), P2X7‐mediated ROS formation in EOC13
microglia was confirmed in the current study. In addition, P2X7 activation was shown to
mediate NO formation in these cells. P2X7‐induced ROS and NO formation have previously
been reported in primary and immortalised microglia (Bartlett, 2011; Gendron et al., 2003;
Kim et al., 2007; Li et al., 2013; Parvathenani et al., 2003), and a role for these processes in
microglia has been highlighted by several studies. In primary murine microglia, P2X7
activation enhanced the activity of the ROS‐producing enzyme NADPH oxidase 2, leading to
enhanced ROS formation (Apolloni et al., 2013b). This enhancement was greater in microglia
derived from ALS mice than from non‐transgenic littermates. In primary rat microglia,
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fibrillar β‐amyloid peptide, which is associated with Alzheimer’s disease, caused ATP release
and autocrine activation of P2X7 leading to ROS formation (Kim et al., 2007). Similarly, α‐
synuclein, associated with Parkinson's disease, induced ROS formation in immortalised
murine microglia via an interaction with P2X7 (Jiang et al., 2015). These α‐synuclein/P2X7‐
mediated ROS partially induced death of neuronal cultures (Jiang et al., 2015). Moreover,
other studies have observed that P2X7‐induced ROS and NO released from primary rat
microglia induced injury of rat neurons (Lai et al., 2013; Parvathenani et al., 2003; Skaper et
al., 2006). Collectively, these data indicate that P2X7‐induced ROS formation from microglia
may be involved in various neuroinflammatory and neurodegenerative disorders. This may
be of particular importance in diseases where microglial P2X7 is reported to be up‐
regulated, such as in ALS (Yiangou et al., 2006).
The current study excluded an essential role for Ca2+ influx in P2X7‐induced ROS formation
in EOC13 microglia. This finding is similar to other observations with other murine cell types,
including submandibular glands (Seil et al., 2008) and erythroid cells (Wang and Sluyter,
2013). In contrast, P2X7‐induced ROS formation in murine macrophages (Martel‐Gallegos et
al., 2013), primary rat microglia (Kim et al., 2007; Parvathenani et al., 2003) and rat
submandibular glands (Fontanils et al., 2010) is dependent on an influx of Ca2+. The reason
for these differences remains unknown, but may reflect differences in experimental
protocols or differences in signalling molecules between different cell types and/or species.
The current study also excluded an essential role for K+ efflux in P2X7‐induced ROS
formation in EOC13 microglia. Both ROS formation and K+ efflux are involved in ATP‐induced
IL‐1β release from macrophages (Chen et al., 2014b; Huang et al., 2012) and epithelial cells
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(Komada et al., 2014). However, it remains to be determined if K+ efflux is required for ROS
formation in these settings.
2.4.3 Role for ROS in P2X7‐mediated cell death
In the current study, a role for P2X7 activation in mediating microglia death was confirmed,
supporting previous observations in primary microglia (Brough et al., 2002), EOC13 microglia
(Bartlett, 2011) and other microglial cell lines (Ferrari et al., 1999). Furthermore, the current
study examined a potential link between P2X7‐induced ROS formation and death in EOC13
microglia. A role for ROS in ATP‐induced death of human intestinal epithelial cells has
previously been described (Souza et al., 2012). Furthermore, a previous study demonstrated
that the ATP‐induced death of murine RAW264.7 macrophages was mediated by ROS
derived from NADPH oxidase downstream of P2X7 activation (Noguchi et al., 2008).
Similarly, ATP‐dependent cancer cell death was attenuated by inhibiting ROS derived from
NADPH oxidases (Draganov et al., 2015). These contrast with another study, which found
that P2X7‐induced ROS formation, but not death, was attenuated in primary macrophages
from NADPH oxidase deficient mice (Moore and MacKenzie, 2009).
A role for ROS formation in the P2X7‐induced death of EOC13 microglia was supported in
the current study using the ROS scavenger NAC. The capacity of NAC to prevent P2X7‐
induced EOC13 microglia death was dependent on the pre‐incubation time with NAC, as
well as the total incubation time with ATP, with only 45‐60 min pre‐incubations with NAC
preventing cell death induced by transient 30‐45 min exposures to ATP. In contrast, 24 h
incubation with NAC induced significant amounts of EOC13 microglia death, equivalent to
that induced by ATP alone. This cytotoxicity of NAC may have occurred due to increased
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toxic metabolic by‐products such as reduced glutathione (Qanungo et al., 2004).
Alternatively, scavenging of ROS by NAC may indicate that low amounts of ROS are
important for EOC13 cell homeostasis. Of note, the ROS inhibitor DPI also induced the death
of EOC13 microglia, albeit over a much faster time course. However, this was only observed
in the presence of ATP, suggesting a synergistic effect of ATP and DPI on cell death. Future
investigations utilising P2X7 antagonists may help to elucidate the mechanism by which this
ROS inhibitor was able to mediate death. Finally, it should be noted that NAC inhibition of
P2X7‐induced death and ROS formation in EOC13 microglia may have been partly due to
direct inhibition of P2X7. NAC inhibited ATP‐induced pore formation by 30% compared to a
74 and 99% inhibition of ATP‐induced ROS formation and cell death, respectively. This direct
inhibition of P2X7 by NAC was not due to an acidic pH, which is known to impair P2X7
function (Liu et al., 2009a), as the NAC‐containing solutions were adjusted to pH 7.4 before
each assay. Thus, these results indicate that cellular signalling involving ROS may modulate
P2X7 activation in EOC13 microglia, or that NAC may directly impair P2X7 at 40 mM. The
concentration of NAC used in these experiments (40 mM) is 4‐8‐fold higher than that used
in a number of similar studies (e.g. Pfeiffer et al., 2007). The requirement for this high
concentration of NAC remains unknown, but may reflect a reduced ability of NAC to cross
the plasma membrane or to be converted to the ROS scavenging product, glutathione, in
EOC13 cells.
2.4.4 Role for P2X7 in proliferation
In the current study, EOC13 microglial proliferation under serum‐containing and serum‐free
conditions was dependent on CSF‐1 (LADMAC conditioned medium), but not P2X7. This
CSF‐1 dependency is consistent with a known role for this factor in EOC13 cells (Walker et
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al., 1995) and mononuclear phagocytes (Chitu and Stanley, 2006). In comparison to the
current study, activation of P2X7 by low (tonic) concentrations of ATP has been
demonstrated to have proliferative effects in primary and other immortalised microglial
(Bianco et al., 2006; Monif et al., 2009; Rigato et al., 2012; Zou et al., 2012), human glioma
(Monif et al., 2014) and P2X7‐transfected lymphoid and HEK‐293 cells (Adinolfi et al., 2005b;
Baricordi et al., 1999). In these studies, a role for P2X7 in cell proliferation was supported by
the use of P2X7 antagonists, knock‐outs and gene silencing. In addition, a number of these
studies utilised the extracellular ATP hydrolysing enzyme apyrase, whose inhibitory effects
on cell proliferation suggest that tonic activation of P2X7 by endogenously secreted ATP is
required. In the current study, the P2X7 antagonist AZ10606120 was utilised, at
concentrations known to inhibit murine P2X7 (Bartlett, 2011). However, none of the above
studies utilised this antagonist, and its stability in culture was not investigated in the current
study. Although, a previous study in our group has shown that 0.1 μM AZ10606120 was
sufficient to block ATP‐induced cell death of human KG‐1 myeloid leukemia cells over 48 h
(Gadeock, 2010). Nevertheless, it is unclear whether P2X7 was sufficiently inhibited over the
length of the current study, and other antagonists or apyrase should be used in future to
confirm the role of P2X7 in EOC13 cell proliferation. Furthermore, given that the MTT assay
measures metabolic activity, rather than cell numbers directly, additional measures of
proliferation should be considered.
The physiological role of P2X7‐mediated microglial proliferation is unclear. In
neurodegenerative diseases such as ALS, microglial proliferation and activation are
considered hallmarks of disease (Lasiene and Yamanaka, 2011). Furthermore, P2X7
immunoreactivities are increased in activated microglia in ALS (Casanovas et al., 2008;
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Yiangou et al., 2006). However, despite this and a reported link between P2X7 over‐
expression and proliferation in microglia (Monif et al., 2009), further work is required to
determine whether P2X7 is involved in microglia proliferation during neuroinflammation. In
addition, the role of P2X7‐mediated microglial proliferation is further obscured by the more
well‐known role of P2X7 activation in inducing microglia death, which was also observed in
the current study. This paradoxical role of P2X7 is thought to be related to the relative ATP
concentration, with tonic concentrations promoting cell proliferation and high sustained
concentrations promoting cell death (Di Virgilio et al., 2009).
2.4.5 Role for P2X7 in phagocytosis
A role for P2X7 in phagocytosis in EOC13 microglia was not established in the current study,
with incubation with P2X7 agonists and beads causing cytotoxicity. In comparison, a role for
P2X7 in the phagocytosis of non‐opsonised particles, including apoptotic cells and bacteria,
has been shown in a number of cell types. This includes microglia, astrocytes, neural
precursor cells and neuroblasts, monocytes and macrophages, and P2X7‐transfected HEK‐
293 cells (Fang et al., 2009; Gu et al., 2010; Gu et al., 2011; He et al., 2013; Lovelace et al.,
2015; Moncao‐Ribeiro et al., 2014; Yamamoto et al., 2013). In these studies, the addition of
ATP or BzATP and the resulting P2X7 activation was reported to impair phagocytic activity.
Similarly, in wild type, but not P2X7 knock‐out mice, injection of ATP prior to injection of
beads or bacteria impaired the phagocytic activity of macrophage in vivo (Gu et al., 2010; Gu
et al., 2011). Collectively, this suggests that P2X7 acts as a scavenger receptor in its
unactivated state. However, unlike the current study, none of the above‐mentioned studies
reported a toxic effect following application of P2X7 agonists in conjunction with non‐
opsonised particles, despite the use of the same beads in some studies (Gu et al., 2012; Gu
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et al., 2010). It is possible that high P2X7‐expressing cells were selectively killed in the
current study, although further investigation would be required to confirm this.
Furthermore, additional controls, such as the phagocytosis inhibitor cytochalasin D, would
be required to confirm that the observed fluorescence correlated with phagocytosis, and
that ATP is capable of inhibiting this process.
There is evidence that P2X7‐mediated phagocytosis is important in CNS health and disease.
Serum glycoproteins associated with Alzheimer's disease inhibited phagocytosis by human
monocytes and P2X7‐transfected HEK‐293 cells (Gu et al., 2012). In contrast, human
cerebrospinal fluid from non‐neurological disease patients, which contains little
glycoprotein, had no inhibitory effects (Gu et al., 2012). Together, this suggests that P2X7
acts as a scavenger receptor in the CNS, and that this system could be disrupted during the
progression of neurodegenerative diseases such as Alzheimer's disease. However, in
contrast, another study found that silencing or antagonising P2X7 in microglia indirectly
increased phagocytosis of Alzheimer's disease‐associated β‐amyloid peptides, by inhibiting
IL‐1β release (Ni et al., 2013). Further obscuring the role for P2X7 during
neuroinflammation, microglial phagocytosis has also been shown to actively induce
neuronal death under inflammatory conditions, including in the presence of bacterial cell
wall components, β‐amyloid peptides or the cytokine TNF‐α (Neher et al., 2011; Neniskyte
et al., 2011; Neniskyte et al., 2014). This process was dependent on the release of soluble
mediators from microglia, in particular the reactive species peroxynitrite, which led to the
exposure of "eat me" signals on neurons (Neher et al., 2011; Neniskyte et al., 2011).
However, given that P2X7 is generally functional during inflammatory states, it is unlikely
that this phagocytotic activity was mediated by basal P2X7 activity. In fact, under conditions
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of high extracellular ATP, such as during inflammation, the resulting P2X7 activation can
mediate the production of reactive species, potentially contributing to the neuronal death
described in these studies. Thus, the physiological role of P2X7‐mediated phagocytosis is
unclear.
2.4.6 Conclusion
In conclusion, in EOC13 microglia, P2X7 activation mediated ROS formation, NO formation
and death. In contrast, a role for P2X7 in EOC13 cell proliferation or phagocytosis was not
established. However, other studies have found evidence for the involvement of this
receptor in both these events (Bianco et al., 2006; Gu et al., 2011; Monif et al., 2009). While
all these microglial responses can be important for normal CNS functioning, they can also
promote neuroinflammation and neurodegeneration in diseases such as ALS, where the
presence of activated microglia is a defining feature (Monif et al., 2010). Furthermore, up‐
regulation of P2X7 is a coexisting feature in many of these diseases (Yiangou et al., 2006).
Together, this suggests that P2X7 may contribute to the progression of ALS and other
neuroinflammatory diseases by mediating inappropriate microglial responses. However,
whether P2X7 up‐regulation is directly causative or is a consequence of neuroinflammation
is still unclear. The EOC13 cell line may be useful for further investigating P2X7‐mediated
events in microglia, and the role of this receptor in microglia‐mediated neuroinflammation.
Given that microglia express other P2 receptors (Burnstock and Knight, 2004), as well as
adenosine receptors (Boison et al., 2010), it remains important to consider the potential
impact of these receptors when studying ATP responses in microglia, and to conduct studies
with specific antagonists when investigating P2X7‐mediated responses.
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P2X7 expression was also confirmed on primary murine microglia in the current study. Given
this expression, the P2X7‐mediated responses observed in EOC13 microglia in the current
study, and the observed up‐regulation of P2X7 in microglia in ALS (Yiangou et al., 2006), the
efficacy of a P2X7 antagonist on disease progression was investigated, as described in the
following chapter (Chapter 3).
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3.1

Background

3.1.1 G93A superoxide dismutase 1 mouse model of ALS
To investigate mechanisms of disease and potential therapeutic strategies, several
transgenic SOD1 ALS mouse models have been generated (Turner and Talbot, 2008),
including the SOD1G93A mouse model (Gurney et al., 1994). SOD1G93A mice carry a high copy
number of a transgene encoding for the G93A variant of human SOD1, and develop an ALS‐
like disease which is characterised by the loss of motor neurons leading to hind limb
weakness and paralysis (Gurney et al., 1994). These mice display similar pathological
hallmarks to those seen in the human disease, including an accumulation of SOD1‐ and
ubiquitin‐containing protein aggregates in motor neurons, the presence of reactive
microglia, and increased expression of cytokines and chemokines such as monocyte
chemoattractant protein‐1 (MCP‐1) (Cheroni et al., 2005; Hall et al., 1998; Kawaguchi‐Niida
et al., 2013). In addition, SOD1G93A mice have a similar gender incidence and prevalence of
disease to human ALS (Cervetto et al., 2013; McCombe and Henderson, 2010; Veldink et al.,
2003). Thus, these mice are widely used in pre‐clinical studies.
3.1.2 Role for P2X7 in neuroinflammation in ALS
Neuroinflammation is emerging as a central component of ALS progression (Henkel et al.,
2009). In the central nervous system (CNS), activation of P2X7 is responsible for mediating a
number of neuroinflammatory events, including microglial activation and proliferation
(Monif et al., 2009). P2X7 immunoreactivity is increased in activated microglia of spinal
cords from (post‐mortem) humans with ALS and advanced‐stage transgenic SOD1G93A rats
(Casanovas et al., 2008; Yiangou et al., 2006). Furthermore, P2X7 is up‐regulated in primary
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microglia from SOD1G93A mice (D'Ambrosi et al., 2009). These cells produce increased
amounts of pro‐inflammatory factors and undergo oxidative stress following ATP
stimulation (Apolloni et al., 2013b; D'Ambrosi et al., 2009; Parisi et al., 2013). These
exacerbated pro‐inflammatory responses lead to the death of neuronal cell lines, and are
abrogated by pharmacological blockade or gene deletion of microglial P2X7. Similarly, ATP‐
induced activation of P2X7 causes neurotoxic phenotypes in wild type (WT) microglia and
WT or SOD1G93A astrocytes, leading to the death of co‐cultured neurons (Gandelman et al.,
2010; Skaper et al., 2006).
3.1.3 Brilliant Blue G
BBG is a non‐competitive P2X7 antagonist (Jiang et al., 2000) which is widely used in in vivo
studies due to its low toxicity and cost (Peng et al., 2009; Remy et al., 2008), and high
selectivity for P2X7 compared to other P2X receptors (Jiang et al., 2000). BBG has had
neuroprotective effects in a number of rodent models of CNS disorders, including models of
Huntington’s disease (Diaz‐Hernandez et al., 2009), multiple sclerosis (Matute et al., 2007)
and spinal cord injury (Peng et al., 2009), suggesting it may be a suitable candidate in
models of diseases characterised by neuroinflammation.
3.1.4 Aims
Given the similarities between human ALS and the murine disease resulting from over‐
expression of human SOD1G93A, and the need for further information on the efficacy of P2X7
receptor blockade on ALS progression, this study aimed to investigate the therapeutic
efficacy of the P2X7 antagonist BBG on disease progression in SOD1G93A mice. In order to
shed light on the complex role of P2X7 in ALS, BBG was administered from pre‐onset, with
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disease parameters monitored throughout. Furthermore, a number of pathological
hallmarks of disease were analysed post‐end‐stage, including motor neuron counts,
microgliosis, lumbar P2X7 and SOD1 protein amounts and serum MCP‐1 concentrations.
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3.2

Methods

3.2.1 Reagents and antibodies
BBG, ethidium bromide, ATP, paraformaldehyde (PFA), RNAlater and glycerol gelatin were
from Sigma‐Aldrich (St. Louis, MO). Sterile 0.9% NaCl was from Fresenius Kabi (Bad
Homburg, Germany). Agarose was from Bioline (Alexandria, Australia). Ammonium‐chloride‐
potassium (ACK) lysing buffer, N‐PER™ neuronal protein extraction reagent, 100x Halt™
protease inhibitor single‐use cocktail, normal horse serum (NHS), DNase/RNase‐free distilled
water and SuperSignal West Pico Chemiluminescent Substrate were from ThermoFisher
Scientific (Waltham, MA). Foetal bovine serum (FBS) was from Lonza (Basel, Switzerland).
Tissue‐Tek® optimal cutting temperature (OCT) compound was from Sakura (Flemingweg,
Netherlands) and 22 mm glass coverslips were from Menzel Glaser (Braunschweig,
Germany). Diploma full‐cream milk powder was from Fonterra (Mount Waverley, Australia).
Bovine serum albumin (BSA) and all other reagent grade chemicals and salts were from
Amresco (Solon, OH). The antibodies (Abs) used are listed in Table 3.1.
3.2.2 Fluorescent cation dye uptake assay
To investigate BBG solubility and stability, ethidium+ uptake assays were performed as
outlined in Section 2.2.4. EOC13 cells (see Section 2.2.2) suspended in NaCl medium (recipe
in Section 2.2.3) (2 × 105 cells/ 1 mL/ tube) were pre‐incubated at 37°C in the absence or
presence of the P2X7 antagonist BBG (as indicated) for 15 min, prior to ethidium+ and ATP
addition.
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Table 3.1 Antibodies used in Chapter 3 to test the efficacy of the P2X7 antagonist Brilliant Blue G on ALS
progression

Antibody target1
Mouse CD45
IgG2b isotype control
Mouse CD8α
Mouse CD25
Mouse/human CD11b
IgG2a isotype control
Mouse CD3ε
Mouse CD11c
IgG isotype control
Mouse CD19
Mouse CD4
Mouse Ly‐6G
IgG2a isotype control
Rabbit IgG
Mouse IgG
Iba1
Neuron‐specific β3 tubulin
P2X7 (extracellular)
Superoxide dismutase 1
IgG isotype control
IgG2a isotype control
Rabbit IgG
Sheep IgG

Conjugate1

Host species

FITC
FITC
PE
PE
PE
PE
PerCP/Cy5.5
PerCP/Cy5.5
PerCP/Cy5.5
APC
APC
APC
APC
Alexa Fluor 647
Alexa Fluor 488
‐
‐
‐
‐
‐
‐
Peroxidase
Peroxidase

Rat
Rat
Rat
Rat
Rat
Rat
Armenian hamster
Armenian hamster
Armenian hamster
Rat
Rat
Rat
Rat
Goat
Goat
Rabbit
Mouse
Rabbit
Sheep
Rabbit
Mouse
Goat
Donkey

Company2 (catalogue
number)
BioLegend (103107)
AbD Serotec (MCA1125FT)
BioLegend (100707)
BioLegend (101903)
BioLegend (101207)
eBioscience (12‐4321‐80)
BioLegend (100327)
BioLegend (117327)
BioLegend (400931)
BioLegend (115511)
BioLegend (100411)
BioLegend (127613)
BioLegend (400511)
Abcam (ab150079)
ThermoFisher (A11001)
Wako (019‐19741)
Abcam (ab78078)
Alomone Labs (APR‐008)
Abcam (ab8866)
Abcam (ab171870)
ICL (RS‐90G2a)
Rockland (611‐103‐122)
Merck Millipore (AB324P)

1

APC, allophycocyanin; Cy5.5, cyanine5.5; FITC, fluorescein isothiocyanate; Iba1, ionised calcium binding
adaptor molecule 1; Ig, immunoglobulin; PE, phycoerythrin; PerCP, peridinin chlorophyll. 2Abcam, Cambridge,
United Kingdom; AbD Serotec, Puchheim, Germany; Alomone Labs, Jerusalem, Israel; BioLegend, San Diego,
CA; eBioscience, San Diego, CA; ICL, Immunology Consults Laboratory, Portland, OR; Merck Millipore, Billerica,
MA; Rockland Immunochemicals, Gilbertsville, PA; ThermoFisher Scientific (Waltham, MA); Wako, Osaka,
Japan.

3.2.3 Animals
Animal studies were performed with the approval (AE12/09 and AE11/29) of the Animal
Ethics Committee of the University of Wollongong (Wollongong, Australia). Mice
hemizygous for the human SOD1G93A transgene and back‐crossed (>5 generations) onto a
C57Bl/6J background (B6‐Tg(SOD1‐G93A)1GUr/j) were provided by Bradley Turner
(University of Melbourne, Melbourne, Australia). Mice were bred and maintained at the
Australian BioResources (ABR) Animal Facility (Moss Vale, Australia) until required. At
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weaning, transgenic SOD1 mice were genotyped and relative SOD1 copy number assessed
(see Sections 3.2.4 and 3.2.5, respectively). At 45‐57 days of age (d), transgenic SOD1 mice
with relatively similar SOD1 copy numbers were transported to and housed at the University
of Wollongong in a temperature‐controlled environment on a 12:12 h light‐dark cycle, with
light onset at 7:00 AM. Mice were matched for SOD1 copy number, age and sex, and divided
into two treatment groups (Table 3.2). Mice were caged with paired littermates where
possible, with 4‐5 females or 3 males per cage. Food and water was available ad libitum.
When mice became symptomatic (clinical score >2; see Section 3.2.8) and unable to access
water or food, longer sippers were placed onto water bottles and food pellets placed
directly onto the cage floor.
To investigate lumbar SOD1 and P2X7 proteins over time, female SOD1G93A mice or WT
littermates lacking the SOD1 transgene at 30, 60, 90 and 120 d (3‐5 per group), genotyped
by the Garvan Institute of Medical Research (Darlinghurst, Australia) mouse genotyping
service, were transported to and processed at the University of Wollongong (see Section
3.2.12).
Table 3.2 Characteristics of mouse treatment groups at the beginning of treatment

Female
Number of Mice (n)
Copy Number (ΔCt)
Starting Age (d)
Starting Weight (g)
Starting ALS Score

Saline
12
6.2 ± 0.2
63.3 ± 0.9
17.2 ± 0.8
0±0

Male
BBG
13
6.2 ± 0.1
63.5 ± 0.8
17.4 ± 0.9
0±0

Saline
9
6.3 ± 0.1
63.4 ± 0.7
22 ± 1
0±0

BBG
8
6.3 ± 0.1
63.6 ± 0.7
21.4 ± 0.4
0±0

No significant differences between groups for any parameter (SOD1 transgene copy number, age, weight or
score) at the beginning of treatment. Copy number is determined as the difference in the crossing points for
the hSOD1 and mApoB curves (ΔCt). Results shown as means ± SD. BBG, Brilliant Blue G.
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3.2.4 Genotyping SOD1 transgenic mice
Mice carrying the human SOD1G93A transgene were differentiated from WT littermates by
multiplex polymerase chain reaction (PCR) and gel electrophoresis. Tail‐tip or ear clip
samples were obtained by staff at the ABR Animal Facility following weaning. Genomic DNA
was extracted at the University of Wollongong from samples using the REDExtract‐N‐Amp™
Tissue PCR Kit (Sigma‐Aldrich), as per the manufacturer’s instruction, except tissue was first
freeze/thawed three times in liquid nitrogen to improve extraction. PCR amplification was
performed in a 10 µL reaction volume, containing 5 µL REDExtract‐N‐Amp PCR Reaction Mix
(Sigma‐Aldrich), 2 µL genomic DNA, 0.4 µL of 20 µM forward and reverse primers for human
SOD1 (hSOD1) and mouse interleukin‐2 (mIL‐2) internal positive control (GeneWorks,
Hindmarsh, Australia) (Table 3.3), and 1.4 μL of UltraPure™ DNase/RNase‐free distilled
water. Primer pairs were generated based on the sequences from the Tg(SOD1) standard
PCR protocol (version 2.0) from Jackson Laboratories.
PCR amplification was performed using a Mastercycler® Pro S (Eppendorf, Hamburg,
Germany). Reactions were held at 95°C for 3 min, followed by 35 three‐segment cycles of
95°C for 1 min, 60°C for 30 s and 72°C for 1 min. Lastly, reactions were held at 72°C for
10 min, and then lowered to 4°C until removed. PCR products were separated on a 1.5% w/v
agarose gel in Tris‐acetate‐EDTA (TAE) buffer (40 mM Tris, 20 mM acetic acid, and 1 mM
ethylenediaminetetraacetic acid disodium salt) and visualised with ethidium bromide
staining. Images of gels were collected using a Gel Logic 212 PRO imaging system
(Carestream Health, Rochester, NY). Transgenic mice were identified as those showing a PCR
product for both hSOD1 (236 bp) and mIL‐2 (324 bp), while WT littermates only showed a
single PCR product corresponding to mIL‐2.
101

Chapter 3 – The efficacy of the P2X7 antagonist Brilliant Blue G on ALS progression

3.2.5 SOD1 copy number assay
To ensure equal transgene copy number, genomic DNA was assessed using multiplex
quantitative real‐time PCR (qPCR). qPCR amplification was performed in a 20 µL reaction
volume, containing 10 µL LightCycler® 480 Probes Master (Roche Diagnostics), 20 ng
genomic DNA, 2 µL of each custom‐made PrimeTime Std qPCR assay mix containing primers
and probes for either hSOD1 or the internal positive control (mouse ApoB) (Integrated DNA
Technologies, Coralville, IA) (Table 3.3), and 3‐6 μL PCR‐grade water (Roche Diagnostics).
Primer/probes were generated based on the sequences from the Sod TgN copy number
qPCR protocol (version 3.0) from Jackson Laboratories.
qPCR amplification was performed using a LightCycler® 480 II (Roche Diagnostics). Reactions
were held at 95°C for 10 min, followed by 40 two‐segment cycles of 95°C for 15 s and 60°C
for 1 min. A single fluorescence acquisition was taken each cycle, using FAM (498‐580 nm)
and Cy5/ Cy5.5 (618‐660 nm) filter combinations. Reactions were then held at 40°C for 30 s.
No‐template controls were included in each run and all samples were run in triplicate. For
each reaction, the relative crossing points of the hSOD1 and mApoB fluorescence curves
were determined using the advanced relative quantification tool in the LightCycler® 480
Software (release 1.5.1.62; Roche Diagnostics). The difference in the crossing points (ΔCt)
for the hSOD1 and mApoB curves was calculated for each animal, and all ΔCt values
compared to ensure equal transgene copy number (Table 3.2).
3.2.6 Brilliant Blue G injections
BBG was diluted at 6 mg/mL in sterile 0.9% NaCl (saline). Both saline and the BBG
preparation were filter‐sterilised through 0.22 μm filters (Merck Millipore) and stored at
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‐20°C until required. Mice were injected intraperitoneally three times per week with BBG
(45.5 mg/kg) from 62‐64 d (i.e. prior to disease onset) until end‐stage (see Section 3.2.10),
using Ultra‐Fine 0.5 mL, 29G syringes (BD Biosciences, San Diego, CA). Control littermates
were treated with the equivalent volume of saline. Injections were performed on alternating
sides of the abdomen to minimise irritation.
Table 3.3 Primer sequences and probes for genotyping SOD1 mice and determining copy number

Primers for genotyping assay
Gene
Primers
PCR Product (bp)
hSOD1
F: 5’‐CATCAGCCCTAATCCATCTGA‐3’
236
R: 5’‐CGCGACTAACAATCAAAGTGA‐3’
mIL‐2
F: 5’‐CTAGGCCACAGAATTGAAAGATCT‐3’
324
R: 5’‐GTAGGTGGAAATTCTAGCATCATCC‐3’
Primer/probes for copy number assay
Gene
PrimeTime Std qPCR Primer/Probes
hSOD1
F: 5’‐GGGAAGCTGTTGTCCCAAG‐3’
R: 5’‐CAAGGGGAGGTAAAAGAGAGC‐3’
Probe: 56‐FAM/CTGCATCTG/Zen/GTTCTTGCAAAACACCA/3IABkFQ
mApoB
F: 5’‐CACGTGGGCTCCAGCATT‐3’
R: 5’‐TCACCAGTCATTTCTGCCTTTG‐3’
Probe: 5Cy5/CCAATGGTCGGGCACTGCTCAA/3IAbRQSp
bp, base pair; hSOD1, human superoxide dismutase 1; mApoB, mouse apolipoprotein B; mIL‐2, mouse
interleukin‐2; PCR, polymerase chain reaction; qPCR, quantitative real‐time PCR; SOD1, superoxide
dismutase 1.

3.2.7 Body weight measurements
Body weight was assessed three times a week prior to each injection using a Classic Plus
PB602‐S/M‐FACT balance (Mettler Toledo, Columbus, OH), with two initial measurements
taken before the first injection, the average of which were defined as the pre‐symptomatic
disease maximum body weight (i.e. beginning at 58‐60 d). Measurements were taken at the
same time of day to prevent diurnal variations.
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3.2.8 ALS score
Mice were scored three times a week prior to each injection to assess neurological deficit,
using the criteria outlined by the ALS Therapy Development Institute (Table 3.4). Scoring
was started at 58‐60 d, and each score was taken at the same time of day.
Table 3.4 Neurological scoring system

Score
0
1
2
3
4

Criteria
Full extension of hind legs away from lateral midline when mouse is suspended by its tail;
mouse can hold this for 2 s, suspended 2‐3 times
Collapse or partial collapse of leg extension towards lateral midline (weakness) or
trembling of hind legs during tail suspension
Toes curl under at least twice during walking of 12 inches, or any part of foot is dragging
along cage bottom/table
Rigid paralysis or minimal joint movement, foot not being used for generating forward
motion
Mouse cannot right itself within 30 s after being placed on either side

3.2.9 Rotarod performance
Motor coordination was assessed weekly, beginning the first week of treatment (58‐63 d),
using a 5‐lane accelerating rotarod (RotaRod Advanced, TSE Systems, Hesse, Germany).
Mice received two training sessions in the week prior to recording. These sessions consisted
of one acclimatisation run with the rod rotating at a constant speed of 10 revolutions per
minute (rpm), followed by two to three runs with the rod accelerating from 4‐20 rpm over
180 s. Short rest intervals (minimum of 30 s) were given between runs. For testing, the rod
was programmed to rotate at a constant speed of 4 rpm for 5 s to allow mice to acclimatise,
followed by acceleration from 4‐20 rpm over 180 s. The length of time mice could remain on
the rod was recorded as the latency to fall, registered automatically by light‐beam sensors
under the rod. Mice were given at least 3 runs, with a minimum of 30 s between runs, to
obtain 3 readings of at least 5 s. The maximum time each animal was able to remain on the
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rod each week was recorded and included in the data analysis. Mice which were unable to
grip the rod due to advanced disease were given a minimum latency to fall of 5 s, the
baseline time.
3.2.10 Survival and end‐stage
Transgenic SOD1G93A mice suffer from paralysis and muscle atrophy as disease progresses
(Gurney et al., 1994). Thus, to minimise suffering, the disease end‐stage was defined when
mice first showed either 1) a 15% loss in body weight compared to their initial pre‐
symptomatic disease maximum body weight or 2) an inability to right themselves within
30 s after being placed on either side (i.e. a score of 4; see Section 3.2.8). Once the end‐
stage had been reached, mice were euthanised by asphyxiation using a slow‐fill carbon
dioxide inhalation technique.
Deceased animals with matching littermate controls were split into three post‐study groups.
For the first two groups, deceased mice were perfused with phosphate‐buffered saline (PBS)
followed by PFA (see Section 3.2.11), or with PBS alone (see Section 3.2.12), and brains and
spinal cords collected for immunohistochemical and biochemical analyses, respectively. For
the third group, serum, spleen and liver (see Sections 3.2.13, 3.2.14 and 3.2.15) were
collected from non‐perfused animals for further analysis.
3.2.11 Immunohistochemistry
3.2.11.1 Spinal cord processing
Immediately following euthanasia, mice were transcardially perfused with PBS followed by
4% PFA once perfusate ran clear. Spinal cords were then dissected, post‐fixed with 4% PFA
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at room temperature for 2 h, and then washed twice with PBS. Following this, spinal cords
were cryoprotected in 30% sucrose in PBS at 4°C for a minimum of 2 d. Tissue was
embedded in OCT medium, frozen by suspending above a layer of liquid nitrogen, and
stored at ‐80°C until ready to be sectioned (maximum of 10 d). Spinal cord transverse
sections of 20 μm thickness were cut from the lumbar regions of the spinal cords on a
CM1950 cryostat (Leica, Mannheim, Germany), using spinal cord enlargement to identify
the lumbar region. Sections were mounted onto StarFrost® advanced adhesive slides
(Knittel Glaser, Braunschweig, Germany) and stored at ‐80°C until required (maximum of 4
weeks).
3.2.11.2 Iba1 and β3‐tubulin staining
Microglia and motor neuron numbers were assessed by staining mounted spinal cords for
Iba1 and β3‐tubulin, respectively (see Sections 3.2.11.3 and 3.2.11.4). Firstly, a pap pen
(Daido Sangyo, Tokyo, Japan) was used to separate tissue sections on the same slide. All
incubations were carried out in a humidified chamber. Sections were fixed with 4% PFA in
PBS at room temperature for 15 min, and then washed three times with PBS over 30 min.
Next, sections were blocked with 20% NHS in PBS at room temperature for 20 min, and then
incubated at 4°C overnight with rabbit anti‐Iba1 polyclonal antibody (pAb) (0.1 μg/ 100 μL)
and mouse β3‐tubulin monoclonal antibody (mAb) (0.5 μg/ 100 μL), or rabbit IgG isotype
control pAb and mouse IgG2a isotype control at corresponding concentrations, all in PBS
containing 1% BSA, 0.2% NHS and 0.05% NaN3. The following day, sections were washed as
above, and incubated at room temperature for 1 h with Alexa Fluor 647‐conjugated goat
anti‐rabbit IgG Ab (0.3 μg/ 100 μL) and Alexa Fluor 488‐conjugated goat anti‐mouse IgG Ab
(0.3 μg/ 100 μL) in PBS containing 0.2% NHS. Cells were washed as above and then
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coverslips mounted onto tissue sections with 50% (v/v) glycerol gelatin in PBS. Coverslips
were sealed with nail varnish. Sections were visualised using a TCS SP5 II confocal imaging
system and images of anterior horns captured using Leica Application Suite Advanced
Fluorescence Lite software (Version 2.6.3) (Leica) (excitation 633, emission collected at 655‐
695 nm for Iba1; excitation 488 nm, emission collected at 510‐550 nm for β3‐tubulin).
Images were taken of 6‐12 anterior horns per animal, for a total of 12 animals (6 per
treatment group). Spinal cord anterior horns were defined as the regions of gray matter on
the ventral side of a horizontal line crossing through the central canal.
3.2.11.3 Microglia density
Microglia density was assessed in anterior horns using images of Iba1‐stained spinal cords
(see Section 3.2.11.2) and ImageJ software (Version 1.48) (National Institutes of Health,
Bethesda, MD). Firstly, thresholds were adjusted into 16‐bit black and white images to
account for any differences in the intensity of staining or in the background fluorescence
between sections. Particles between 10‐1000 pixel units were then counted, and the
percent area showing positive immunostaining for Iba1 of the total anterior horn calculated.
Percent areas from the right and left anterior horns for each section were averaged, and
then the average count from 3‐6 sections used as a single measurement per animal for
statistical analyses.
3.2.11.4 Motor neuron counts
The numbers of motor neurons in anterior horns were manually counted using images of
β3‐tubulin‐stained spinal cords (see Section 3.2.11.2) visualised in Leica Application Suite
Advanced Fluorescence Lite software. Motor neurons were defined as cells with cell body

107

Chapter 3 – The efficacy of the P2X7 antagonist Brilliant Blue G on ALS progression

diameters of at least 15 μm showing positive immunostaining for β3 tubulin. Counts from
the right and left anterior horns for each section were averaged, and then the average count
from 3‐6 sections used as a single measurement per animal for statistical analyses.
3.2.12 Immunoblotting
3.2.12.1 Spinal cord protein extraction
Immediately following euthanasia, mice were transcardially perfused with PBS. Spinal cords
were then dissected, and the lumbar portion excised using spinal cord enlargement to
identify the region. Lumbar spinal cord segments were snap‐frozen in liquid N2 and stored at
‐80°C until required. Detergent‐soluble proteins were extracted from lumbar spinal cords by
homogenising tissue in ice‐cold neuronal protein extraction reagent containing 100x Halt™
protease inhibitor cocktail using a micropestle. A ratio of 10 μL extraction reagent per 1 mg
of tissue was utilised. Homogenates were incubated on ice for 10 min and cleared
(20,000 × g at 4°C for 10 min). To extract detergent‐insoluble proteins, the resulting pellet
was resuspended in 0.5 M Tris HCl (pH 6.8) containing 2% w/v SDS at the same volume as
utilised for soluble protein extraction (to maintain a consistent concentration with the
original solution), and incubated at room temperature for 10 min. Unsolubilised material
was cleared (20,000 × g for 15 min). Soluble and insoluble protein samples were stored at
‐20°C until required.
3.2.12.2 P2X7 and SOD1 protein detection
Soluble protein (50 μg) or an equivalent volume of insoluble protein were separated under
reducing conditions (5% β‐mercaptoethanol) using Any kD Mini‐PROTEAN TGX Stain‐Free
Gels (Bio‐Rad, Hercules, CA). Before immunoblotting, equal protein loading was confirmed
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by visualising stain‐free gels with a Bio‐Rad Criterion Stain Free Imager and Image Lab
software. Proteins were then transferred to nitrocellulose membranes (Bio‐Rad) using a Bio‐
Rad Trans‐Blot Turbo Transfer System. To allow for separate P2X7 and SOD1
immunoblotting, membranes were cut horizontally between 25 and 37 kDa, using the pre‐
stained marker as a guide. Both halves were then blocked at room temperature for 1 h with
Tris‐buffered saline (250 mM NaCl and 50 mM Tris, pH 7.5) containing 0.2% Tween‐20 and
5% milk powder, and then incubated at 4°C overnight with either an anti‐P2X7 pAb (1:500)
or anti‐SOD1 pAb (1:1000) in Tris‐buffered saline containing 0.2% Tween‐20 and 5% milk
powder. The following day, membranes were washed three times over 30 min with Tris‐
buffered saline containing 0.2% Tween‐20. Membranes were then incubated at room
temperature for 1 h with peroxidise‐conjugated anti‐rabbit (1:1000) or anti‐sheep (1:500)
IgG Ab (for P2X7 or SOD1, respectively) in Tris‐buffered saline containing 0.2% Tween‐20
and 5% milk powder. Membranes were washed as above, and proteins visualised using
chemiluminescent substrate and Amersham Hyperfilm ECL (GE Healthcare, Little Chalfont,
Buckinghamshire, UK). Films were processed using GBX Developer and Replenisher, and GBX
Fixer and Replenisher as per the manufacturer’s instructions (Kodak Australasia,
Collingwood, Australia). Images of films were collected using a GS‐800 Calibrated
Densitometer (Bio‐Rad). Relative P2X7 and SOD1 was quantified from these images using
ImageJ software, normalising to a single soluble protein sample included on all gels.
3.2.13 Serum monocyte chemoattractant protein‐1 measurements
Blood was collected immediately following euthanasia via cardiac puncture using a 27G
PrecisionGlide needle (BD Biosciences). Blood was then incubated at room temperature for
45‐90 min to allow for coagulation, and blood cells removed by centrifugation (1700 x g for
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5 min). Serum was stored at ‐80°C until needed. The amount of MCP‐1 present in serum was
measured using a mouse CCL2 (MCP‐1) ELISA Ready‐SET‐Go! kit (eBioscience), as per the
manufacturer’s instructions.
3.2.14 Splenocyte phenotyping
Spleens from euthanised mice were homogenised in PBS and filtered through Falcon 70 μm
nylon filters (BD Biosciences). Cells were washed with PBS (300 x g for 5 min), resuspended
in lysing buffer (155 mM NH4Cl, 10 mM KHCO3 and 0.1 mM Na2EDTA, pH 7.4), and incubated
at room temperature for 5 min. Cells were then washed as above and resuspended in cold
PBS containing 2% FBS. Cells (1 x 106/ tube) were incubated on ice for 20 min with
combinations of fluorochrome‐conjugated (see Table 3.1) anti‐mouse mAb: CD45, CD8, CD3
and CD19; CD45, CD25, CD3 and CD4; CD45, CD11b, CD11c and Ly6G; or corresponding
isotype controls. Cells were washed as above, and events collected using a LSRFortessa X‐20
Cell Analyzer (BD Biosciences) (excitation 488 nm, emission collected with 525/50 and
695/40 band‐pass filters for FITC‐ and PerCP/Cy5.5‐conjugated Abs, respectively; excitation
561, emission collected with 585/15 band‐pass filter for PE‐conjugated Abs; excitation 640,
emission collected with 670/30 band‐pass filter for APC‐conjugated Abs). Percentages of
leukocyte subsets were determined using FlowJo software (Tree Star, Ashland, OR).
3.2.15 P2X7 expression by qPCR
Small sections of livers and spleens dissected from euthanised mice, approximately 5 mm3 in
size, were cut and stored in RNAlater at 4°C. After 1‐2 d, tissues were transferred to ‐20°C
until needed. P2X7 expression in livers and spleens was kindly assessed by Debbie Watson
(University of Wollongong, Wollongong, Australia). Firstly, tissues were removed from
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RNAlater and total RNA isolated using TRIzol reagent (ThermoFisher Scientific), as per the
manufacturer’s instructions. cDNA was synthesised from isolated RNA using a GeneAmp PCR
System 9700 (ThermoFisher Scientific) and qScript cDNA Synthesis Kit (Quanta Biosciences,
Gaithersburg, MD), as per the manufacturer’s instructions. qPCR amplification was
performed in a 10 µL reaction volume, containing 5 μL 2x TaqMan Universal Master Mix II
(ThermoFisher Scientific), 2 μL liver or spleen cDNA, 0.5 μL of 20x TaqMan Gene Expression
Assay‐Specific primers/probes (ThermoFisher Scientific), and PCR‐grade water. Standard
primers for murine P2RX7 (FAM‐labelled; Mm00440578_m1) and murine glyceraldehyde 3‐
phosphate

dehydrogenase

(GAPDH)

(VIC‐labelled;

Mm99999915_g1)

were

used.

Amplification was performed using an Eco Real‐Time PCR System (Illumina, San Diego, CA).
Reactions were held at 50°C for 2 min and 95°C for 10 min, followed by 40 two‐segment
cycles of 95°C for 15 s and 60°C for 1 min. A single fluorescence acquisition was taken each
cycle, using FAM (505‐545 nm) and VIC (562‐596 nm) filter combinations. No‐template
controls were included in each run and all samples were run in triplicate. cDNA obtained
from the spleen of a BALB/c mouse (provided by Dr Debbie Watson, University of
Wollongong) was also included in each run to compare relative P2X7 expression (given a
value of 1). Relative gene expression was normalised to the murine GAPDH housekeeping
gene and determined using EcoStudy software (version 4.1.2.0) (Illumina).
3.2.16 Data presentation and statistical analyses
Data is presented as mean ± SD, unless otherwise indicated. Differences between multiple
treatments were compared by ANOVA paired with Tukey’s HSD post‐tests. For single
comparisons, unpaired student’s t‐tests were performed. For body weight measurements,
differences between treatment groups at each recorded time‐point and over the entire
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period were compared using unpaired student’s t‐tests. For ALS score, rotarod performance
and survival data, differences in the values of BBG‐ and saline‐treated mice were assessed
using Kaplan‐Meier analysis paired with log‐rank tests, considering the time to reach a
consistent score of 2, drop to a consistent run of less than 60 s or end‐stage, respectively, as
an event. To prevent decomposition of means due to animals reaching end‐stage, for
weight, score and rotarod analyses, the last values prior to euthanasia were carried forward
until the last mouse in each group had reached end‐stage. These values were used to
compute means at the end of the study. The software package Prism 5 for Windows
(Version 5.01) (GraphPad Software, San Diego, CA) was used for all statistical analyses, with
differences considered significant for P < 0.05.
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3.3

Results

3.3.1 The P2X7 antagonist Brilliant Blue G inhibits ATP‐induced pore formation in EOC13
microglia and retains its inhibitory activity after being frozen for 15 weeks
BBG was chosen to test the benefits of pharmacological blockade of P2X7 in a mouse model
of ALS. BBG is recommended by the manufacturer to be prepared at a concentration of
1 mg/mL (Sigma‐Aldrich). Firstly, to determine if BBG can be prepared at the relatively high
concentration of 6 mg/mL (to allow its use in the proposed in vivo study), the inhibitory
action of 30 μM BBG on ATP‐induced pore formation in EOC13 cells was investigated, using
BBG prepared from 1 and 6 mg/mL stock solutions. This BBG concentration has previously
been shown to inhibit ATP‐induced pore formation in EOC13 cells by 75 ± 2% (Bartlett,
2011). In the current study, pre‐incubation of EOC13 cells with 30 μM BBG prepared from
either a fresh 1 or 6 mg/mL stock solution resulted in similar and significant impairment of
ATP‐induced ethidium+ uptake by 82 ± 2 or 82 ± 1 %, respectively (Figure 3.1a).
Next, to determine if BBG retains its activity after being stored for 15 weeks at ‐20°C, the
length of time required for the proposed in vivo study, the inhibitory action of 30 μM BBG
prepared from fresh and frozen stock solutions was investigated. As above, pre‐incubation
of EOC13 cells with 30 μM BBG prepared from either a fresh 1 mg/mL stock solution or
6 mg/mL stock solution frozen for 15 weeks resulted in similar and significant impairment of
ATP‐induced ethidium+ uptake by 79.7 ± 0.4 or 79.1 ± 0.6%, respectively (Figure 3.1b).
BBG did not significantly alter the basal ethidium+ uptake into EOC13 cells (Figure 3.1a,b) or
the percentage of viable cells, as assessed by forward and side scatter (control basal, 59 ±
3%; 1 mg/ml BBG basal, 56 ± 2%; 6 mg/ml BBG basal, 57 ± 2%; control ATP, 63 ± 1%;
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1 mg/ml BBG ATP, 59 ± 1; 6 mg/ml BBG ATP, 60 ± 1; P > 0.05, n = 3). Thus, BBG stocks were
stored in aliquots at ‐20°C for the duration of the in vivo study below.

Figure 3.1 The P2X7 antagonist Brilliant Blue G (BBG) inhibits ATP‐induced pore formation in EOC13
microglia when made from 6 mg/mL stocks, and retains its inhibitory activity after being frozen for 15
weeks. Suspended EOC13 cells in NaCl medium were pre‐incubated in the absence (control) or presence of
30 μM BBG at 37°C for 15 min, and then incubated in the absence (basal) or presence of 1 mM ATP at 37°C for
5 min in the presence of 25 μM ethidium+. Incubations were stopped by the addition of MgCl2 medium. Mean
fluorescence intensities (MFIs) of ethidium+ (pore formation) were determined by flow cytometry and results
shown as means ± SD, n = 3; ∗∗∗P < 0.001 compared to corresponding basal; †††P < 0.001 compared to control
ATP. BBG was prepared from (a) fresh 1 or 6 mg/mL stock solutions or (b) fresh 1 mg/mL stock solution or
6 mg/mL stock solution frozen for 15 weeks.

3.3.2 Brilliant Blue G treatment reduces body weight loss and prolongs survival in female
but not male SOD1G93A mice, but has no affect on clinical score or motor
coordination
3.3.2.1 SOD1G93A mouse treatment group selection
WT and SOD1G93A mice were distinguished by PCR using primers for hSOD1 and mIL‐2.
Transgenic mice were identified as those showing 230 and 300 bp PCR products,
corresponding to hSOD1 and mIL‐2, respectively, while WT littermates only showed a
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300 bp PCR product corresponding to mIL‐2 (Figure 3.2a). Since a background level of copy
loss of the human SOD1G93A transgene has been observed and correlated with an extension
of lifespan (Alexander et al., 2004), transgene copy number for each mouse expressing
SOD1G93A was then analysed by qPCR. Representative fluorescence curves for one SOD1G93A
and WT mouse are shown in Figure 3.2b. All SOD1G93A mice had similar ΔCt values, with no
differences between groups (female saline group, 6.2 ± 0.2; female BBG group, 6.2 ± 0.1;
male saline group, 6.3 ± 0.1; male BBG group, 6.3 ± 0.1; ANOVA, P = 0.522, n = 8‐13).

Figure 3.2 Representative genotyping and SOD1 copy number data from B6‐Tg(SOD1‐G93A)1GUr/j mice.
Genomic DNA was isolated from tail‐tip or ear clip samples and amplified by (a) RT‐PCR using primers for
human SOD1 (hSOD1) and mouse interleukin‐2 (mIL‐2) or (b) qPCR using primers for hSOD1 and mouse
apolipoprotein B (mApoB). (a) PCR products were separated and visualised on a 1.5% agarose gel with
ethidium bromide staining. SOD1G93A mice were identified as those showing a PCR product for both hSOD1 and
mIL‐2, while wild type (WT) littermates were identified by a single PCR product corresponding to mIL‐2. (b)
Representative hSOD1 and mApoB fluorescence curves for SOD1G93A mice, WT mice and no‐DNA controls (Nil)
are presented. Samples displayed are in triplicate. (a and b) Results shown are from one WT and one SOD1G93A
mouse and are representative of all SOD1 genotyping and copy number analyses.
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3.3.2.2 Brilliant Blue G treatment reduces body weight loss in female but not male
SOD1G93A mice
SOD1G93A mice were treated with saline or BBG from 62‐64 d (i.e. prior to disease onset)
until end‐stage, and body weight, ALS score and motor coordination recorded for the
duration of the study to assess disease progression.
Body weight of saline‐ and BBG‐treated SOD1G93A mice was maintained or rose until
approximately 105 d, after which continuous body weight loss was observed, with both
treatment groups plateauing at the ethical endpoint of 85% of the initial body weight
(Figure 3.3a). Overall, BBG‐treated mice had greater initial weight gain and a slower decline
in weight compared to saline‐treated mice over the entire period of the study (P = 0.014,
n = 21) (Figure 3.3a). Furthermore, on 19 out of 39 weight measurements days (days 63, 66,
80, 82, 84, 87, 89, 91, 94, 96, 98, 101, 103, 105, 108, 117, 119, 122 and 131) BBG‐treated
mice had significantly greater percentage body weights compared to saline‐treated mice
(P < 0.05, n = 21) (Figure 3.3a).
The effects of P2X7 antagonism in a mouse model of ALS have previously been reported to
be gender‐dependent (Cervetto et al., 2013). Thus, a subgroup analysis by gender was
performed to elucidate whether the differences in weight observed following BBG
treatment were gender dependent. Body weight loss occurred in a comparable manner for
both saline‐ and BBG‐treated male mice (P = 0.649, n = 8‐9) (Figure 3.3b). Furthermore,
there were no significant differences in male body weight as a percentage of the pre‐
symptomatic disease maximums on any weight measurement day. In contrast, BBG‐treated
female mice had significantly greater initial weight gain and a slower decline in weight
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compared to saline‐treated female mice over the entire period of the study (P = 0.006, n =
12‐13). Furthermore, on 21 out of 39 weight measurements days (days 63, 66, 73, 80, 82,
84, 87, 89, 91, 94, 96, 98, 101, 103, 105, 108, 117, 119, 122, 126 and 131) BBG‐treated
female mice had significantly greater percentage body weights compared to saline‐treated
female mice (P < 0.05, n = 12‐13) (Figure 3.3c).

G93A

Figure 3.3 Brilliant Blue G (BBG) treatment reduces body weight loss in female but not male SOD1
mice.
SOD1G93A mice were injected with 45.5 mg/kg BBG or an equivalent volume of saline 3 times per week from 62‐
64 d until end‐stage. Body weight was assessed 3 times per week during this period and results are shown as
the mean percentages ± SD of the pre‐disease (asymptomatic) maximum body weight for (a) all, (b) male or (c)
female BBG‐ and saline‐treated mice. Body weight was compared between saline‐ and BBG‐treated mice over
the entire period using unpaired student's t‐tests.
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3.3.2.3 Brilliant Blue G treatment does not improve clinical scores in male or female
SOD1G93A mice
To assess neurological deficit, mice were scored from 58‐60 d using the criteria outlined by
the ALS Therapy Development Institute (Table 3.4). At 58‐60 d, all saline‐ and BBG‐treated
mice had clinical scores of 0 (Figure 3.4a). These scores were maintained until 75 d, when
some mice in each treatment group began attaining scores of 1. From 75‐98 d, average
clinical scores for both saline‐ and BBG‐treated mice increased with similar trajectories,
leading to a plateau at a score of 1 from 101‐117 d for both groups. From 117 d, scores
again began to rapidly increase, with average scores rising slower for BBG‐treated mice
compared to saline‐treated mice between 126‐150 d. Finally, for saline‐ and BBG‐treated
mice, clinical scores appeared to plateau at approximately 2.5 at 145 and 150 d,
respectively. This plateau occurred at a lower score than the maximum score of 4, as most
mice lost 15% of their initial body weight before higher scores were attained. In fact, most
mice at end‐stage had scores of 2 (45%) or 3 (52%), with a score of 4 only observed in one
(BBG‐treated) mouse. Overall, considering the time to maintain a consistent score of 2 as an
event, there was no significant difference in score between saline‐ and BBG‐treated mice
(P = 0.349, n = 21) (Figure 3.4a).
Next, a subgroup analysis by gender was performed to elucidate whether differences in
score could be observed following BBG treatment in each gender. Score trajectories similar
to those described above were observed for both male and female saline‐ and BBG‐treated
mice (Figure 3.4b,c), except males plateaued at a score of 1 earlier (from 94‐115 d) and
females plateaued at a score of 1 for longer (101‐122 d). Overlapping score trajectories
were observed over the entire period, with no overall significant differences in score
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between saline‐ and BBG‐treated male mice when considering the time to maintain a
consistent score of 2 as an event (P = 0.647, n = 8‐9) (Figure 3.4b). For females, overlapping
score trajectories were initially observed. However average scores rose slower for BBG‐
treated female mice compared to saline‐treated mice between 122 and 150 d (Figure 3.4c).
Despite this, considering the time to maintain a consistent score of 2 as an event, there was
no significant difference in score between female saline‐ and BBG‐treated mice (P = 0.084,
n = 12‐13).

Figure 3.4 Brilliant Blue G (BBG) treatment does not improve ALS score in male or female SOD1G93A mice.
SOD1G93A mice were injected with 45.5 mg/kg BBG or an equivalent volume of saline 3 times per week from 62‐
64 d until end‐stage. Neurological deficit was assessed 3 times per week during this period, using the ALS score
criteria outlined by the ALS Therapy Development Institute (see Table 3.4). Results shown as mean score ± SD
for (a) all, (b) male or (c) female BBG‐ and saline‐treated mice. ALS score was compared between saline‐ and
BBG‐treated mice using log‐rank tests.
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3.3.2.4 Brilliant Blue G treatment does not improve motor coordination in male or female
SOD1G93A mice
Motor coordination was assessed weekly using an accelerating rotarod, beginning at 58‐
63 d. Motor coordination initially rose for both saline‐ and BBG‐treated mice, consistent
with mice continuing to learn how to use the rod, and was then maintained with some
variation until 95 d (Figure 3.5a). After 95 d, motor coordination rapidly declined for both
treatment groups, with comparable rates of decline (considering the time to reach a latency
to fall consistently less than 60 s P = 0.311, n = 21) (Figure 3.5a).
After stratifying the data by gender, similar patterns of motor deficit to that described
above were observed for both male and female saline‐ and BBG‐treated mice (Figure
3.5b,c), again with comparable rates of decline between those treated with saline and those
with BBG (considering the time to reach a latency to fall consistently less than 60 s
P = 0.390, n = 8‐9 and P = 0.586, n = 12‐13 for males and females, respectively).
3.3.2.5 Brilliant Blue G treatment prolongs survival in female but not male SOD1G93A mice
End‐stage was considered reached once mice displayed either a 15% loss in body weight
compared to their initial pre‐symptomatic disease maximum body weight, or an inability to
right themselves within 30 s after being placed on either side (i.e. a score of 4). The resulting
Kaplan‐Meier survival curves are shown in Figure 3.6. BBG treatment, beginning at 62‐64 d,
did not affect the survival rate of SOD1G93A mice (saline 141 ± 6 d vs. BBG 144 ± 6 d,
P = 0.270, n = 21), with similar rates of decline in percent survival observed for both saline‐
and BBG‐treated mice (Figure 3.6a). However, there appeared to be a slight tendency for
this rapid decline to be delayed in BBG‐treated mice (Figure 3.6a).

120

Chapter 3 – The efficacy of the P2X7 antagonist Brilliant Blue G on ALS progression

Figure 3.5 Brilliant Blue G (BBG) treatment does not improve motor coordination in male or female SOD1G93A
G93A
mice. SOD1
mice were injected with 45.5 mg/kg BBG or an equivalent volume of saline 3 times per week
from 62‐64 d until end‐stage. Motor coordination was assessed once per week during this period, using an
accelerating rotarod programmed to rotate at a constant acclimatising speed of 4 rpm for 5 seconds (s),
followed by acceleration from 4‐20 rpm over 180 s. Results shown as mean latency to fall ± SD for (a) all, (b)
male or (c) female BBG‐ and saline‐treated mice. The latency to fall was compared between saline‐ and BBG‐
treated mice using log‐rank tests.

When considering males alone, survival was similarly not affected by BBG treatment (saline
143 ± 7 d vs. BBG 142 ± 6 d, P = 0.582, n = 8‐9), again with similar rates of decline observed
for both saline‐ and BBG‐treated mice (Figure 3.6b). Conversely for females, BBG treatment
extended survival (saline 139 ± 6 d vs. BBG 145 ± 6 d, P = 0.035, n = 12‐13) (Figure 3.6c).
Whilst similar rates of decline were observed for both female saline‐ and BBG‐treated mice,
this decline was delayed following BBG treatment in females.
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Figure 3.6 Brilliant Blue G (BBG) treatment prolongs survival in female but not male SOD1G93A mice. SOD1G93A
mice were injected with 45.5 mg/kg BBG or an equivalent volume of saline 3 times per week from 62‐64 d until
end‐stage. Mice were euthanised once either a 15% loss in body weight compared to initial pre‐symptomatic
disease maximum body weight was reached or an inability to right within 30 s after being placed on either side
was demonstrated. Results shown as percent survival for (a) all, (b) male or (c) female BBG‐ and saline‐treated
mice. Survival was compared between saline‐ and BBG‐treated mice using log‐rank tests.

3.3.3 Brilliant Blue G treatment does not reduce motor neuron loss or microgliosis in
SOD1G93A mice
3.3.3.1 The mis‐identification of a wild type mouse was confirmed, allowing for its use as a
control in immunohistochemistry
Over the course of the project one BBG‐treated mouse continued to gain weight, retained a
score of 0 and maintained rotarod motor coordination, suggesting a WT genotype.
Treatment was continued for this mouse, but this mouse was excluded from the study. At
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the end of the study, tissue was taken for re‐genotyping. This tissue showed a single PCR
product corresponding to mIL‐2, while the original tissue (provided by the ABR) was
confirmed to have both 230 and 300 bp PCR products, corresponding to hSOD1 and mIL‐2,
respectively (Figure 3.7). Thus the mouse in question had a WT genotype and was included
as control tissue for immunohistochemistry.

Figure 3.7 Brilliant Blue G‐treated mouse which did not develop disease had a wild type genotype. Genomic
DNA isolated from original or post‐euthanasia skin samples, or from control skin samples from SOD1G93A and
wild type (WT) mice, was amplified by RT‐PCR using primers for human SOD1 (hSOD1) and mouse interleukin‐2
(mIL‐2). PCR products were separated and visualised on a 1.5% agarose gel with ethidium bromide staining.

3.3.3.2 Brilliant Blue G treatment does not reduce motor neuron loss in SOD1G93A mice
To determine the effect of BBG‐treatment on motor neuron loss, neurons in the anterior
horn of lumber spinal cords from end‐stage saline‐ and BBG‐treated mice were labelled with
a neuron‐specific β3 tubulin Ab, images captured with confocal microscopy and motor
neurons counted. The lumbar spinal cord was chosen as this is the CNS tissue in which lower
motor neurons reside and that is predominately damaged during ALS (Apolloni et al., 2013a).
Representative images of an anterior horn of the WT mouse, and saline‐ and BBG‐treated
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SOD1G93A mice, are shown (Figure 3.8a). The average number of motor neurons, identified
as cells with cell body diameters of at least 15 μm, was on average 33% lower in SOD1G93A
mice compared to the WT control (SOD1G93A 19.4 ± 1.6 vs. WT 29 motor neurons) (Figure
3.8b). However, there was no difference in the number of motor neurons between saline‐
and BBG‐treated SOD1G93A mice (saline 19.3 ± 2.0 vs. 19.5 ± 1.4 motor neurons, P = 0.868,
n = 6) (Figure 3.8b). Of note, at necropsy, BBG (blue colouring) was not evident in CNS
tissues, but was observed in peripheral tissues such as spleen and liver (data not shown).

Figure 3.8 Brilliant Blue G (BBG) treatment does not reduce motor neuron loss in the anterior horn of
SOD1G93A mice. Lumbar spinal cord transverse cross sections (20 μm) from BBG‐ or saline‐treated SOD1G93A
mice at end‐stage, or from the wild type (WT) littermate of corresponding age, were fixed with
paraformaldehyde and labelled with an anti‐β3‐tubulin mAb or corresponding isotype control, and Alexa Fluor
488‐conjugated anti‐IgG Ab, and analysed by confocal microscopy. (a) Representative confocal images of
anterior horn are shown. Bars represent 100 μm. (b) Neurons with diameters of at least 15 μm (motor
neurons) were counted in each anterior horn. Results shown as mean motor neuron count per anterior horn
± SD, n = 1 WT mouse (no SD) or n = 6 SOD1G93A mice (male and female). Symbols represent individual animals.
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3.3.3.3 Brilliant Blue G treatment does not reduce microgliosis in SOD1G93A mice
P2X7 is reported to be directly involved in microglial activation (Monif et al., 2010). Thus,
microglia in the anterior horn of lumber spinal cords from end‐stage saline‐ and BBG‐treated
mice were labelled with the microglial marker Iba‐1, images captured with confocal
microscopy and density of microglia assessed. Representative images of an anterior horn of
the WT mouse, and saline‐ and BBG‐treated SOD1G93A mice, are shown (Figure 3.9a). The
amounts of microgliosis were substantially higher in SOD1G93A mice compared to the WT
control (SOD1G93A 2.6 ± 0.6% vs. WT 0.9%, i.e. 3‐fold higher) (Figure 3.9b). However, there

Figure 3.9 Brilliant Blue G (BBG) treatment does not reduce microgliosis in the anterior horn of SOD1G93A
mice. Lumbar spinal cord transverse cross sections (20 μm) from BBG‐ or saline‐treated SOD1G93A mice at end‐
stage, or from the wild type (WT) littermate of corresponding age, were fixed with paraformaldehyde and
labelled with an anti‐Iba1 pAb or corresponding isotype control, and Alexa Fluor 647‐conjugated anti‐IgG Ab,
and analysed by confocal microscopy. (a) Representative confocal images of anterior horn are shown. Bars
represent 100 μm. (b) Results shown as mean percent area positive for Iba‐1 ± SD, n = 1 WT mouse (no SD) or
n = 6 SOD1G93A mice (male and female). Symbols represent individual animals.

125

Chapter 3 – The efficacy of the P2X7 antagonist Brilliant Blue G on ALS progression

was no difference in the amount of microgliosis between saline‐ and BBG‐treated SOD1G93A
mice (saline 2.6 ± 0.3% vs. 2.5 ± 0.8%, P = 0.821, n = 6) (Figure 3.9b).
3.3.4 Brilliant Blue G treatment does not affect the amount of detergent‐soluble or
‐insoluble lumbar SOD1 or P2X7 protein in SOD1G93A mice
To determine whether prolonged BBG treatment reduced the amount of P2X7 and SOD1 in
the lumbar spinal cords of end‐stage SOD1G93A mice, detergent‐soluble and ‐insoluble
protein fractions, prepared from lumbar spinal cords of saline‐ and BBG‐treated mice, were
examined by immunoblotting with anti‐P2X7 and anti‐SOD1 pAb and densitometry. All
samples were normalised to one soluble sample (indicated in red). SOD1 (16 kDa) was
present in both soluble and insoluble fractions, with similar amounts detected between
saline‐ and BBG‐treated mice (soluble P = 0.842, n = 7; insoluble P = 0.149, n = 7) (Figure
3.10a,c).
Immunoblotting with a P2X7 Ab raised against an extracellular epitope revealed multiple
proteins, with approximate sizes of 155, 60 and 50 kDa, as well as a doublet around 73‐
89 kDa (Figure 3.10b,d). This doublet most likely corresponds to full‐length P2X7 monomers
(P2X7A) (Masin et al., 2012). There was no difference in total P2X7 amounts between saline‐
and BBG‐treated mice in either soluble or insoluble fractions (soluble P = 0.821, n = 7;
insoluble P = 0.776, n = 7) (Figure 3.10b,d). There was also no difference in amounts of
P2X7A between saline‐ and BBG‐treated mice in either soluble or insoluble fractions (soluble
P = 0.571, n = 7; insoluble P = 0.689, n = 7) (Figure 3.10b,d).
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Figure 3.10 Brilliant Blue G (BBG) treatment does not affect the amount of detergent‐soluble or ‐insoluble
lumbar SOD1 or P2X7 protein in SOD1G93A mice. (a and b) Soluble or (c and d) insoluble protein fractions from
homogenised BBG‐ or saline‐treated SOD1G93A mouse lumbar spinal cords at end‐stage were separated by SDS‐
PAGE under reducing conditions, transferred to nitrocellulose membranes, and incubated with (a and c) anti‐
SOD1 or (b and d) anti‐P2X7 pAbs. Representative blots are indicated. Results shown as mean (a and b) soluble
or (c and d) insoluble SOD1 or P2X7 ± SD, n = 7 mice (male and female). Amounts shown are relative to
corresponding soluble proteins of one saline mouse (indicated in red). Symbols represent individual animals.

3.3.5 Brilliant Blue G treatment partially increases serum MCP‐1 concentrations in
SOD1G93A mice
MCP‐1, an inflammatory chemokine involved in the recruitment of monocyte‐derived cells
such as microglia, is up‐regulated in ALS mice (Kawaguchi‐Niida et al., 2013) and patients
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(Henkel et al., 2004; Nagata et al., 2007; Wilms et al., 2003). Thus, the concentrations of
MCP‐1 in the serum of end‐stage saline‐ and BBG‐treated mice was investigated to
determine whether BBG treatment was able to reduce serum MCP‐1. Low concentrations of
MCP‐1 were detected in both saline‐ and BBG‐treated mice (Figure 3.11). In contrast to
expectations, serum MCP‐1 concentrations were 1.4‐fold higher in BBG‐treated mice
compared to saline‐treated mice; a difference approaching statistical significance (P = 0.052,
n = 6).

Figure 3.11 Brilliant Blue G (BBG) treatment partially increases serum monocyte chemoattractant protein‐1
(MCP‐1) concentrations in SOD1G93A mice. Serum from BBG‐ or saline‐treated SOD1G93A mice at end‐stage was
collected and MCP‐1 concentrations determined using an ELISA. Results shown as means ± SD, n = 6 (male and
female). Symbols represent individual animals.

3.3.6 Brilliant Blue G treatment does not affect the distribution of splenocytes from
SOD1G93A mice
Injection of BBG over 8 weeks has been shown to alter the percentage of Treg cells in mice
(Zhao et al., 2013). Therefore, to determine if long‐term exposure to BBG altered Treg or
other immune cells in the current study, the percentage of splenocyte subsets of the
leukocytes (CD45+) from end‐stage saline and BBG‐treated SOD1G93A mice was next
investigated and compared by flow cytometry. There were no differences in the
percentages of B cells (CD19+CD3‐; P = 0.362, n = 6), total T cells (CD3+CD19‐; P = 0.615, n =
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Figure 3.12 Brilliant Blue G (BBG) treatment does not affect the distribution of splenocytes from SOD1G93A
mice. Splenic cells from BBG‐ or saline‐treated SOD1G93A mice at end‐stage were labelled with fluorochrome‐
conjugated anti‐CD45 and (a‐c) anti‐CD8, ‐CD3 and ‐CD19, (d‐e) anti‐CD25, ‐CD3 and ‐CD4, or (f‐h) anti‐CD11b,
‐CD11c and ‐Ly6G mAb. The percentage of (a) B cells (CD19+CD3‐), (b) T cells (CD3+CD19‐), (c) CD8+ T cells
(CD8+CD3+CD19‐), (d) CD4+ T cells (CD4+CD3+), (e) regulatory T (Treg) cells (CD25+CD4+CD3+), (f) dendritic
cells (DCs; CD11b±CD11c+), (g) macrophages (MOs; CD11b+CD11c‐Ly6G‐) and (h) polymorphonuclear
neutrophils (PMNs; CD11b+CD11c‐Ly6G+) of the total leukocyte (CD45+) population were determined by flow
cytometry. Results shown as means ± SD, n = 6 (male and female). Symbols represent individual animals.
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6), CD8+ T cells (CD8+CD3+CD19‐; P = 0.643, n = 6), CD4+ T cells (CD4+CD3+; P = 0.549, n =
6), Treg cells (CD25+CD4+CD3+; P = 0.239, n = 6), dendritic cells (DCs; CD11b±CD11c+;
P = 0.981, n = 6), macrophages (MOs; CD11b+CD11c‐Ly6G‐; P = 0.130 n = 6) or
polymorphonuclear neutrophils (PMNs; CD11b+CD11c‐Ly6G+; P = 0.084, n = 6) between
saline‐ and BBG‐treated mice (Figure 3.12).
3.3.7 Brilliant Blue G treatment does not affect P2X7 expression in the spleens or livers of
SOD1G93A mice
To determine if the prolonged BBG treatment altered P2X7 expression in non‐CNS tissues,
the expression of murine P2X7, relative to murine GAPDH expression, in spleens and livers
from end‐stage saline‐ and BBG‐treated mice was determined by qPCR. Relative P2X7
expression in either the spleens (P = 0.644, n = 6) or livers (P = 0.942, n = 6) was similar
between saline‐ and BBG‐treated mice (Figure 3.13). Relative P2X7 expression was 10‐fold
greater in spleens compared to livers (Figure 3.13).

Figure 3.13 Brilliant Blue G (BBG) treatment does not affect P2X7 expression in the spleens or livers of
SOD1G93A mice. RNA was isolated from (a) spleens and (b) livers from BBG‐ or saline‐treated SOD1G93A mice at
end‐stage. cDNA was synthesised from isolated RNA and amplified by qPCR using primers for mP2X7 and
mouse GAPDH (mGAPDH) to determine mP2X7 expression (normalised to mGAPDH). mP2X7 expression is
relative to one control sample (obtained from BALB/c spleen; not shown). Results shown as means ± SD, n = 6
(male and female). Symbols represent individual animals.
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3.3.8 The amount of detergent‐soluble or ‐insoluble lumbar SOD1 or P2X7 protein does
not change over time in female SOD1G93A mice
To determine whether the amount of SOD1 or P2X7 protein in the lumbar spinal cords of
SOD1G93A mice change with age, and whether differences exist in SOD1 or P2X7 protein
between SOD1G93A mice and their WT littermates lacking the SOD1 transgene, detergent‐
soluble and ‐insoluble lumbar spinal cord fractions were prepared and proteins examined by
immunoblotting. Given that BBG treatment delayed weight loss and prolonged survival in
females, but not males, female mice were used for these analyses. SOD1 (16 kDa) was
present in both soluble and insoluble fractions derived from SOD1G93A mice, but was
negligible in fractions derived from WT littermates (Figure 3.14a,b). The amount of
detergent‐soluble and ‐insoluble SOD1 did not significantly change over time in lumbar
spinal cords of SOD1G93A mice (soluble P = 0.160, n = 4‐5; insoluble P = 0.794, n = 4‐5).
Similar to previous observations, immunoblotting with a P2X7 Ab raised against an
extracellular epitope revealed multiple proteins, with approximate sizes of 160, 60 and
50 kDa, as well as a doublet around 80‐90 kDa (Figure 3.14c,d). Total P2X7 amounts were
similar between fractions derived from WT and SOD1G93A mice at each time point. The
amount of detergent‐soluble or ‐insoluble total P2X7 did not significantly change over time
in lumbar spinal cords of WT or SOD1G93A mice (SOD1 soluble P = 0.144, n = 4‐5; WT soluble
P = 0.292, n = 3‐4; SOD1 insoluble P = 0.869, n = 4‐5; WT insoluble P = 0.445, n = 3‐4) (Figure
3.14c,d). Similarly, there were no differences in amounts of lumbar P2X7A between WT and
SOD1G93A mice at each time point for either fraction, and no significant differences in the
amount of lumbar P2X7A over time for SOD1G93A mice (soluble P = 0.170, n = 4‐5; insoluble P
= 0.115, n = 4‐5). Conversely, WT mice at 60 and 90 d had significantly less detergent‐soluble
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Figure 3.14 The amount of detergent‐soluble or ‐insoluble lumbar SOD1 or P2X7 protein does not change
over time in female SOD1G93A mice. (a and c) Soluble or (b and d) insoluble protein fractions from
homogenised female wild type (WT) or SOD1G93A mouse lumbar spinal cords at different ages were separated
by SDS‐PAGE under reducing conditions, transferred to nitrocellulose membranes, and incubated with (a and
b) anti‐SOD1 or (c and d) anti‐P2X7 pAbs. Representative blots are indicated. Results shown as mean (a and c)
soluble or (b and d) insoluble SOD1 or P2X7 ± SD, n = 3‐5 mice; *P < 0.05 compared to corresponding 30 d.
Amounts shown are relative to corresponding soluble proteins of one WT mouse at 30 days of age (indicated
in red). Symbols represent individual animals.
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lumbar P2X7A than at 30 d (P = 0.007, n = 3‐4), and at 90 and 120 d had significantly more
detergent‐insoluble lumbar P2X7A than at 30 d (P = 0.027, n = 3‐4) (Figure 3.14c,d).
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3.4

Discussion

3.4.1 Summary of results
In the current study, BBG treatment beginning at pre‐onset of clinical ALS (62‐64 d) delayed
weight loss and prolonged survival in female, but not male, SOD1G93A mice. Treatment had
no effect on ALS score or motor coordination in either sex. Furthermore, BBG treatment had
no effect on motor neuron loss, microgliosis, lumbar SOD1 or P2X7 protein amounts, serum
MCP‐1, splenocyte immunophenotype, or P2X7 expression in the spleen or liver at end‐
stage. Together, this suggests a limited efficacy of BBG on ALS progression as used in the
current study. This may suggest that the treatment regime (including antagonist) employed
was not the most suitable, or that P2X7 is not essential for ALS development in mice.
Furthermore, there was no difference in the amount of lumbar P2X7 protein observed in
SOD1G93A mice of different ages or between SOD1G93A and WT mice at any age. Despite this,
given the importance of P2X7 activation in neurological disease pathways, and observations
by others (Section 3.1.2) and with female SOD1G93A mice (this study), further investigations
into the role of P2X7 in ALS progression are still warranted.
3.4.2 Comparison of the present study with previous murine studies utilising Brilliant
Blue G as an ALS therapeutic
During the course of the current study, two other studies investigated the therapeutic
effects of BBG in SOD1G93A murine models of ALS (Apolloni et al., 2014; Cervetto et al.,
2013). In both these studies, positive outcomes were obtained, including delayed disease
onset, improved motor coordination, disease scores and motor neuron survival, and
reduced weight loss and microgliosis. Comparisons of these studies with the current study
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highlight important parameters effecting drug efficacy in murine ALS models, which should
be considered in future studies.
3.4.2.1 Effect of gender on disease outcomes
In the current study, BBG treatment slowed weight loss and extended survival in female, but
not male, mice. This is consistent with the extended lifespan of female heterozygous and
homozygous P2X7 knock‐out (P2X7KO)/SOD1G93A mice compared to P2X7WT/SOD1G93A mice
(Apolloni et al., 2013a). Gender also affected P2X7 antagonism in another study
investigating BBG efficacy in the SOD1G93A murine model of ALS. However, in contrast to the
current study, BBG significantly delayed the time taken for 10% weight loss and a decline in
motor coordination to be observed in male, but not female, mice in this study (Cervetto et
al., 2013). Furthermore, this gender dependency was not observed for any reported
parameters, including weight or motor coordination, following BBG treatment in the study
by Apolloni et al. (2014).
Differences in the genetic background of SOD1 mice may have an impact on the gender‐
specific outcomes of pharmacological studies. Differences in disease progression and
survival have been observed in SOD1G93A mice on SJL/J, C57BL/6J and C57BL/6J x SJL/J hybrid
backgrounds (Heiman‐Patterson et al., 2005). In this previous study, female mice on
C57BL/6J x SJL/J hybrid and SJL/J, but not on C57BL/6J, backgrounds survived significantly
longer than male mice (Heiman‐Patterson et al., 2005). This is consistent with the delayed
10% weight loss, delayed decline in motor performance and extended survival reported for
vehicle‐treated female compared to male SOD1G93A mice on a C57BL/6J x SJL/J hybrid
background (Cervetto et al., 2013). However, given that both the current study and the
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study by Apolloni et al, (2014) used SOD1 mice on a C57BL/6J background, additional
factors, such as sex, need to be considered.
Differences in sex hormones, in particular oestrogens, have been linked to improved disease
outcomes in females. Oestrogens are thought to be important in a wide range of CNS
processes, including in cell survival, mitochondrial function, oxidative stress, axonal sprouting,
synaptic transmission and neurogenesis (see Garcia‐Segura et al., 2001). In SOD1G93A mice,
removal of ovaries from females increased body weight loss, worsened simple motor
function and reduced lifespan compared to sham‐operated mice (Choi et al., 2008;
Groeneveld et al., 2004). These parameters were all reversed by oestrogen therapy (Choi et
al., 2008; Groeneveld et al., 2004). Furthermore, treatment of SOD1G93A mice with genistein,
a phytoestrogen, delayed disease onset and death in male, but not female mice (Trieu and
Uckun, 1999). Together, these studies support a neuroprotective role for oestrogen in ALS
and implicate sex hormones in the correlation between gender and ALS progression.
While the mechanism of oestrogen‐mediated neuroprotection is poorly understood,
oestrogen has been shown to inhibit P2X7‐mediated events in some cell types. In particular,
the oestrogen hormone 17β‐oestradiol inhibits P2X7‐mediated cation flux in monkey kidney
COS cells expressing human P2X7 (Cario‐Toumaniantz et al., 1998), and Ca2+ influx and
apoptosis in human uterine cervical cells (Gorodeski, 2004; Wang et al., 2004a). Although
there is limited data on the effects of 17β‐oestradiol or other oestrogen hormones on P2X7
in the CNS (see Crain and Watters, 2010), together these studies suggest that the beneficial
effects of BBG in female ALS mice may be due to additive or synergistic antagonism of P2X7.
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3.4.2.2 Effect of vehicle composition on Brilliant Blue G efficacy
Vehicle composition is another factor that may have influenced the efficacy of BBG
observed in the current study compared to previous studies. In the current study, dimethyl
sulfoxide (DMSO) was not included in the vehicle for BBG delivery, while DMSO was present
in the vehicle solution in both previous studies investigating the therapeutic effects of BBG
(Apolloni et al., 2014; Cervetto et al., 2013). DMSO is widely used in vitro and in vivo due to
its ability to solubilise a broad range of hydrophobic substances (Szmant, 1975). In the
current study, DMSO was excluded as BBG was soluble in its absence. Furthermore, DMSO is
well known to be toxic, especially when used chronically or at concentrations greater than
10% (Kloverpris et al., 2010). Indeed, in a recent study, intravitreal delivery of DMSO was
found to be toxic to rat retinal ganglion cells, a type of neuronal cell, at low doses (2‐4%)
(Galvao et al., 2014). Despite this, DMSO, albeit at much lower concentrations (0.2%), was
used to solubilise BBG for P2X7 antagonism in SOD1G93A mice (Apolloni et al., 2014; Cervetto
et al., 2013).
Intraperitoneally delivered DMSO is able to cross the blood‐brain barrier (Broadwell et al.,
1982). Thus, it is possible that the lack of DMSO in the current study prevented adequate
BBG blood‐brain barrier penetrance. This is supported by the lack of observable blue
colouring in the CNS of post‐mortem mice. While the colouring of CNS tissues resulting from
BBG treatment in previous murine models of ALS were not disclosed, in a study of spinal
cord injury, intravenous administration of a similar concentration of BBG in the absence of
DMSO resulted in blue colouring in the injury area, but not surrounding tissue (Peng et al.,
2009). This suggests that BBG entered the site of injury mainly via the disrupted spinal
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blood‐brain barrier in this study, and that DMSO may be required in the drug vehicle for
adequate BBG blood‐brain barrier penetrance.
3.4.2.3 Effect of Brilliant Blue G dose on efficacy
The limited efficacy of BBG in the current study may have been due to the dose used. BBG
was used at 45.5 mg/kg due to the efficacy of this dose in murine models of other
neurodegenerative conditions, including Huntington’s disease and spinal cord injury (Diaz‐
Hernandez et al., 2009; Peng et al., 2009). This dose also improved disease outcomes in
C57BL/6J x SJL/J hybrid SOD1G93A mice (Cervetto et al., 2013). However, in the study of
Apolloni et al. (2014), 50 mg/kg BBG had no effect on disease outcomes in C57BL/6J
SOD1G93A mice. When the BBG dose was increased to 250 mg/kg in this study,
improvements in behavioural scores, motor performance and median disease onset were
observed (Apolloni et al., 2014). This may indicate that the BBG dose utilised in the current
study was insufficient to fully antagonise P2X7 in the CNS of C57BL/6J SOD1G93A mice.
3.4.2.4 Effect of the timing of treatment commencement on disease outcomes
An important consideration when designing a mouse study aimed at testing the therapeutic
efficacy of a substance is the timing of treatment commencement. In the current study, BBG
treatment was started before the onset of disease. In comparison, Cervetto et al. (2013)
began treatment after disease onset, with a similar BBG dosage, number of treatments per
week and delivery route utilised as in the current study. Thus, the greater efficacy seen in
this study may be explained by the timing of treatment commencement. In the study by
Apolloni et al. (2014), BBG treatment was started at late pre‐onset, resulting in a wide range
of beneficial effects on disease progression. Whilst this study only observed these effects by
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utilising a five‐fold higher dose of BBG than that used in the current study, these high BBG
doses were not effective when began during the asymptomatic or pre‐onset phases of
disease. Collectively, this suggests a very tight window for therapeutic intervention targeting
P2X7. This is further supported by the exacerbated disease progression observed in
SOD1G93A mice lacking P2X7 (Apolloni et al., 2013a), and suggests that P2X7 may play a dual
role in ALS progression. In this regard, P2X7 activation may be neuroprotective in the initial
stages of disease, but neuroinflammatory or neurotoxic as the disease progresses. This is
consistent with the trophic and toxic actions mediated by P2X7 in surveilling and activated
microglia, respectively (Gendron et al., 2003; Hide et al., 2000; Monif et al., 2009; Shieh et
al., 2014).
3.4.3 Effect of Brilliant Blue G on pathological hallmarks of ALS
3.4.3.1 Effect of Brilliant Blue G on microgliosis and motor neuron death
Microgliosis and loss of motor neurons are two major hallmarks of disease in ALS. Whilst
these disease hallmarks were observed in the current study, there were no differences at
end‐stage between untreated and BBG‐treated mice. In contrast, BBG treatment reduced
lumbar microglia activation and inflammatory microglial markers, enhanced neurotrophic
factors and improved motor neuron survival at end‐stage in the study by Apolloni et al.
(2014). This is consistent with the anti‐inflammatory effects resulting from P2X7 inhibition
in vitro, whereby BBG treatment reduced the release of pro‐inflammatory factors and
subsequent toxicity of SOD1G93A microglia towards neuronal cells (Apolloni et al., 2013b;
D'Ambrosi et al., 2009). In the current study, motor neuron and microglial numbers were
assessed without stratifying for gender due to the small n values of available samples.
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However, given the limited clinical efficacy of BBG, increasing the n value to allow for
gender stratification may not be worthwhile. Furthermore, there is limited evidence that
gender influences motor neuron loss (Veldink et al., 2003).
3.4.3.2 Effect of Brilliant Blue G on the accumulation of misfolded SOD1
An accumulation of SOD1‐containing aggregates is another major hallmark of disease in ALS.
In the current study, detergent‐insoluble SOD1 was present in lumbar spinal cords of
SOD1G93A mice at end‐stage. However, there were no differences in the amounts of
detergent‐insoluble SOD1 between saline‐ and BBG‐treated SOD1G93A mice. Consistent with
this data, ablation of P2X7 does not modify the lumbar SOD1 content in SOD1G93A mice
(Apolloni et al., 2013a). BBG, but not other P2X7 antagonists, prevents protease‐resistant
prion protein accumulation in scrapie‐infected microglial and neuronal cell lines, and in the
brains of prion‐infected mice (Iwamaru et al., 2012). This suggests that BBG has anti‐
aggregation properties, independent of its P2X7 interactions. However, given the current
data, the anti‐aggregation properties of BBG may be restricted to anti‐prion activities,
consistent with a molecular framework analogous to other anti‐prion compounds (Iwamaru
et al., 2012).
While detergent‐insoluble SOD1 was present in lumbar spinal cords of SOD1G93A mice at
end‐stage, there was no significant change in the amount of insoluble protein between 30
and 120 d. Inclusions are known to increase with disease duration (Watanabe et al., 2001)
and SOD1‐positive aggregates are reported to increase between 14 and 200 d (Puttaparthi
et al., 2003) in spinal cord tissue of SOD1G93A mice. However, in the current study, only the
16 kDa SOD1 species was investigated, and changes in the amount of higher molecular
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weight species may have been observed over time or following BBG treatment. Moreover,
due to potential differences in breeding colonies and methodological procedures, it is not
possible to compare relative amounts of insoluble SOD1 between studies.
3.4.4 P2X7 expression in the lumbar spinal cord of SOD1G93A mice
P2X7 protein was detected in the lumbar spinal cord of SOD1G93A mice treated with either
saline or BBG. Similar amounts were detected between treatments, consistent with the lack
of effect of BBG on lumbar spinal P2X7 amounts in other studies (Apolloni et al., 2014). In
the current study, a number of bands were detected in addition to the expected full length
P2X7A isoform (73‐89 kDa). These proteins were approximately 160, 80, 60 and 50 kDa in
size, and may correspond to P2X7 dimers, non‐glycosylated P2X7, P2X7 splice variants or
P2X7 breakdown products. Alternatively, some of these bands may represent non‐specific
Ab binding, which is controversially thought to occur in rodent brain tissue (Sim et al., 2004).
In this latter study, 75, 60 and 50 kDa bands were observed in brain tissue of both P2X7WT
and P2X7KO after immunoblotting with the same P2X7 Ab as used in the current study. Thus,
the possibility remains that the examination of P2X7 in the spinal cords of mice using this Ab
is limited.
C‐terminal truncated P2X7 variants have recently been identified in mice (Masin et al.,
2012). One of these, termed P2X713B, is detected in the mouse CNS and has a molecular
mass of approximately 60 kDa (Masin et al., 2012), similar to one of the proteins detected in
this current and other studies (Barth et al., 2007). Interestingly, when expressed in human
embryonic kidney (HEK)‐293 cells, the majority of P2X713B was retained in the endoplasmic
reticulum and not efficiently trafficked to the cell surface (Masin et al., 2012). This may
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explain differences in the amount of 60 kDa protein in detergent‐soluble and ‐insoluble
fractions in the current study. However, further work would be required to identify whether
this band does indeed correspond to a P2X7 splice variant.
In the current study, the amount of lumbar spinal cord P2X7 did not change significantly
with age in female SOD1G93A mice. It has been reported that there is no sexual dimorphism
in P2X7 expression at any age (Crain et al., 2009). However, while microglial P2X7 expression
was maintained at similar levels from 21 to 365 d in healthy C57Bl/6 mice in one mixed‐sex
study (Crain et al., 2009), another found that P2X7 protein increased with age in healthy
Sprague–Dawley rats (Lai et al., 2013). Furthermore, similar amounts of lumbar P2X7 protein
were present in spinal cords from WT and SOD1G93A mice at all investigated time points in
the current study, while P2X7 immunoreactvities have been reported to be increased in
spinal cords from (post‐mortem) humans with ALS and advanced‐stage transgenic SOD1G93A
rats (Casanovas et al., 2008; Yiangou et al., 2006). Thus, given the potential of non‐specific
Ab binding with currently available P2X7 antibodies, it may be worthwhile investigating
P2X7 mRNA or developing P2X7 antibodies with greater specificity.
In the current study, P2X7 was detected in both detergent‐soluble and ‐insoluble fractions.
The presence of detergent‐insoluble P2X7 has been reported in mouse lung alveolar
epithelial cells, HEK‐293 cells transfected with WT P2X7, mouse peritoneal macrophages and
rat submandibular glands (Barth et al., 2007; Garcia‐Marcos et al., 2006; Gonnord et al.,
2009). In these studies, it was suggested that P2X7 partially localised with detergent‐
resistant membranes, or lipid rafts, at the plasma membrane. This association was reported
to be dependent on the post‐translational modification of P2X7 by palmitic acid (Gonnord et
al., 2009). In the current study, the amount of detergent‐insoluble 75 kDa P2X7 was
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relatively low, suggesting that the majority of 75 kDa P2X7 was localised in the plasma
membrane. Determining whether the detergent‐insoluble 75 kDa protein represented lipid
raft‐associated or intracellular P2X7 was beyond the scope of the current work.
3.4.5 Effect of Brilliant Blue G on serum monocyte chemoattractant protein‐1
The amount of MCP‐1 in end‐stage SOD1G93A mouse serum was used in the current study to
assess the efficacy of BBG. Opposite to expectations, BBG‐treated mice had higher
concentrations of serum MCP‐1 compared to saline‐treated mice, although the amounts
present were at the lower limits of detection for both treatment groups. While this
difference was not significant, a post hoc calculation using the means of each group
suggested that a sample size of at least seven would be required to gain significance
(http://www.statisticalsolutions.net/pss_calc.php, accessed July 24, 2015, alpha = 0.05 and
power = 0.80).
Reports on the actual amounts of serum MCP‐1 in ALS mice are limited. Furthermore,
previous BBG studies in ALS mice did not investigate MCP‐1. Regardless, it was expected
that higher amounts would be detected given that SOD1 mouse MCP‐1 mRNA transcripts
and immunoreactivity (Henkel et al., 2006; Kawaguchi‐Niida et al., 2013), and human ALS
serum and plasma MCP‐1 amounts (Baron et al., 2005; Mitchell et al., 2010), are increased.
Furthermore, given that P2X7 mediates MCP‐1 expression and release in WT primary
microglia (Shieh et al., 2014), and BBG treatment attenuated P2X7‐mediated MCP‐1 release
from primary human astrocytes and rodent microglia (Fang et al., 2011; Tewari et al., 2015),
it was expected that long‐term BBG treatment would have a suppressive effect on serum
MCP‐1 concentrations.
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In a number of studies, serum MCP‐1 amounts were similar between ALS patients and non‐
inflammatory neurological disease and/or healthy controls (Kuhle et al., 2009; Nagata et al.,
2007; Wilms et al., 2003). In contrast, cerebrospinal fluid (CSF) MCP‐1 amounts were much
higher in ALS patients compared to controls in these and other studies (Baron et al., 2005;
Henkel et al., 2004; Kuhle et al., 2009; Nagata et al., 2007; Wilms et al., 2003). This suggests
that MCP‐1 is synthesised in the intrathecal space during ALS and that it may have been
more informative to analyse CSF instead of serum. Lastly, as murine MCP‐1 has been
reported to increase with age in SOD1G93A mice (Manzano et al., 2011; Noh et al., 2014), the
trend for increased MCP‐1 in BBG‐treated mice may correlate with the slightly older ages of
these mice at end‐stage. In this regard, it may have been more informative to look at MCP‐1
at the same time‐points in control and treated mice, and at different stages of disease.
3.4.6 Effect of Brilliant Blue G on the distribution of splenocytes
In the current study, long term treatment with BBG had no effect on the relative proportion
of B cells, T cells, Treg cells, dendritic cells, macrophages or neutrophils within the spleens of
end‐stage SOD1G93A mice. This suggests that blockade of P2X7 does not affect leukocyte
homeostasis. Consistent with this concept, similar proportions of peripheral blood
monocytes, lymphocytes and neutrophils, as well as peritoneal macrophages, are also
observed in both P2X7WT and P2X7KO mice (Labasi et al., 2002; Solle et al., 2001). In contrast,
P2X7KO mice are reported to have increased percentages of splenic, peripheral blood and
lymphoid Treg cells compared to P2X7WT mice (Aswad et al., 2005). Furthermore,
pharmacological blockade or genetic knock‐down of P2X7 increases the percentage of Treg
cells in murine models of graft‐versus‐host disease, systemic lupus erythematosus and
colitis (Hofman et al., 2015; Wilhelm et al., 2010; Zhao et al., 2013). Given this, it is
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somewhat surprising that BBG did not increase Treg cell numbers in the current study.
However, Treg cells were assessed using CD4 and CD25, but not with the additional Treg cell
marker FoxP3. Therefore, quantification of Treg cells in the current study is limited, with
some effector/memory T cells most likely present within the CD4+CD25+ population
(Seddiki et al., 2006). Alternatively, since Treg cells are dysfunctional in SOD1G93A mice
(Beers et al., 2011), it is possible that P2X7 activity does not influence Treg cells in ALS mice.
3.4.7 Confounding effects
3.4.7.1 Neurological scoring system ambiguity
The neurological scoring system used in the current study was designed by the ALS Therapy
Development Institute, and is designed to assess the onset and progression of disease in an
unbiased manner. This system has 5 scores, including no symptoms (0), signs of muscle
weakness (1), mild paralysis (2), rigid paralysis (3) and an inability to right (4) (Table 3.4). In
the current study, disease progression was characterised by increasing neurological scores
alongside decreasing body weight, leading to and consistent with ALS‐mediated death (Scott
et al., 2008). However, some issues were encountered in assigning early scores. Firstly,
some trouble was encountered in initially defining a score of 1, with occasional “partial
collapse” and “trembling of hindlimbs” observed without any signs of gait abnormality or
muscle deterioration. This occurred at earlier time points (75‐101 d) than expected for
disease onset in the SOD1G93A strain (84‐112 d) used (Gurney et al., 1994; Mancuso et al.,
2012). This issue has similarly been reported in other studies, where WT mice, in addition to
SOD1G93A mice, also occasionally received scores of 1 (Lewis, 2014). Thus, these initial
observations may have suggested normal muscle weakness, rather than a loss of muscular
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strength. Secondly, there was a relatively large window of time between mice being
assigned scores of 1 and 2, with mice continuing to be scored as 1, but showing
deteriorating gaits that did not yet qualify them for scores of 2. Together, this suggests that
additional and more detailed scores may be required. To this end, the neurological scoring
system utilised in this current study has been extended to 8 scores by others (Ari et al.,
2014; Gianforcaro et al., 2013). Furthermore, other scoring systems have been developed.
This includes the Beers/Appel/Simpson/Henkel (BASH) scoring system, which has 9 scores
incorporating more specific detail on signs of muscle weakness and deterioration, as well as
changes to weight (Beers et al., 2006). More detailed scoring systems such as these may be
more suitable for mapping disease onset and progression in murine models of ALS.
3.4.7.2 Rotarod noise
In the current study, each mouse had a variable ability to stay on the rod, resulting in a
substantial amount of noise in the rotarod data set. This suggests that earlier training may
have been required to better acclimatise mice to the activity, or alternatively, that the
rotarod routine employed was not the most suitable. Similar to previous murine ALS studies
(Cervetto et al., 2013), an accelerating rotarod program was employed in the current study.
This program was chosen based on the experience of other researchers using the same mice
(Bradley Turner, personal communication). In contrast, other murine ALS studies have
successfully employed constant speed programs (Apolloni et al., 2014). Regardless, the use
of multiple techniques to assess motor function would have provided a more reliable
quantification of disease progression. The paw grip endurance test, also known as the
hanging wire test, is a simple and sensitive test reported to have a higher diagnostic
accuracy than the rotarod test (Weydt et al., 2003). In addition, this test does not require
146

Chapter 3 – The efficacy of the P2X7 antagonist Brilliant Blue G on ALS progression

training to achieve a consistent baseline or specialised equipment, making it a suitable test
to carry out alongside rotarod trials.
3.4.8 Conclusion
In conclusion, BBG treatment reduced body weight loss and prolonged survival in female
SOD1G93A mice. This represents the first report of an extension in survival following P2X7
blockade in an ALS mouse model. Given that this result was seen only in females, the
importance of considering sex in pre‐clinical studies is clear, consistent with reports by
others (Cervetto et al., 2013). Despite this, in the current study, BBG had no effect on body
weight loss or survival in male SOD1G93A mice, or on ALS score, motor coordination, motor
neuron

loss,

microgliosis,

lumbar

SOD1

or

P2X7,

serum

MCP‐1,

splenocyte

immunophenotype or P2X7 expression at end‐stage in either gender. While the other two
studies investigating the efficacy of BBG in ALS found more beneficial effects of this
compound at molecular and phenotypic levels, these effects did not correlate with an
extension in life span in these studies (Apolloni et al., 2014; Cervetto et al., 2013). Together,
the different outcomes obtained from these three studies highlight how drug regime may
influence disease outcomes in murine models of ALS.
BBG treatment in SOD1G93A mice has resulted in a number of positive effects to date. Thus,
pharmacological antagonism of P2X7 may represent a strategy for improving disease
outcomes via targeting of the neuroinflammatory component of the disease. While BBG
treatment in the current study resulted in no or limited beneficial effects at molecular and
phenotypic levels at end‐stage, respectively, this may be suggestive of a role for P2X7 in
select disease pathways. This is consistent with the multi‐systemic and multi‐factorial nature
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of this disease. Furthermore, given that BBG is commonly used as a protein dye, and hence
is potentially capable of binding a range of molecules and modulating their function,
alternative P2X7 antagonists might lead to more positive outcomes. Consequently, the use
of newly synthesised CNS‐permeable antagonists with higher affinities for P2X7 and
improved pharmacokinetic profiles should be considered in future studies (Bhattacharya et
al., 2013). Furthermore, nucleoside reverse transcriptase inhibitors, Food and Drug
Administration‐approved HIV therapeutics, have recently been found to inhibit P2X7‐
mediated inflammation and disease in murine inflammatory models (Fowler et al., 2014).
Thus further investigations of the efficacy of these compounds in murine ALS models may
also be worthwhile.
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4.1

Background

4.1.1 Transfer of protein misfolding between cells in ALS
Amyotrophic lateral sclerosis (ALS) is characterised by a focal onset of motor neuron
degeneration, followed by an outward spreading of disease pathology to neighbouring cells
or to other central nervous system (CNS) cells via axonal pathways (Brettschneider et al.,
2014; Ravits and La Spada, 2009; Shaw, 2002). Furthermore, the transfer of protein
misfolding between cells and organisms has been demonstrated in ALS models (Ayers et al.,
2014; Ayers et al., 2016; Brundin et al., 2010; Munch et al., 2011). Thus, it has been
suggested that ALS progression occurs via a prion‐like propagation of protein misfolding and
aggregation between neighbouring cells (Munch et al., 2011), a hypothesis gaining in
popularity (reviewed in Zeineddine and Yerbury, 2015). Accumulating evidence suggests a
role for superoxide dismutase 1 (SOD1) in this process.
SOD1 is secreted by neuronal cells in culture, via both active and passive mechanisms
(Brundin et al., 2010; Zeineddine and Yerbury, 2015). In particular, human wild type (WT)
and mutant SOD1 have been reported to be secreted via both exosomes (Gomes et al.,
2007; Grad et al., 2014), and in association with cell death as free aggregates (Grad et al.,
2014). In addition to cell culture medium, SOD1 is present in the cerebrospinal fluid of ALS
mice and patients (Frutiger et al., 2008; Turner et al., 2005; Zetterstrom et al., 2011),
suggesting that similar SOD1 release mechanisms operate in vivo. However, the precise
mechanisms of SOD1 release in vivo and the triggers underpinning these are currently
unknown.
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4.1.2 SOD1 uptake and neurodegeneration
Once released into the extracellular space, SOD1 proteins need to gain access to the cytosol
of naïve cells to propagate protein misfolding and aggregation. Exogenously applied native
and aggregated WT and mutant SOD1 are internalised by neuronal cells via
macropinocytosis (Grad et al., 2014; Sundaramoorthy et al., 2013), a form of non‐selective
endocytosis which allows for the engulfment of large amounts of solute macromolecules
(reviewed in Zeineddine and Yerbury, 2015). Once internalised, the protein is able to enter
the cytosol and initiate a self‐perpetuating seeding of aggregation of natively folded SOD1
(Grad et al., 2014; Munch et al., 2011). In human embryonic kidney (HEK)‐293 or human WT
SOD1‐expressing murine primary spinal cord cultures, this uptake and self‐perpetuating
seeding of aggregation can be neutralised using antibodies which react with misfolded SOD1
epitopes (Grad et al., 2014). However, to the best of our knowledge, the uptake of native
WT SOD1 has not been reported to seed aggregation. In addition to neuronal cells, uptake
of WT and mutant SOD1 into microglial cells via endocytosis has also been observed
(Meissner et al., 2010). In this study, mutant SOD1 rapidly gained access to the cytosol,
where it then accumulated. However, it was not investigated in this study whether this
accumulation correlated with the seeding of natively folded SOD1.
The uptake of SOD1 into naïve cells initiates neurodegenerative pathways similar to those
observed in ALS. In neuronal cells, aggregated WT or mutant SOD1 uptake inhibits protein
transport between the endoplasmic reticulum (ER) and Golgi apparatus, resulting in Golgi
fragmentation, the induction of ER stress and apoptotic cell death (Sundaramoorthy et al.,
2013). ER stress is a well‐recognised characteristic of ALS, being reported in rodent ALS
models and in human ALS patients (Atkin et al., 2006; Atkin et al., 2008; Saxena et al., 2009).
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In microglia, uptake of mutant SOD1 results in the activation of caspase‐1, leading to the
secretion of interleukin‐1β (Meissner et al., 2010). In addition, treatment of microglial cells
with recombinant mutant SOD1 or mutant SOD1 secreted from neuronal cells induces
morphological changes, tumour necrosis factor (TNF)‐α and interleukin‐1β mRNA expression
and protein release, as well as cyclooxygenase‐2 and inducible nitric oxide synthase mRNA
expression (Roberts et al., 2013; Urushitani et al., 2006; Zhao et al., 2010). However, the
uptake of SOD1 into microglia was not directly established in these studies. Together, this
export and import of SOD1 may explain how protein misfolding and aggregation propagates
between neighbouring cells in ALS, resulting in disease progression.
4.1.3 Aims
Activation of P2X7 on neuronal cells leads to a number of membrane‐related changes,
including the release of microvesicles and exosomes (Faure et al., 2006; Moores et al.,
2005). In addition, P2X7 activation in these cells has been reported to be associated with the
induction of cell death (Franco et al., 2013; Gandelman et al., 2013; Wang et al., 2004b).
Thus, this study aimed to investigate whether P2X7 is involved in the release of SOD1 from
neuronal cells and, if so, the mechanisms involved, the characteristics of the material
released, and whether the released SOD1 is internalised by non‐transfected (naïve)
neuronal and microglial cells. Furthermore, this study aimed to investigate the effects of
SOD1 uptake on naïve cells, including analyses of cell morphology, cytokine release and ER
stress.
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4.2

Methods

4.2.1 Reagents and antibodies
DMEM/F12 medium, GlutaMAX, penicillin‐streptomycin, Lipofectamine 2000, Lipofectamine
LTX, Lipofectamine 3000, OPTI‐MEM reduced serum medium, 0.05% trypsin, SuperSignal
West Pico Chemiluminescent Substrate and the restriction endonucleases HindIII and BamHI
were from ThermoFisher Scientific (Waltham, MA). Foetal bovine serum (FBS) (heat‐
inactivated before use) was from Bovogen Biologicals (East Keilor, Australia). Agarose was
from Bioline (Alexandria, Australia) and the P2X7 antagonist AZ10606120 was from Tocris
Bioscience (Ellisville, MO). ATP, ionomycin, ethidium bromide, trichloroacetic acid (TCA) and
casein (heat‐denatured before use; HDC) were from Sigma‐Aldrich (St. Louis, MO). Protease
inhibitor cocktail tablets (complete, Mini, EDTA‐free) were from Roche Diagnostics
(Penzberg, Germany). Diploma full‐cream milk powder was from Fonterra (Mount Waverley,
Australia) and uranyl acetate was from ProSciTech (Kirwan, Australia). Phenyl‐methyl‐
sulfonyl‐fluoride (PMSF), n‐dodecyl β‐D‐maltoside, sodium dodecyl sulfate (SDS) and β‐
mercaptoethanol were from Amresco (Solon, OH). All other reagent grade chemicals and
salts were from Sigma‐Aldrich or Amresco. The antibodies (Abs) used and their respective
companies are listed in Table 4.1.
4.2.2 Cell lines
HEK‐293 and murine microglial EOC13 cells were from the American Type Culture Collection
(Manassas, VA). Murine lymphoblast LADMAC cells, originally obtained from the American
Type Culture Collection, were kindly provided by Iain Campbell (University of Sydney,
Sydney, Australia). Mouse neuroblastoma x spinal cord hybrid cells (NSC‐34) (Cashman et

153

Chapter 4 – P2X7‐mediated release of SOD1 from NSC‐34 motor neurons

al., 1992) were kindly provided by Neil Cashman (University of British Columbia, Vancouver,
Canada). Cells were maintained in DMEM/F12 medium (incomplete culture medium)
supplemented with 10% FBS and 2 mM GlutaMAX at 37°C/5% CO2 (NSC‐34 complete culture
medium). HEK‐293 were additionally maintained in 100 U/mL penicillin and 100 μg/mL
streptomycin. EOC13 cells were additionally maintained in 20% LADMAC conditioned
medium (EOC13 complete culture medium).
Table 4.1 Antibodies used in Chapter 4 to investigate P2X7‐mediated release of SOD1 from NSC‐34 motor
neurons

Antibody target1

Conjugate

Green fluorescent protein
Superoxide dismutase 1
Superoxide dismutase 1
Rabbit IgG
Rabbit IgG
Sheep IgG
P2X7, extracellular epitope
Rabbit IgG
IgG isotype control
Rabbit IgG

‐
‐
‐
Peroxidase
Peroxidase
Peroxidase
‐
Peroxidase
‐
5 nm gold

1

Host species1
(clonality)
Rabbit (pAb)
Rabbit (pAb)
Sheep (pAb)
Goat (pAb)
Donkey (pAb)
Donkey (pAb)
Rabbit (pAb)
Goat (pAb)
Rabbit (pAb)
Goat (pAb)

Company2
(catalogue number)
Abcam (ab290 or ab6556)
Enzo (ADI‐SOD‐100)
Abcam (ab8866)
Bio‐Rad (1706515)
GE (NA934)
Merck Millipore (AB324P)
Alomone Labs (APR‐008)
Rockland (611‐103‐122)
Abcam (ab171870)
Abcam (ab27235)

2

Ig, immunoglobulin; pAb, polyclonal antibody. Abcam, Cambridge, United Kingdom; Alomone Labs,
Jerusalem, Israel; Bio‐Rad, Hercules, CA; Enzo Life Sciences, Plymouth Meeting, PA; GE Healthcare Life
Sciences; Little Chalfont, Buckinghamshire, UK; Merck Millipore, Billerica, MA; Rockland Immunochemicals,
Gilbertsville, PA.

4.2.3 Cell transfections
4.2.3.1 Plasmid purification
pFUW expression vectors containing SOD1G85R and SOD1G127X cDNAs were provided by
Edward Pokrishevsky (University of British Columbia, Vancouver, Canada) (Grad et al., 2011).
pEGFP‐N1 expression vectors containing SOD1WT and SOD1G93A cDNAs were provided by
Bradley Turner (University of Melbourne, Melbourne, Australia) (Turner et al., 2005).
Chemically competent DH5α Escherichia coli cells were provided by Jason McArthur
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(University of Wollongong, Wollongong, Australia). Cells were transformed with the SOD1‐
containing plasmids using heat shock (42°C), as per the manufacturer’s instructions.
Transformed cells were then spread onto lysogeny broth (10% w/v NaCl, 10% w/v tryptone
and 5% w/v yeast; LB) agar plates containing 50 μg/mL kanamycin sulphate, and incubated
at 37°C/5% CO2 overnight. The next day, overnight starter cultures derived from single
transformed bacterial colonies were prepared in sterile LB containing 50 μg/mL kanamycin
sulphate. Plasmid DNA was then purified from bacterial cells using the CompactPrep
Plasmid Maxi Kit (Qiagen, Hilden, Germany), as per the manufacturer’s instructions. The
concentration and quality (260/280 ratio) of DNA within samples was assessed using a
NanoDrop 2000c dual‐mode UV‐Vis Spectrophotometer (ThermoFisher Scientific). To
confirm purification of plasmid DNA, the samples were digested with HindIII and BamHI,
enzymes with single corresponding restriction sites in the expected plasmids (determined
using NEBcutter V2.0; Vincze et al., 2003). Digestions were carried out at 37°C for 1 h.
Digested products (1 μg/well) were separated on a 1% agarose gel in Tris‐acetate‐EDTA
(TAE) buffer (40 mM Tris, 20 mM acetic acid, and 1 mM ethylenediaminetetraacetic acid
disodium salt) and visualised with ethidium bromide staining.
4.2.3.2 Cell transfection using Lipofectamine 2000
NSC‐34 cells in complete culture medium (4 – 7 x 105 cells/mL) were incubated overnight at
37°C/5% CO2. Cells were then washed once with incomplete culture medium and incubated
in incomplete culture medium containing 0.5 μg plasmid DNA and Lipofectamine 2000 for
5 h at 37°C/5% CO2. The medium was then replaced with complete culture medium, and the
cells incubated for a further 67 h (72 h total) at 37°C/5% CO2.
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4.2.3.3 Cell transfection using Lipofectamine LTX
NSC‐34 cells in complete culture medium (6 x 105 cells/mL) were incubated overnight at
37°C/5% CO2. Cells were then incubated in complete culture medium containing 1.5 μg
plasmid DNA and Lipofectamine LTX (diluted in OPTI‐MEM Reduced Serum Medium) for 5 h
at 37°C/5% CO2. The medium was then replaced with complete culture medium, and the
cells incubated for a further 67 h (72 h total) at 37°C/5% CO2.
4.2.3.4 Cell transfection using Lipofectamine 3000
NSC‐34 cells in complete culture medium (4 – 7 x 105 cells/mL) were incubated overnight at
37°C/5% CO2. Cells were then incubated in complete culture medium containing 2.5 μg
plasmid DNA, P3000 reagent and Lipofectamine 3000 (diluted in OPTI‐MEM Reduced Serum
Medium) for 72 h at 37°C/5% CO2.
4.2.3.5 Collection of transfected cells and conditioned media
To confirm transfection, cells were visualised by fluorescence microscopy using an Eclipse
TE2000 inverted microscope (Nikon, Tokyo, Japan). In some experiments, images were
captured using Image‐Pro AMS (Version 6.1) (Media Cybernetics, Rockville, MD). Following
transfection (72 h), conditioned media were collected, and cells and conditioned media
processed as described below.
4.2.4 SOD1 release assay
Following transfection (72 h), NSC‐34 cells were washed twice with incomplete culture
media and then pre‐incubated in incomplete culture media in the absence or presence of
10 µM AZ10606120 at 37°C for 1 h. Cells were then incubated with ATP (as indicated) or
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2 µM ionomycin at 37°C for 20 min. In some experiments, NaCl (145 mM NaCl, 5 mM NaOH,
and 10 mM HEPES, pH 7.4) or KCl (150 mM KCl, and 10 mM HEPES, pH 7.4) medium was
added to incomplete culture medium 5 min prior to ATP, to give final Na+ and K+
concentrations of 50 mM. Cells were visualised by differential interference contrast (DIC)
imaging using an Eclipse TE2000 inverted microscope (Nikon), and DIC images were
captured using Image‐Pro AMS (Version 6.1) (Media Cybernetics). Conditioned media were
collected and processed as described below.
4.2.5 Filter trap assay
Conditioned media from transfected cells were incubated with an equal volume of
phosphate‐buffered saline (PBS) containing 1% SDS at room temperature, and then SDS‐
resistant material separated onto a cellulose acetate membrane (0.2 µm; GE Healthcare,
Little Chalfont, Buckinghamshire, UK) using a Bio‐Dot SF Microfiltration System (Bio‐Rad,
Hercules, CA) under vacuum. The membrane was washed with PBS containing 1% SDS,
followed by PBS, and then enhanced green fluorescent protein (EGFP) detected as per
immunoblotting (See Section 4.2.6).
4.2.6 EGFP and SOD1 protein detection by immunoblotting
Conditioned media from transfected cells were fractionated into soluble and pelletable
fractions by centrifugation (20,000 x g for 30 min). In some experiments, a differential
centrifugation protocol was carried out at 4°C, whereby cells were centrifuged at 500 x g for
10 min to obtain fraction 1, 10,000 x g for 20 min to obtain fraction 2, and 100,000 x g for
2 h to obtain fraction 3. Supernatants were incubated 4:1 with chilled TCA on ice for 20 min
to precipitate remaining (fraction 4) protein. Precipitated protein was collected by
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centrifugation (18,000 x g for 10 min, 4°C), washed twice with chilled acetone and then
dried. Fractions (as indicated) were separated under reducing conditions (5% β‐
mercaptoethanol) using Any kD Mini‐PROTEAN TGX Stain‐Free Gels (Bio‐Rad, Hercules, CA)
or Novex 4‐20% Tris‐Glycine Gels (ThermoFisher Scientific, MA). Proteins were then
transferred to nitrocellulose membranes using a Trans‐Blot Turbo Transfer System (both
Bio‐Rad). Membranes were blocked at room temperature for 1 h with either HDC or Tris‐
buffered saline (250 mM NaCl and 50 mM Tris, pH 7.5) containing 0.2% Tween‐20 and 5%
milk powder (for EGFP or SOD1, respectively), and then incubated at 4°C overnight with
either an anti‐EGFP pAb (1:1000‐1:10000) or anti‐SOD1 pAb (1:1000) in corresponding
blocking solution. The following day, membranes were washed three times over 15 min with
PBS containing 0.1% Triton X‐100 or three times over 30 min with Tris‐buffered saline
containing 0.2% Tween‐20 (for EGFP or SOD1, respectively). Membranes were then
incubated at room temperature for 1 h with peroxidise‐conjugated anti‐rabbit (1:2000) IgG
Ab for EGFP, or anti‐sheep (1:500) or anti‐rabbit (1:10,000) IgG Ab for SOD1, in
corresponding blocking solution. Membranes were washed as above, and proteins
visualised using chemiluminescent substrate and Amersham Hyperfilm ECL (GE Healthcare)
or a VersaDoc Imaging System (Bio‐Rad). Films were processed using GBX Developer and
Replenisher, and GBX Fixer and Replenisher as per the manufacturer’s instructions (Kodak
Australasia, Collingwood, Australia). Images of films and blots were collected using a GS‐800
Calibrated Densitometer and/or Quantity One 1‐D Analysis Software (Version 4.6.9) (both
Bio‐Rad), respectively. Relative EGFP and SOD1 was quantified from these images using
ImageJ software (Version 1.48) (National Institutes of Health, Bethesda, MD).
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4.2.7 P2X7 protein detection by immunoblotting
Cells were washed three times with PBS (300 × g for 5 min) and lysed (1 x 106 ‐ 1 x 107
cells/mL) over 60 min in ice‐cold lysis buffer (50 mM BisTris, 750 mM 6‐aminohexanoic acid,
1% n‐dodecyl β‐D‐maltoside, 1 mM PMSF, and protease inhibitor cocktail, pH 7.0). Cells
were sheared by passing ten times through a 21 G needle and stored at −20°C un l needed.
Cells were then thawed and cleared (16,000 × g at 4°C for 10 min). Supernatants (20 μg
protein/lane) were separated under reducing conditions (5% β‐mercaptoethanol) using Any
kD Mini‐PROTEAN TGX Stain‐Free Gels (Bio‐Rad). Before immunoblotting, equal protein
loading was confirmed by visualising stain‐free gels with a Bio‐Rad Criterion Stain Free
Imager and Image Lab software. Proteins were then transferred to nitrocellulose
membranes using a Trans‐Blot Turbo Transfer System (all Bio‐Rad). Immunoblotting and
visualisation was performed as per SOD1 in Section 4.2.6, using an anti‐P2X7 pAb (1:500)
and peroxidise‐conjugated anti‐rabbit IgG Ab (1:1000).
4.2.8 Fluorescent cation dye uptake assay
NSC‐34 cells in complete culture medium (5 ‐ 7 x 105 cells/mL) were incubated overnight at
37°C/5% CO2. In some experiments, non‐transfected (NT) cells or cells transfected with
SOD1G93A‐EGFP (see Section 4.2.3.2) were then incubated for an additional 72 h. Adherent
cells were washed twice with incomplete culture medium and pre‐incubated in incomplete
culture media in the absence or presence of 10 μM AZ10606120 at 37°C for 1 h. Cells were
then incubated with 25 μM ethidium+ in the absence or presence of ATP (as indicated) at
37°C for 20 min. Incubations were stopped by the addition of an equal volume of ice‐cold
incomplete culture medium containing 20 mM MgCl2 (MgCl2 medium). Cells were then
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harvested using 0.05% trypsin (5 min, 37°C), and centrifugation (300 x g for 5 min). Cells
were washed once with incomplete culture medium and events collected using a LSR II flow
cytometer (BD Biosciences, San Diego, CA) (excitation 488 nm, emission collected with
575/26 band‐pass filter). The mean fluorescence intensity (MFI) of relative cation uptake
was determined using FlowJo software (Tree Star, Ashland, OR).
4.2.9 Lactate dehydrogenase release assay
To quantify the contribution of cytotoxicity to ATP‐mediated SOD1 release, a SOD1 release
assay was performed 72 h following transfection with SOD1G93A‐EGFP (see Sections 4.2.3.2
and 4.2.4). Conditioned media were collected and remaining adherent cells lysed using Lysis
Solution from a lactate dehydrogenase (LDH) Cytotoxicity Detection Kit (Roche Diagnostics,
Penzberg, Germany). Total LDH and LDH in conditioned media was quantified using the LDH
Cytotoxicity Detection Kit, as per the manufacturer’s instructions, and a SpectraMax Plus
384 Microplate Reader and SoftMax Pro software (Molecular Devices, Silicon Valley, CA)
(492‐690 nm). Percent cytotoxicity was calculated as the absorbance of conditioned media
LDH as a fraction of the absorbance of total LDH.
4.2.10 Visualising real‐time SOD1 release
NSC‐34 cells in 8‐chamber µ‐slides (Ibidi, Planegg‐Martinsried, Germany) were transfected
with SOD1G93A‐EGFP using Lipofectamine 3000 (see Section 4.2.3.4). Following transfection
(72 h), NSC‐34 cells were washed twice with incomplete culture media and then pre‐
incubated in incomplete culture media at 37°C for 1 h. Cells were visualised using a DM IBRE
inverted microscope and TCS SP confocal imaging system (Leica, Mannheim, Germany) at
37°C (excitation 488 nm, emission collected at 500‐540 nm). After identifying a cell with
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fluorescent aggregates, ATP was added (to give a final concentration of 5 mM) and then
fluorescent and bright‐field images captured every 30 s for 20 min using Leica Confocal
Software, starting immediately following ATP addition.
4.2.11 Transmission electron microscopy
Negative staining transmission electron microscopy (TEM) was performed using substrate
carbon‐coated nickel grids (ProSciTech). First, a SOD1 release assay was performed 72 h
following transfection with SOD1G93A‐EGFP (see Sections 4.2.3.2 and 4.2.4). Conditioned
media were collected, and a pelletable fraction obtained by centrifugation (20,000 x g for
30 min). Pelletable fractions were washed and resuspended in 50 mM phosphate buffer or
PBS (both pH 7.5). Fractions (2 µL) were then loaded onto TEM grids and incubated at room
temperature for 1 min. Grids were washed 3‐5 times with Milli‐Q water, blotting grids
between washes. In some experiments, grids were then immunogold‐labelled. Firstly, grids
were blocked at room temperature for 40 min with HDC, and then incubated at room
temperature for 1 h with anti‐EGFP pAb (1:1000) or equivalent amount of IgG. Grids were
washed three times over 15 min with HDC, and then incubated at room temperature for 1 h
with 5 nm gold particle‐conjugated anti‐rabbit IgG Ab (1:200). Grids were washed as above,
and then washed five times with Milli‐Q water. Labelled and non‐labelled grids were stained
with Milli‐Q water containing 2% uranyl acetate at room temperature for 3 min. Grids were
dried by blotting, further dried at room temperature for 5 min, and then stored at room
temperature until required. Structures were visualised using a JEOL JEM2011 transmission
electron microscope (Akishima, Japan), with the assistance of David Mitchell (University of
Wollongong, Wollongong, Australia). Images were captured using Gatan Microscopy Suite
(Version 2.30.542.0) (Pleasanton, CA).
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4.2.12 Effects of pelletable fractions of conditioned media from SOD1G93A‐EGFP expressing
NSC‐34 motor neurons on naïve cells
4.2.12.1 Cell culture
Conditioned media were collected from non‐transfected NSC‐34 cells after 72 h, from
NSC‐34 cells 72 h following transfection with SOD1G93A‐EGFP or EGFP, or from these cells
following the SOD1 release assay (see Sections 4.2.3.2, 4.2.3.4 and 4.2.4). A pelletable
fraction was obtained by centrifugation (20,000 x g for 30 min) and resuspended in
complete culture media (200 ‐ 500 µL), in the absence or presence of EOC13, naïve NSC‐34
or x‐box binding protein 1 (XBP1)‐tomato‐transfected NSC‐34 cells [transfected as per
Section 4.2.3.4; pCAX‐F‐XBP1‐Venus DNA was kindly provided by Masayuki Miura (University
of Tokyo, Tokyo, Japan) and the venus sequence replaced with tdTomato from
pcDNA3.1(+)Luc2tdT by GenScript (Piscataway, NJ)]. Fractions resuspended in the absence
of cells were added to adherent cells plated 24 h prior. Fractions resuspended in the
presence of cells were plated. All cells were plated in 24‐well plates at 5 × 104 cells/ 0.5 mL/
well, in 12‐well plates at 3 × 105 cells/ 0.4 mL/ well or in 8‐chamber slides at 2 × 104 cells/
0.2 mL/ chamber. Cells in the absence or presence of pelletable fractions of conditioned
media were then incubated at 37°C/5% CO2 for 2 or 24 h. Cells were visualised by
differential interference contrast (DIC) and fluorescence imaging using an Eclipse TE2000
inverted microscope (Nikon) or IncuCyte ZOOM live cell imaging system (Essen BioScience,
Ann Arbor, MI). DIC, fluorescent and merged images were captured using Image‐Pro AMS
(Version 6.1) (Media Cybernetics) or IncuCyte ZOOM software (Version 2015A) (Essen
BioScience). Conditioned media were collected, and cells and conditioned media processed
as summarised (Figure 4.1) and described below.
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(excitation 488 nm, emission collected with 515/20 band‐pass filter). The percentage of cells
positive for EGFP was assessed using FlowJo software.
4.2.12.4 EGFP uptake by confocal microscopy
EOC13 cells incubated in chamber slides for 2 or 24 h with pelletable material from
transfected NSC‐34 cells (see Section 4.2.12.1) were visualised using a DM IBRE inverted
microscope and TCS SP confocal imaging system (Leica) at 37°C (excitation 488 nm, emission
collected at 500‐540 nm). Fluorescent and bright‐field 30‐step z‐stacks were captured using
Leica Confocal Software and either compressed to form single images or orthogonally
sectioned to confirm that fluorescent particles present were intracellular. In some
experiments, cells were fixed with 4% PFA in PBS at room temperature for 15 min, washed
with PBS, and then stored in PBS at 4°C for visualisation at a later date.
4.2.12.5 ER stress by flow cytometry
XBP1‐tomato‐transfected NSC‐34 cells incubated for 24 h with pelletable material from
transfected NSC‐34 cells (see Section 4.2.12.1) were harvested using 0.05% trypsin (5 min,
37°C) and then washed by centrifugation (300 x g for 5 min). Events were collected using a
LSR II flow cytometer (BD Biosciences) (excitation 488 nm, emission collected with 515/20
band‐pass filter; excitation 532, emission collected with 575/26 band‐pass filter), and EGFP
association (see Section 4.2.12.3) and the MFI of relative spliced XBP1 determined using
FlowJo software.
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4.2.12.6 ER stress by confocal microscopy
XBP1‐tomato‐transfected NSC‐34 cells incubated in chamber slides for 24 h with pelletable
material from transfected NSC‐34 cells (see Section 4.2.12.1) were fixed with 4% PFA in PBS
at room temperature for 15 min, washed with PBS, and then stored in PBS at 4°C until
required. Cells were visualised using a DM IBRE inverted microscope and TCS SP confocal
imaging system (Leica) (excitation 561 nm, emission collected at 590‐650 nm). Fluorescent
and bright‐field 30‐step z‐stacks were captured using Leica Confocal Software and
compressed to form single images.
4.2.13 Data presentation and statistical analyses
Data is presented as the mean ± SD. Differences between multiple treatments were
compared by ANOVA paired with Tukey’s HSD post‐tests. For single comparisons, unpaired
student’s t‐tests were performed. The software package Prism 5 for Windows (Version 5.01)
(GraphPad Software, San Diego, CA) was used for these statistical analyses, with differences
considered significant for P < 0.05.
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4.3

Results

4.3.1 P2X7 mediates SOD1 release from NSC‐34 motor neurons
To determine the potential role for P2X7 activation in the release of SOD1 from NSC‐34
motor neurons, the ability to detect SOD1 in conditioned media from cells transfected with
SOD1G93A‐EGFP was first investigated. Given that filter trap analysis and immunoblotting had
previously been used for SOD1 detection in conditioned media (Grad et al., 2014), these
techniques were utilised. NSC‐34 cells were transfected with EGFP or SOD1G93A‐EGFP,
incubated for 72 h (Figure 4.2a), and then conditioned media collected. Filter trap analysis
unexpectedly identified small amounts of anti‐EGFP reactive and SDS‐resistant material
larger than the 0.2 µm pore size in conditioned media from non‐transfected NSC‐34 cells
(Figure 4.2b). Small amounts of this material was also observed from NSC‐34 cells
transfected with EGFP (Figure 4.2b). Substantially more EGFP‐positive SDS‐resistant material
was identified in conditioned medium from NSC‐34 cells transfected with SOD1G93A‐EGFP
(Figure 4.2b). However, due to the detection of EGFP in media from non‐transfected cells,
suggestive of cross‐contamination of wells, this approach was not investigated further.
Next, conditioned media was fractionated into soluble and pelletable fractions (20,000 x g,
30 min) and analysed by immunoblotting. No EGFP was identified in either fraction derived
from conditioned medium of non‐transfected cells (Figure 4.2c). Conversely, 26 kDa EGFP
was identified in both fractions derived from conditioned medium of cells transfected with
EGFP (Figure 4.2c). In comparison, 46 kDa EGFP‐tagged SOD1 and 26 kDa cleaved EGFP were
identified in the pelletable, but not soluble, fraction derived from conditioned media of cells
transfected with SOD1G93A‐EGFP (Figure 4.2c). A molecular size of 46 kDa is consistent with
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the previously reported molecular weight of SOD1G93A‐EGFP (Turner et al., 2005). Given that
no EGFP signal was obtained in non‐transfected cells and no EGFP‐tagged SOD1 was
obtained in soluble fractions following immunoblotting, this method was adopted for
subsequent investigations of pelletable fractions.

G93A

Figure 4.2 Mutant SOD1 ‐EGFP (mSOD1) is detectable in conditioned media of NSC‐34 motor neurons
transiently transfected with mSOD1. (a‐c) Following transfection (72 h) using Lipofectamine 2000, non‐
transfected (NT) NSC‐34 cells or NSC‐34 cells transiently transfected with EGFP or mSOD1 were (a) visualised
by microscopy to confirm transfection. Bars represent 100 μm and results are representative of n > 20
transfections. (b and c) Conditioned media were then collected. (b) Conditioned media were incubated with
PBS containing 1% SDS. SDS‐resistant material was then separated onto cellulose acetate by filter‐trap, and
then incubated with anti‐EGFP Ab. Results shown as mean band density relative to corresponding NT ± SD, n =
2, with a representative blot indicated. (c) Conditioned media were fractionated into pelletable (P) and soluble
(S) fractions by centrifugation. Fractions were then separated by SDS‐PAGE under reducing conditions and
transferred to a nitrocellulose membrane. Membrane was incubated with anti‐EGFP Ab. Results show one
experiment.

To investigate whether P2X7 activation mediated SOD1 release from NSC‐34 motor neurons,
cells transfected with SOD1‐EGFP variants for 72 h were incubated in incomplete culture
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medium in the absence or presence of varying concentrations of ATP for 20 min, and then
SOD1 or EGFP in pelletable fractions of conditioned media identified by immunoblotting
with an anti‐EGFP Ab. To avoid overlooking potential differences in the amounts of material
released, total conditioned media were investigated rather than equal protein amounts.
Pelletable fractions of conditioned media from cells transfected with EGFP or SOD1WT‐EGFP
and incubated in the absence of ATP contained EGFP and SOD1WT protein, respectively
(Figure 4.3a). In comparison, very little SOD1G93A was present in the pelletable fraction of
conditioned media from cells transfected with SOD1G93A‐EGFP and incubated in the absence
of ATP. Incubation with ATP (1‐5 mM) induced EGFP and SOD1 release from cells
transfected with EGFP or either SOD1‐EGFP variant (SOD1WT or SOD1G93A), with increasing
amounts detected with increasing ATP concentrations and compared to cells incubated in
the absence of ATP (Figure 4.3a).
ATP‐mediated SOD1 release was then investigated during a short‐term visit to an overseas
laboratory (University of British Columbia, Vancouver, Canada) using non‐EGFP mutant
SOD1 variants and an anti‐SOD1 Ab. SOD1 was detected in pelletable fractions of
conditioned media from NSC‐34 cells transfected with or without SOD1G85R or SOD1G127X and
incubated in the absence of ATP (Figure 4.3b). Again, ATP (3‐5 mM) induced SOD1 release
from cells transfected with SOD1 variants (SOD1G85R or SOD1G127X). In addition, ATP
(3‐5 mM) induced endogenous mouse SOD1 release from non‐transfected cells.
To further characterise SOD1 release from NSC‐34 cells, cells were transfected with mutant
SOD1G93A‐EGFP (mSOD1) for 72 h and then incubated in incomplete culture medium in the
absence or presence of varying concentrations of ATP for 20 min as above. mSOD1 was
identified by immunoblotting with an anti‐EGFP Ab. ATP (3‐5 mM) induced significant
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Figure 4.3 P2X7 mediates SOD1 release from NSC‐34 motor neurons. Following transfection (72 h) using (a, c
and d) Lipofectamine 2000 or (b) Lipofectamine LTX, NSC‐34 cells (transiently expressing (a) EGFP, wild type
SOD1‐EGFP (WT SOD1), (a, c and d) mutant SOD1G93A‐EGFP (mSOD1), (b) mutant SOD1G85R (G85R), mutant
SOD1G127X (G127X) or expressing endogenous mouse SOD1) were pre‐incubated in incomplete culture medium
in the (a‐d) absence (control) or (d) presence of 10 μM AZ10606120 at 37°C for 1 h. Cells were then incubated
in the absence (basal) or presence of (a‐c) varying concentrations (as indicated) or (d) 5 mM ATP at 37°C for
20 min. Conditioned media were collected and a pelletable fraction obtained by centrifugation. Pelletable
fractions were separated by SDS‐PAGE under reducing conditions, transferred to nitrocellulose membranes,
and incubated with (a, c and d) anti‐EGFP or (b) anti‐SOD1 Abs. Results representative of (a) n = 1‐3 and (b) n =
2‐3. (c and d) Results shown as mean band density (c) as a percent of maximum or (d) relative to
corresponding control basal ± SD, n = 3, with representative blots indicated [(c) includes data from (a) and is
reshown for comparison to (d)]; ∗∗∗P < 0.001 or ∗∗P < 0.01 compared to (c) 0 mM ATP or (d) corresponding
basal; ††P < 0.01 or †P < 0.05 compared to (c) 1 mM ATP or (d) control ATP.

mSOD1 release compared to cells incubated in the absence of ATP or presence of 1 mM ATP
(Figure 4.3c). To confirm that the observed ATP‐induced mSOD1 release was mediated by
P2X7, cells were pre‐incubated with the P2X7 antagonist AZ10606120. Pre‐incubation of

169

Chapter 4 – P2X7‐mediated release of SOD1 from NSC‐34 motor neurons

cells with 10 μM AZ10606120 completely inhibited 5 mM ATP‐induced mSOD1 release
(Figure 4.3d).
4.3.2 NSC‐34 motor neurons express functional P2X7
The above data indicates that P2X7 mediates ATP‐induced mSOD1 release from transfected
NSC‐34 cells (Figure 4.3). However, the presence of functional P2X7 in NSC‐34 cells has not
previously been reported. Thus, the presence of P2X7 was examined in NSC‐34 cells obtained
from routine cell culture. The presence of total P2X7 protein in NSC‐34 cells was first
examined by probing separated whole lysates with anti‐P2X7 pAb. Murine EOC13 microglia
(Bartlett, 2011) and P2X7‐transfected HEK‐293 cell lysates were used as positive controls.
Immunoblotting revealed one major protein band of approximately 75 kDa for both positive
control cell lysates (Figure 4.4a). This band was also present in NSC‐34 cell lysates, but at a
lower intensity than the positive controls (Figure 4.4a). Major protein bands of approximately
150 and 65 kDa were also present in NSC‐34 cell lysates (possibly representing SDS‐resistant
dimers and non‐glycosylated P2X7, respectively) (Figure 4.4a). To determine whether P2X7
was functional in NSC‐34 cells, an ethidium+ uptake assay was performed. ATP (5 mM) was
found to induce a small but significant ethidium+ uptake into adherent cells (Figure 4.4b).
The ethidium+ uptake assay was then performed using cells cultured under the same
conditions (72 h incubation) used to investigate SOD1 release. Further, to confirm a
potential role for P2X7 in ATP‐induced ethidium+ uptake, cells were pre‐incubated in the
absence or presence of AZ10606120 prior to ATP addition. ATP (5 mM) induced ethidium+
uptake into (non‐transfected) cells, which was completely blocked by pre‐incubation of cells
with 10 μM AZ10606120 (Figure 4.5a). Next, to determine whether transfection with SOD1‐
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Figure 4.4 NSC‐34 motor neurons express low amounts of functional P2X7. (a) EOC13 microglia, murine P2X7‐
expressing HEK‐293 (mP2X7) and NSC‐34 cell lysates were separated by SDS‐PAGE under reducing conditions,
transferred to nitrocellulose membranes and incubated with anti‐P2X7 pAb. Results are representative of
three experiments. (b) Adherent NSC‐34 cells were incubated in incomplete culture medium in the absence
(basal) or presence of 5 mM ATP at 37°C for 20 min in the presence of 25 μM ethidium+. Incubations were
stopped by the addition of MgCl2 medium. Mean fluorescence intensities (MFI) of ethidium+ uptake (pore
formation) were determined by flow cytometry and results shown as means ± SD, n = 3; ∗∗∗P < 0.001 compared
to basal.

+
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Figure 4.5 P2X7 mediates ATP‐induced ethidium uptake into mutant SOD1 ‐EGFP (mSOD1)‐transfected
NSC‐34 motor neurons in a similar manner to non‐transfected (NT) cells. Following transfection (72 h) using
Lipofectamine 2000, adherent (a and b) NT NSC‐34 cells or (b) NSC‐34 cells transiently transfected with mSOD1
were pre‐incubated in incomplete culture medium in the (a and b) absence (control) or (a) presence of 10 μM
AZ10606120 at 37°C for 1 h. (a and b) Cells were then incubated in the absence (basal) or presence of 5 mM
ATP at 37°C for 20 min in the presence of 25 μM ethidium+. Incubations were stopped by the addition of MgCl2
medium. Mean fluorescence intensities (MFI) of ethidium+ uptake (pore formation) were determined by flow
cytometry and results shown as means ± SD, n = 3; ∗∗∗P < 0.001 compared to corresponding basal; †††P < 0.001
compared to control ATP.
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EGFP variants alters P2X7 function, ethidium+ uptake into non‐transfected cells and cells
transfected with mSOD1 was investigated 72 h following transfection. ATP was found to
induce similar and significant ethidium+ uptake into both transfected and non‐transfected
cells (Figure 4.5b), indicating that the transfection process does not alter P2X7 function in
NSC‐34 cells.
4.3.3 P2X7 mediates mSOD1 release from NSC‐34 motor neurons independently of cell
death
P2X7 activation is well known to induce cell death under certain circumstances, such as high
ATP concentrations and prolonged stimulation (Adinolfi et al., 2005b). To investigate
whether P2X7‐mediated mSOD1 release from NSC‐34 cells occurred via cell death, mSOD1‐
transfected cells were assessed by microscopy and an LDH release (cytotoxicity) assay
following ATP stimulation. Morphologically, there were no observable differences in cells
incubated in the absence or presence of ATP, with the majority of cells displaying discrete
cell bodies with short, spindled shaped processes (Figure 4.6a). Similarly, there were no
observable differences when cells were pre‐incubated in the absence or presence of
AZ10606120 (Figure 4.6a). Consistent with microscopy, no significant differences in LDH
release were observed in cells pre‐incubated in the absence or presence of AZ10606120, or
absence or presence of ATP, with less than 6% of the total cellular LDH released in each
treatment group (Figure 4.6b). Collectively, these results suggest that P2X7‐mediated
mSOD1 release occurs via a mechanism independent of cell death.
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Figure 4.6 P2X7‐mediated mutant SOD1G93A‐EGFP (mSOD1) release from NSC‐34 motor neurons transiently
transfected with mSOD1 occurs independently of cell death. Following transfection (72 h) using
Lipofectamine 2000, NSC‐34 cells transiently expressing mSOD1 were pre‐incubated in incomplete culture
medium in the absence (control) or presence of 10 μM AZ10606120 at 37°C for 1 h. Cells were then incubated
in the absence (basal) or presence of 5 mM ATP at 37°C for 20 min. (a) DIC images of cell morphology were
acquired by microscopy. Bars represent 100 μm. Results are representative of n > 20 fields of view. (b)
Conditioned media were collected and remaining adherent cells lysed. The total amount of lactate
dehydrogenase (LDH) and LDH in conditioned media was measured and used to determine the cytotoxicity as
mean percent LDH release ± SD, n = 3.

4.3.4 ATP induces membrane blebbing from NSC‐34 motor neurons
To examine the mechanism of ATP‐induced mSOD1 release from NSC‐34 cells, cells
containing SOD1G93A aggregates were identified by confocal microscopy via the EGFP tag.
ATP (5 mM) was added, and then images collected every 30 s for 20 min. At this higher
magnification relative to light microscopy (Figure 4.6), morphological changes were
observed within minutes of ATP addition (Figure 4.7), consistent with those reported
following P2X7 activation in other cell types (Pfeiffer et al., 2004; Verhoef et al., 2003;
Virginio et al., 1999). These changes in NSC‐34 cells were characterised by membrane
blebbing, which occurred both in cells expressing and not expressing mSOD1 (examples
indicated by green and black arrows, respectively). Blebs ranged in size from 1‐3 µm. While
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Figure 4.7 ATP induces membrane blebbing from NSC‐34 motor neurons. Following transfection (72 h) using
Lipofectamine 3000, NSC‐34 cells in incomplete culture medium transiently expressing mSOD1 were visualised
by confocal microscopy. ATP was added (5 mM final) and fluorescent and bright‐field images captured every
30 s for 20 min. Results show two mSOD1‐transfected cells at 0, 1.5, 5 and 20 min after ATP addition. During
the 20 min, cells tended to shift out of focus and a refocused image of these cells at 20 min is also included. A
bleb from a transfected and non‐transfected cell are indicated upon first appearance by a green and black
arrow, respectively. Bars represent 25 μm. Results are representative of six experiments.

mSOD1 appeared to be released in blebs, evident from the presence of EGFP signal, the
larger mass of cytosolic aggregates (identified as the EGFP+ foci) appeared to remain
intracellular following refocusing at 20 min (Figure 4.7). As imaging was conducted in one z‐
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plane, the movement of blebs could not be reliably tracked. As above (Figure 4.6), there was
no evidence of cell death after 20 min (Figure 4.7).
4.3.5 Calcium influx, but not potassium efflux, is involved in mSOD1 release from NSC‐34
motor neurons
Since P2X7 is a ligand‐gated cation channel (Jarvis and Khakh, 2009), the possible roles for
cation fluxes in P2X7‐mediated mSOD1 release were next investigated. Ca2+ is important in
phospholipid redistribution in cellular membranes, as well as vesicle release (Barclay et al.,
2005; Bucki et al., 1998), therefore this cation was investigated first. However, in
preliminary studies, incubation of cells in different types of media lacking Ca2+ or the
addition of intracellular or extracellular Ca2+ chelators (1,2‐bis(o‐aminophenoxy)ethane‐
N,N,N',N'‐tetraacetic acid and ethylene glycol tetraacetic acid) resulted in the detachment of
cells (data not shown). This also occurred with cells plated onto the adhesion‐promoting
factor poly‐D‐lysine. Thus, despite numerous conditions and attempts a role for Ca2+ in
P2X7‐mediated mSOD1 release could not be directly investigated.
As an alternative approach to exploring a role for Ca2+ influx in P2X7‐mediated mSOD1
release, the Ca2+ ionophore ionomycin, which induces Ca2+ influx without affecting
intracellular K+ (Andrei et al., 2004), was investigated. Following transfection (72 h), mSOD1‐
tranfected cells were incubated in the absence or presence of 5 mM ATP or 2 µM ionomycin
for 20 min, assessed by microscopy and then the pelletable fractions from conditioned
media immunoblotted for SOD1. Morphologically, there were no observable differences in
cells incubated in the absence or presence of ionomycin, with the majority of cells displaying
discrete cell bodies with short, spindled shaped processes (Figure 4.8a). In contrast to above
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(Figure 4.6) and incubation with ionomycin, cells incubated with ATP had smaller cell bodies
and retracted processes (Figure 4.8a), consistent with ATP‐induced changes in membrane
structure (Qu and Dubyak, 2009). However, again there was no morphological evidence of
cell death following ATP or ionomycin treatment (Figure 4.8a). Immunoblotting of pelletable
fractions revealed similar and significant mSOD1 in conditioned media of mSOD1‐tranfected
NSC‐34 cells incubated with either ATP or ionomycin compared to cells incubated in the
absence of both compounds (Figure 4.8b). This suggests a role for Ca2+ influx in inducible
(and indirectly P2X7‐mediated) mSOD1 release from NSC‐34 motor neurons.

Figure 4.8 Calcium influx mediates mutant SOD1G93A‐EGFP (mSOD1) release from NSC‐34 motor neurons
transiently transfected with mSOD1. Following transfection (72 h) using Lipofectamine 3000, NSC‐34 cells
transiently expressing mSOD1 were incubated in incomplete culture medium in the absence (basal) or
presence of 5 mM ATP or 2 µM ionomycin at 37°C for 20 min. (a) DIC images of cell morphology were acquired
by microscopy. Bars represent 100 μm. Results are representative of six experiments. (b) Conditioned media
were collected and a pelletable fraction obtained by centrifugation. Pelletable fractions were separated by
SDS‐PAGE under reducing conditions, transferred to nitrocellulose membranes, and incubated with anti‐SOD1
Ab. Results shown as mean band density relative to corresponding basal ± SD, n = 4, with a representative blot
indicated; ∗∗P < 0.01 compared to basal.

Next, the role of K+ efflux in P2X7‐mediated mSOD1 release from NSC‐34 cells was
investigated. ATP‐induced mSOD1 release was examined from cells in incomplete media
containing 50 mM Na+ or K+, the latter of which prevents the loss of intracellular K+ (Sanz
and Di Virgilio, 2000). Incubation with 5 mM ATP induced a similar but significant release of
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pelletable mSOD1 into conditioned media of cells in incomplete culture medium containing
Na+ or K+ (Figure 4.9). This indicated that P2X7‐mediated mSOD1 release from NSC‐34 motor
neurons is not dependent on K+ efflux.

Figure 4.9 Potassium efflux is not required for ATP‐induced mutant SOD1G93A‐EGFP (mSOD1) release from
NSC‐34 motor neurons transiently transfected with mSOD1. Following transfection (72 h) using Lipofectamine
3000, NSC‐34 cells transiently expressing mSOD1 were incubated in incomplete culture medium supplemented
with the presence of 50 mM Na+ (NaCl) or K+ (KCl), and in the absence (basal) or presence of 5 mM ATP at 37°C
for 20 min. Conditioned media were collected and a pelletable fraction obtained by centrifugation. Pelletable
fractions were separated by SDS‐PAGE under reducing conditions, transferred to nitrocellulose membranes,
and incubated with anti‐SOD1 Ab. Results shown as mean band density relative to corresponding NaCl basal
± SD, n = 3, with a representative blot indicated; ∗P < 0.05 compared to corresponding basal.

4.3.6 ATP‐induced mSOD1 released from NSC‐34 motor neurons is structurally
heterogeneous
In an attempt to characterise the ATP‐induced mSOD1 released from NSC‐34 cells, and
determine with what exocytic structures it was associated, conditioned media were
collected following incubation in the absence or presence of ATP, and then differentially
centrifuged to obtain four fractions (F1‐F4). These fractions have been used by others to
isolate cell debris/organelles (F1), insoluble protein (F2), exosomes (F3) and soluble proteins
(F4) (Gomes et al., 2007). ATP‐induced mSOD1 was present in all four fractions, suggesting a
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heterogeneous pattern of release (Figure 4.10). F1 and F4 each represented approximately
30% of the total amount of ATP‐induced mSOD1 released, with F2 and F3 each representing
20% of this material (Figure 4.10).
Figure 4.10 ATP‐induced mutant SOD1G93A‐EGFP
(mSOD1) released from NSC‐34 motor neurons
transiently transfected with mutant mSOD1 is
structurally heterogeneous. Following transfection
(72 h) using Lipofectamine 3000, NSC‐34 cells
transiently expressing mSOD1 were incubated in
incomplete culture medium in the absence (basal, B)
or presence (ATP, A) of 5 mM ATP at 37°C for 20
min. Conditioned media were collected and
differentially centrifuged at 500 x g for 10 min to
obtain fraction 1 (F1), 10,000 x g for 20 min to
obtain fraction 2 (F2), and 100,000 x g for 2 h to
obtain fraction 3 (F3). Remaining soluble proteins
were precipitated to obtain fraction 4 (F4). Fractions
were separated by SDS‐PAGE under reducing
conditions,
transferred
to
nitrocellulose
membranes, and incubated with anti‐SOD1 Ab.
Results shown as (top panel) representative blot,
(middle panel) mean band density relative to F1
basal ± SD, n = 3, or (bottom panel) mean percent of
total ATP‐induced mSOD1 release ± SD, n = 3;
∗∗P < 0.01 or ∗P < 0.05 compared to corresponding
basal; ††P < 0.01 or †P < 0.05 compared to F1 ATP; ‡P
< 0.05 compared to F1.

Next, the pelletable fraction of conditioned media (derived from centrifugation at
20,000 x g, 30 min) from mSOD1‐transfected NSC‐34 cells incubated in the absence or
presence of ATP were collected and visualised by TEM. The main structures observed in
fractions from cells incubated with ATP were fibrillar, ranging from 100 – 700 nm in length
(indicated by arrows) (Figure 4.11a). These fibrillar structures were largely absent from the
corresponding fraction obtained from cells incubated in the absence of ATP (Figure 4.11a).
To determine if the mSOD1 released co‐localised with these fibrillar structures following
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ATP treatment, pelletable fractions of conditioned media from ATP‐treated cells were
probed with immunogold labelled anti‐EGFP pAb and visualised by TEM. mSOD1, identified
by round black gold particles (indicated by arrows), were identified alone and in association
with fibrillar‐like structures (Figure 4.11b). No immunogold labelling was evident in
corresponding isotype controls (Figure 4.11b).

Figure 4.11 ATP‐induced mutant SOD1G93A‐EGFP (mSOD1) released from NSC‐34 motor neurons transiently
transfected with mSOD1 is structurally heterogeneous. Following transfection (72 h) using Lipofectamine
2000, NSC‐34 cells transiently expressing mSOD1 were incubated in incomplete culture medium in the absence
(basal) or presence of 5 mM ATP at 37°C for 20 min. Conditioned media were collected and a pelletable
fraction obtained by centrifugation. Pelletable fractions were loaded onto transmission electron microscopy
(TEM) grids and (a) visualised by TEM, or (b) incubated with an anti‐EGFP or corresponding isotype control and
visualised by TEM. (a) Fibrillar structures and (b) gold labels are indicated by black arrows. Bars represent (a)
0.5 or (b) 0.1 µm. Results are representative of (a) one or (b) two experiments.
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4.3.7 mSOD1 released from NSC‐34 motor neurons during transfection associates with
naïve cells, coinciding with altered morphology, increased TNF‐α release and ER
stress
4.3.7.1 mSOD1 released from NSC‐34 motor neurons during transfection alters morphology
of and associates with naïve NSC‐34 and EOC13 cells
To investigate the effects of extracellularly applied mSOD1 on non‐transfected (naïve)
NSC‐34 and EOC13 cells, these cells were incubated with 72 h pelletable fractions; 72 h
pelletable fractions were obtained by centrifugation (20,000 x g, 30 min) of conditioned
media from 72 h mSOD1‐transfected NSC‐34 motor neurons, and resuspension of the
pelletable material in fresh complete culture media. Naïve NSC‐34 cells have previously
been reported to internalise SOD1 aggregates after 2 h incubation (Zeineddine et al., 2015).
Thus, the effects of the 72 h pelletable fractions on naïve cells were also investigated after
2 h co‐incubation in the current study. After 2 h, both naïve EOC13 and NSC‐34 cells had
altered morphology, characterised by smaller cell bodies and a less healthy appearance,
compared to cells incubated in the presence of fresh complete culture media alone (Figure
4.12a). To determine if this change in morphology corresponded with an association with
mSOD1, cells were analysed by flow cytometry for the presence of EGFP (using the gating
strategy outlined; Figure 4.12b). Approximately 10% of naïve EOC13 and NSC‐34 cells
incubated with 72 h pelletable fractions were associated with mSOD1, which was
significantly greater than in the absence of this material (Figure 4.12b). This is consistent
with prior studies (Zeineddine et al., 2015), suggesting that cells are internalising mSOD1
from 72 h pelletable fractions.
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Figure 4.12 Mutant SOD1 ‐EGFP (mSOD1) released from mSOD1‐transfected NSC‐34 motor neurons over
72 h can alter morphology of and associates with naïve NSC‐34 motor neurons and EOC13 microglia after 2 h
incubation. Conditioned media were collected from NSC‐34 cells transiently expressing mSOD1 72 h following
transfection using Lipofectamine 3000. Pelletable fractions were obtained by centrifugation, resuspended in
complete culture media (72 h pelletable fractions) and added to suspended NSC‐34 and EOC13 cells. After 2 h
plated in the presence of complete culture media alone (control) or with 72 h pelletable fractions, (a) DIC
images of cell morphology were acquired by microscopy. Bars represent 100 μm. Results are representative of
n = 3‐12. (b) After visualising, cells were firstly gated on forward (FSC) and side scatter to exclude debris and
doublets (not shown) and then the percentage of EGFP positive cells determined by flow cytometry. Results
shown as (top panel) dot plots of one representative set of data demonstrating the gating strategy and
(bottom panel) mean percentage of EGFP positive cells ± SD, n = 3; ∗∗∗P < 0.001 compared to corresponding
control.
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4.3.7.2 Association of mSOD1 with naïve EOC13 microglia coincides with altered
morphology and TNF‐α release
The addition of recombinant aggregated SOD1G93A to EOC13 cells has been reported to
induce TNF‐α and MCP‐1 release from these cells after 12‐24 h (Roberts et al., 2013). Thus,
having established that the released mSOD1 was able to associate with naïve EOC13 cells
after 2 h, it was next investigated whether this material was retained over 24 h and able to
induce the release of TNF‐α and MCP‐1. As above (Figure 4.12a), EOC13 cells incubated with
72 h pelletable fractions had altered morphology after 2 h, characterised by smaller cell
bodies and a less healthy appearance, compared to cells incubated in the presence of fresh
complete culture media alone (Figure 4.13a). After 24 h, the morphology of cells incubated
with 72 h pelletable fractions more closely resembled cells incubated in the absence of this
material, with the majority of cells with long, spindled shaped processes and a less grainy
appearance (Figure 4.13a).
The above cells were then analysed by flow cytometry for the presence of the EGFP tag. A
significant proportion of EOC13 cells incubated with 72 h pelletable fractions for 2 or 24 h
were associated with mSOD1 (approximately 12% and 7%, respectively) compared to cells
incubated in the absence of this material (Figure 4.13b). After 24 h of incubation,
significantly fewer EOC13 cells were associated with mSOD1 than after 2 h (Figure 4.13b).
To determine whether association with mSOD1 correlated with TNF‐α and MCP‐1 release,
conditioned media from EOC13 cells incubated in the absence or presence of 72 h pelletable
fractions for 24 h were collected and analysed for the presence of these proteins. EOC13
cells incubated with 72 h pelletable fractions released higher amounts of TNF‐α, but not
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Figure 4.13 Mutant SOD1G93A‐EGFP (mSOD1) released from mSOD1‐transfected NSC‐34 motor neurons over
72 h can alter morphology of and associates with EOC13 microglia, coinciding with tumour necrosis factor
(TNF)‐α release. Conditioned media were collected from NSC‐34 cells transiently expressing mSOD1 72 h
following transfection using Lipofectamine 3000. Pelletable fractions were obtained by centrifugation,
resuspended in complete culture media (72 h pelletable fractions) and added to suspended EOC13 cells. After
(a and b) 2 or (a‐d) 24 h plated in the presence of complete culture media alone (control) or with 72 h
pelletable fractions, (a) DIC images of cell morphology were acquired by microscopy. Bars represent 100 μm.
Results are representative of twelve experiments. After visualising, cells were (b) gated on forward and side
scatter to exclude debris and doublets (not shown) and then the percentage of EGFP positive cells determined
by flow cytometry and (c and d) EOC13 conditioned media collected and (c) TNF‐α and (d) monocyte
chemoattractant protein‐1 (MCP‐1) concentrations determined using an ELISA. Results shown as mean (b)
percentage of EGFP positive cells, (c) TNF‐α release or (d) MCP‐1 release ± SD, n = 3; ∗∗∗P < 0.001, ∗∗P < 0.01 or
∗P < 0.05 compared to (b) corresponding control or (c) EOC13 cells incubated in the absence of 72 h pelletable
fractions; (b) †P < 0.05 compared to 2 h mSOD1; (c and d) ‡‡‡P < 0.001 or ‡‡P < 0.01 compared to 72 h pelletable
fractions in the absence of EOC13 cells.
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MCP‐1, after 24 h compared to those incubated in the absence of this material (Figure
4.13c,d), consistent with prior reports using purified SOD1G93A (Roberts et al., 2013).
However, EOC13 cells released relatively high amounts of MCP‐1 constitutively, which may
have obscured any 72 h pelletable fraction‐mediated MCP‐1 release (Figure 4.13d). Seventy‐
two h pelletable fractions incubated for 24 h under the same conditions but in the absence
of cells contained negligible amounts of TNF‐α or MCP‐1, indicating that EOC13 cells were
the source of these cytokines (Figure 4.13c,d).
4.3.7.3 EGFP released from NSC‐34 motor neurons during transfection associates with
naïve EOC13 cells, coinciding with altered morphology and TNF‐α release
In addition to mSOD1, EGFP was also released from transfected NSC‐34 motor neurons
(Figure 4.3a). Therefore, the effects of co‐incubation of EGFP 72 h pelletable fractions
(generated as per mSOD1 72 h pelletable fractions) with naïve EOC13 microglia were
compared to that of mSOD1 72 h pelletable fractions. As an additional control, pelletable
fractions were also derived from conditioned media of non‐transfected NSC‐34 motor
neurons which had been incubated for 72 h (NT 72 h pelletable fractions). After 2 h, EOC13
cells incubated with EGFP 72 h pelletable fractions had altered morphology, characterised
by smaller cell bodies and a less healthy appearance, compared to cells incubated in the
presence of NT 72 h pelletable fractions or culture media alone (Figure 4.14a). This altered
morphology was similar to that observed following 2 h co‐incubation with mSOD1 72 h
pelletable fractions (Figure 4.14a). After 24 h, the morphology of cells co‐incubated with
either EGFP or mSOD1 72 h pelletable fractions more closely resembled controls, with the
majority of cells with long, spindled shaped processes and a more healthy appearance
(Figure 4.14a).
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Figure 4.14 EGFP released from EGFP‐transfected NSC‐34 motor neurons over 72 h can alter morphology of
and associates with EOC13 microglia, coinciding with tumour necrosis factor (TNF)‐α release. Conditioned
media were collected from non‐transfected (NT) NSC‐34 cells and NSC‐34 cells transiently expressing EGFP or
mutant SOD1G93A‐EGFP (mSOD1) 72 h following transfection using Lipofectamine 3000. Pelletable fractions
were obtained by centrifugation, resuspended in complete culture media (72 h pelletable fractions) and added
to suspended EOC13 cells. After (a) 2 or (a‐c) 24 h plated in the presence of complete culture media alone
(control) or with 72 h pelletable fractions, (a) DIC images of cell morphology were acquired by microscopy.
Bars represent 100 μm. Results are representative of six experiments. After visualising, cells were (b) gated on
forward and side scatter to exclude debris and doublets (not shown) and then the percentage of EGFP positive
cells determined by flow cytometry. (c) EOC13 conditioned media were collected and TNF‐α concentrations
determined using an ELISA. Results shown as mean (b) percentage of EGFP positive cells or (c) TNF‐α release ±
SD, n = 3; ∗∗∗P < 0.001, ∗∗P < 0.01 or ∗P < 0.05 compared to control; †††P < 0.001, ††P < 0.01 or †P < 0.05
compared to NT.

To determine if this change in morphology corresponded with cells associating with EGFP,
cells incubated with EGFP 72 h pelletable fractions for 24 h were analysed by flow cytometry
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for the presence of EGFP. Approximately 4% of naïve EOC13 cells incubated with EGFP 72 h
pelletable fractions were associated with EGFP, which was significantly greater than in the
presence of NT 72 h pelletable fractions or culture media alone (Figure 4.14b). A similar
proportion (approximately 3%) of naïve EOC13 cells incubated with mSOD1 72 h pelletable
fractions were found to be associated with mSOD1 (Figure 4.14b), suggesting that the
mechanisms involved in this association are not specific to SOD1.
To determine whether EGFP association coincided with TNF‐α release, conditioned media
from EOC13 cells was collected and analysed for the presence of this cytokine. EOC13 cells
incubated with EGFP 72 h pelletable fractions released significantly greater amounts of TNF‐
α compared to those incubated in the presence of NT 72 h pelletable fractions or culture
media alone (Figure 4.14c). EOC13 cells incubated with mSOD1 72 h pelletable fractions
released greater amounts of TNF‐α compared to those incubated with EGFP 72 h pelletable
fractions, although this did not reach statistical significance (Figure 4.14c).
4.3.7.4 Association of mSOD1 with naïve NSC‐34 motor neurons coincides with ER stress
Uptake of SOD1 into neuronal cells has been reported to induce ER stress (Sundaramoorthy
et al., 2013). Given that mSOD1 released from mSOD1‐expressing NSC‐34 cells associated
with naïve NSC‐34 cells after 2 h in the current study (Figure 4.12), it was next investigated
whether this material induced ER stress in these cells after 24 h. NSC‐34 cells transfected
with XBP1‐tomato were used to investigate this. During ER stress, XBP1 is spliced, resulting
in the production of a fluorescent XBP1‐tomato fusion protein, which can be detected by
fluorescent microscopy or flow cytometry (see Iwawaki et al., 2004). As no differences in cell
morphology or TNF‐α release were observed between cells incubated in the presence of NT
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72 h pelletable fractions or culture media alone (Figure 4.14), and to reduce reagent costs,
the culture media alone control was not included. XBP1‐tomato‐transfected NSC‐34 cells
incubated for 24 h with EGFP or mSOD1 72 h pelletable fractions had a larger proportion of
fluorescent cells, as observed by fluorescent microscopy, compared to those incubated with
NT 72 h pelletable fractions (Figure 4.15a).

Figure 4.15 Mutant SOD1G93A‐EGFP (mSOD1) released from mSOD1‐transfected NSC‐34 motor neurons over
72 h associates with NSC‐34 motor neurons, coinciding with endoplasmic reticulum (ER) stress. Conditioned
media were collected from non‐transfected (NT) NSC‐34 cells and NSC‐34 cells transiently expressing EGFP or
mSOD1 72 h following transfection using Lipofectamine 3000. Pelletable fractions were obtained by
centrifugation, resuspended in complete culture media (72 h pelletable fractions) and added to adherent x‐box
binding protein 1 (XBP1)‐transfected NSC‐34 cells. After 24 h plated in the presence of 72 h pelletable
fractions, (a) DIC and fluorescent images were acquired by microscopy and merged. Bars represent 300 μm.
Results are representative of four experiments. (b and c) After visualising, cells were gated on forward and side
scatter to exclude debris and doublets (not shown) and then the (b) percentage of EGFP positive cells and (c)
mean fluorescence intensities (MFI) of spliced XBP1 (ER stress) determined by flow cytometry. Results shown
as mean (b) percentage of EGFP positive cells or (c) ER stress ± SD, n = 4; ∗∗∗P < 0.001 or ∗∗P < 0.01 compared to
NT; †††P < 0.001 or †P < 0.05 compared to EGFP.
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Flow cytometry was next employed to determine whether SOD1 or EGFP were associated
with these cells. In addition, flow cytometry was employed to determine whether
differences in fluorescence could be observed between cells incubated with EGFP and
mSOD1 72 h pelletable fractions, which could not be observed from fluorescence
microscopy due to the high cellular confluency. Approximately 7% and 4% of NSC‐34 cells
incubated with EGFP or mSOD1 72 h pelletable fractions for 24 h were associated with EGFP
or mSOD1, respectively, which was significantly greater than cells incubated with NT 72 h
pelletable fractions (Figure 4.15b). Furthermore, significantly fewer cells were associated
with mSOD1 compared to EGFP after 24 h (Figure 4.15b). NSC‐34 cells incubated with
mSOD1 72 h pelletable fractions had significantly greater ER stress compared to cells
incubated with EGFP or NT 72 h pelletable fractions when measured by flow cytometry
(Figure 4.15c). This suggests that mSOD1 72 h pelletable fractions induce ER stress in naïve
cells.
4.3.8 ATP‐induced mSOD1 released from transfected NSC‐34 motor neurons is
internalised by naïve cells, coinciding with increased TNF‐α release and ER stress
4.3.8.1 ATP‐induced mSOD1 released from NSC‐34 motor neurons is internalised by naïve
EOC13 microglia
To determine whether the ATP‐induced mSOD1 released by mSOD1‐transfected NSC‐34
cells was also internalised by naïve cells, naïve EOC13 cells were incubated with basal and
ATP‐induced pelletable fractions, and mSOD1 uptake examined by confocal microscopy
using the EGFP tag. Basal and ATP‐induced pelletable fractions were obtained by
centrifugation (20,000 x g, 30 min) of conditioned media from 72 h mSOD1‐transfected
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NSC‐34 motor neurons treated in the absence or presence of ATP for 20 min, respectively,
and resuspension of the pelletable material in fresh complete culture media. In addition, to
confirm that P2X7 mediated the ATP‐induced mSOD1 release, pelletable fractions were also
derived from conditioned media of mSOD1‐transfected NSC‐34 motor neurons pre‐
incubated in the presence of AZ10606120 prior to ATP addition (AZ10606120/ basal or ATP‐
induced pelletable fractions). Since less material is released from these cells during the
20 min ATP incubation, compared to the 72 h time‐point previously investigated (Section
4.3.7), pelletable fractions were added to only a small number of cells, requiring
investigation by confocal microscopy rather than flow cytometry. mSOD1 was associated
with naïve EOC13 cells incubated for 2 h with ATP‐induced pelletable fractions, but not in
those incubated with basal pelletable fractions or complete culture media alone (Figure
4.16a). Notably, this mSOD1 (indicated by green arrows) was intracellular, as determined by
orthogonal sectioning of images (Figure 4.16a), indicative of mSOD1 internalisation.
Moreover, mSOD1 was still observed in naïve EOC13 cells after 24 h of incubation with ATP‐
induced pelletable fractions, but not in those incubated with basal pelletable fractions
(Figure 4.16b). Furthermore, less mSOD1 was observed in naïve EOC13 cells incubated for
24 h with AZ10606120/ATP‐induced pelletable fractions compared to ATP‐induced
pelletable fractions (Figure 4.16b).
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Figure 4.16 P2X7‐mediated mutant SOD1G93A‐EGFP (mSOD1) released from mSOD1‐transfected NSC‐34
motor neurons is internalised by EOC13 microglia after 2 h incubation. Following transfection (72 h) using
Lipofectamine 3000, NSC‐34 cells transiently expressing mSOD1 were pre‐incubated in incomplete culture
medium in the (a and b) absence (control) or (b) presence of 10 μM AZ10606120 at 37°C for 1 h. (a and b) Cells
were then incubated in the absence or presence of 5 mM ATP at 37°C for 20 min. Conditioned media were
collected and pelletable fractions obtained by centrifugation. Pelletable fractions were resuspended in
complete culture media and added to suspended EOC13 cells. After (a) 2 or (b) 24 h plated in the presence of
complete culture media alone (EOC13 control) or with pelletable fractions, EGFP association was visualised by
confocal microscopy. (a and b) Results shown as 2D images made up of 30 compressed z‐stacks. Bars represent
25 μm and results are representative of (a) six or (b) three experiments. (a, right panel) To determine if the
visualised EGFP was intracellular, images were orthogonally sectioned. Orthogonal sectioning of the cell is
outlined in yellow and intracellular particles are indicated by green arrows.
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4.3.8.2 Internalisation of ATP‐induced mSOD1 by naïve EOC13 microglia coincides with
TNF‐α release
Having established that P2X7‐mediated mSOD1 released by mSOD1‐transfected NSC‐34 cells
was internalised by naïve cells, it was next investigated if this process coincided with TNF‐α
release. Conditioned media from EOC13 cells incubated for 24 h in the absence or presence
of basal or ATP‐induced pelletable fractions were collected, and analysed for the presence
of TNF‐α. EOC13 cells incubated in the presence of complete culture media alone released
TNF‐α (Figure 4.17). This constitutive release was significantly potentiated by incubation
with either basal or ATP‐induced pelletable fractions (Figure 4.17). Cells incubated with ATP‐
induced pelletable fractions released significantly greater TNF‐α compared to those
incubated with basal pelletable fractions (Figure 4.17).

Figure 4.17 EOC13 microglia incubated with ATP‐induced pelletable fractions released from mutant
SOD1G93A‐EGFP (mSOD1)‐transfected NSC‐34 motor neurons release tumour necrosis factor (TNF)‐α after
24 h. Following transfection (72 h) using Lipofectamine 3000, NSC‐34 cells transiently expressing mSOD1 were
incubated in the absence or presence of 5 mM ATP at 37°C for 20 min. Conditioned media were collected and
pelletable fractions obtained by centrifugation. Pelletable fractions were resuspended in complete culture
media and added to suspended EOC13 cells. After 24 h, conditioned media from EOC13 cells plated in the
presence of complete culture media alone (EOC13 control) or with pelletable fractions were collected, and
TNF‐α concentrations determined using an ELISA. Results shown as mean TNF‐α release ± SD, n = 3;
∗∗∗P < 0.001 or ∗∗P < 0.01 compared to EOC13 control; †††P < 0.001 compared to mSOD1.

192

Chapter 4 – P2X7‐mediated release of SOD1 from NSC‐34 motor neurons

4.3.8.3 Internalisation of ATP‐induced mSOD1 by naïve NSC‐34 motor neurons coincides
with ER stress
To determine whether the P2X7‐mediated mSOD1 released by mSOD1‐transfected NSC‐34
cells also induced ER stress in naïve cells, naïve XBP1‐transfected NSC‐34 cells were
incubated for 24 h in the absence or presence of basal or ATP‐induced pelletable fractions,
and ER stress examined by confocal microscopy. Again, since less material is released from
transfected NSC‐34 cells during the 20 min ATP incubation, compared to the 72 h time‐point
previously investigated (Section 4.3.7.4), pelletable fractions were added to only a small
number of cells, requiring investigation by confocal microscopy. Cells incubated with
complete culture media alone or basal pelletable fractions for 24 h had a negligible amount
of fluorescent cells (Figure 4.18). In comparison, cells incubated with ATP‐induced pelletable
fractions had a greater proportion of fluorescent cells (Figure 4.18).

Figure 4.18 Naïve NSC‐34 motor neurons incubated with ATP‐induced pelletable fractions released from
mutant SOD1G93A‐EGFP (mSOD1)‐transfected NSC‐34 motor neurons display endoplasmic reticulum (ER)
stress after 24 h. Following transfection (72 h) using Lipofectamine 3000, NSC‐34 cells transiently expressing
mSOD1 were incubated in the absence or presence of 5 mM ATP at 37°C for 20 min. Conditioned media were
collected and pelletable fractions obtained by centrifugation. Pelletable fractions were resuspended in
complete culture media and added to adherent x‐box binding protein 1 (XBP1)‐transfected NSC‐34 cells. After
24 h plated in the presence of complete culture media alone (NSC‐34 control) or with pelletable fractions,
spliced XBP1 (ER stress) was visualised by confocal microscopy. Results shown as 2D images made up of 30
compressed z‐stacks. Bars represent 50 μm and results are representative of two experiments.
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4.4

Discussion

4.4.1 Summary of results
The current study demonstrated that murine NSC‐34 motor neurons, under routine culture
conditions or following transfection with mSOD1, express functional P2X7, consistent with
reports of P2X7 expression on primary rodent motor neurons (Franco et al., 2013;
Gandelman et al., 2013; Wang et al., 2004b; Yu et al., 2008). The current study also
confirmed that SOD1 and EGFP can be passively released from transfected NSC‐34 cells.
Notably, P2X7 activation enhanced the release of mSOD1 from transfected NSC‐34 cells.
Furthermore, the P2X7 agonist ATP enhanced the release of SOD1G85R, SOD1G127X, SOD1WT
and endogenous mouse SOD1 from these cells. However, ATP also induced EGFP release
from NSC‐34 cells, indicating that P2X7‐mediated SOD1 release is not specific for this
protein. P2X7‐mediated mSOD1 release occurred independently of cell death, via a process
which may involve Ca2+ influx, but not K+ efflux. P2X7‐mediated mSOD1 release coincided
with membrane blebbing, while differential centrifugation and TEM indicated that the P2X7‐
mediated material released from NSC‐34 cells was structurally heterogeneous.
Both passively and ATP‐induced released mSOD1 associated with naïve cells, with direct
evidence that ATP‐induced released mSOD1 could be internalised. Passively released
mSOD1 associated with naïve EOC13 and NSC‐34 cells, coinciding with altered cell
morphology, TNF‐α release from EOC13 cells and ER stress in NSC‐34 cells. Similarly, mSOD1
released following ATP stimulation was internalised by EOC13 cells, coinciding with TNF‐α
release from these cells and the induction of ER stress in NSC‐34 cells. However, passively
released EGFP was also associated with both cell types, coinciding with a small but
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significant TNF‐α release from EOC13 cells but minimal ER stress in NSC‐34 cells. Although
not investigated, EGFP released following ATP stimulation would likely have had similar
effects on naïve cells.
While multiple SOD1 release mechanisms are likely to operate in ALS, the current study
indicates that P2X7 activation by extracellular ATP is one mechanism by which SOD1 may be
secreted from neuronal cells. In this way, P2X7 may be involved in the propagation of
protein misfolding in ALS, contributing to disease progression.
4.4.2 SOD1 release from NSC‐34 motor neurons
4.4.2.1 Passive SOD1 release following transfection
In the current study, SOD1 was released from NSC‐34 cells in a passive manner during the
72 h following transfection. SOD1 has previously been reported to be secreted via
constitutive mechanisms (Santillo et al., 2007; Urushitani et al., 2006). However, in the
current study, there was noticeable cell death over the 72 h transfection period (data not
shown). This suggests that the passive SOD1 release may have been due to cell death.
Consistent with this, SOD1 release following 72 h transfection has been attributed to cell
death in another study (Grad et al., 2014). An alternative, but not mutually exclusive,
explanation is that NSC‐34 cells release ATP during the 72 h transfection period, which
causes P2X7‐mediated SOD1 release in an autocrine fashion. However, this seems unlikely
given the requirement for relatively high ATP concentrations to induce SOD1 release.
Nevertheless, this possible explanation could be tested through inclusion of P2X7
antagonists or ATP‐degrading enzymes in the culture medium.
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4.4.2.2 ATP‐mediated SOD1 release
In the current study, the P2X7 agonist ATP enhanced SOD1 release in a concentration‐
dependent manner, with low and significantly greater amounts released following
stimulation with 1 and 3‐5 mM ATP, respectively. This ATP concentration response is
consistent with that observed for mature IL‐1β release from other cell types (Sanz and Di
Virgilio, 2000; Stoffels et al., 2015). The release of mature IL‐1β is one of the most well
known downstream P2X7 signalling pathways (see Section 1.4.5). Thus, the similarities in
ATP concentration responses suggest that ATP‐induced SOD1 release is similarly mediated
by P2X7. Further supporting a role for P2X7, pre‐incubation with the P2X7 antagonist
AZ10606120 completely impaired SOD1 release mediated by 5 mM ATP.
ATP induced the release of both EGFP and non‐EGFP SOD1 variants, suggesting that ATP‐
mediated SOD1 release was not an artefact of the GFP tag. Due to the availability of GFP
antibodies and advantages of visualising GFP fusion proteins, the majority of the work in the
current study utilised mSOD1. However, future work should further investigate SOD1
release using non‐EGFP SOD1 variants.
As noted above, a relatively high concentration (5 mM) of extracellular ATP was used in the
current study to induce SOD1 release. Under normal conditions, extracellular ATP amounts
are maintained in the nanomolar range (Vitiello et al., 2012). However, under pathological
conditions of cell damage or death in vivo such as those that may occur during ALS, greater
amounts of ATP are released (Idzko et al., 2014), potentially reaching the millimolar range in
the local microenvironment of the cell. This ATP could potentially act on neuronal P2X7 to
induce SOD1 release, as observed in the current study.
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4.4.2.3 SOD1WT release
In addition to mutant SOD1, ATP stimulation also induced WT and endogenous mouse SOD1
release. WT SOD1 has been reported previously to be actively secreted by neuronal cells in
culture (Gomes et al., 2007; Grad et al., 2014; Turner et al., 2005). Supporting this notion,
WT SOD1 is able to be translocated from the cytosol to the ER‐Golgi pathway (Urushitani et
al., 2008). Furthermore, incubation of neuronal cells with an inhibitor of intracellular protein
transport reduced WT SOD1 secretion (Turner et al., 2005).
Once localised to the extracellular space, misfolded WT SOD1 is reported to be capable of
transmitting and propagating protein misfolding (Grad et al., 2014). This may explain the
clinically indistinguishable nature of sporadic and familial ALS, whereby misfolded WT SOD1,
similar to mutant SOD1, could promote the systematic progression of disease from region to
region. In contrast, intraspinal infusion of WT SOD1 was able to delay disease progression
and death in ALS, suggesting a neuroprotective role for extracellular WT SOD1 (Turner et al.,
2005). However, the folding state of secreted WT SOD1, and whether this SOD1 was
neuroprotective or able to propagate protein misfolding and aggregation, was not
investigated in the current study.
4.4.2.4 EGFP release
In addition to SOD1, EGFP was also found to be released passively and following stimulation
with ATP. This would suggest that P2X7‐mediated SOD1 release occurs via a non‐specific
mechanism. Consistent with this, P2X7 activation in monocytes and macrophages resulted
in the release of molecules including interleukins, caspases and cathepsins (see Section
1.4.5). GFP has previously been reported to be secreted via a non‐classical pathway by a
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number of cell lines (Tanudji et al., 2002). However, unlike the current study, the GFP
secreted was non‐fluorescent, suggesting that it was misfolded. In comparison, low amounts
of fluorescence were detected in conditioned media of EGFP‐transfected cells in another
study (Roh et al., 2013). These authors suggested that this constitutive release may have
reflected low amounts of cell lysis. Indeed in the current study, passively released
fluorescent EGFP may have also resulted from death associated with transfection.
Furthermore, the presence of non‐fluorescent misfolded EGFP cannot be ruled out. It has
been proposed that non‐classical secretion might be a route by which cells remove harmful
cytosolic proteins resulting from misfolding, mislocation or overabundance (Carta et al.,
2013). Thus, EGFP release in the current study may have been employed by cells to clear
over‐expressed EGFP protein. Given that protein misfolding and the accumulation of
cytosolic proteins such as SOD1 are well‐known features of ALS, further investigation of
SOD1 release is worthwhile.
4.4.3 Mechanism of P2X7‐mediated SOD1 release from NSC‐34 motor neurons
4.4.3.1 SOD1 release via “non‐classical” release pathways
Reports from this current and other studies suggest that SOD1 is able to be secreted by a
range of cells, suggesting a generalised mechanism of SOD1 release (Walker et al., 2009). In
addition, SOD1 was localised to all four fractions obtained from differential centrifugation in
the current study, suggesting the presence of multiple release pathways. However, SOD1 is
primarily a cytosolic protein and does not possess a signal peptide (Zelko et al., 2002). Thus,
it seems unlikely that SOD1 would be released via a “classical” pathway of secretion
involving targeting to the ER. Given this, there are at least three potential explanations as to
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how SOD1 may be released: via 1) “classical” release involving a yet to be identified
secretion sequence, 2) cell lysis or 3) “non‐classical” release. A number of proteins lacking
signal sequences have been described to be non‐classically secreted, including interleukin‐
1β and interleukin‐18 (Carta et al., 2013). While the precise mechanisms involved in their
release are unknown, these cytokines have been reported to be externalised via vesicles
(including secretory lysosomes, microvesicles and exosomes), as well as via pyroptosis, a
form of programmed cell death (Carta et al., 2013). Furthermore, P2X7‐induced release of
IL‐1β has been associated with each of these mechanisms (Dubyak, 2012). Using the
SecretomeP 1.0f Server (Bendtsen et al., 2004) and sequence data for human SOD1, SOD1 is
predicted to be non‐classically secreted (http://www.cbs.dtu.dk/ services/SecretomeP/,
accessed December 13, 2015). Given the lack of identified signal peptide and the
involvement of P2X7 in SOD1 release in the current study, SOD1 may be released via similar
“non‐classical” mechanisms to interleukin‐1β and interleukin‐18.
4.4.3.2 SOD1 release via death
In the current study, P2X7 stimulation of NSC‐34 motor neurons mediated mSOD1 release
without major morphological changes or basal LDH release, suggesting that SOD1 was
released via a mechanism independent of cell death. Furthermore, real‐time imaging
suggested that some cells retained large intracellular aggregates, and that these cells
remained intact after 20 min ATP stimulation. However, differential centrifugation revealed
that approximately 35% of the ATP‐induced material released after 20 min pelleted at
500 x g. This would suggest that some released mSOD1 was associated with cells or cell
debris. Alternatively, this may indicate the presence of large extracellular aggregates. Thus,
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it is difficult to completely rule out cell death as a mechanism of P2X7‐mediated SOD1
release.
In recent studies, P2X7 activation on cultured motor neurons was found to induce
apoptosis, via a pathway dependent on peroxynitrite and FAS (Franco et al., 2013;
Gandelman et al., 2013). However, death was only induced by micromolar [ATP]
(Gandelman et al., 2013). In comparison, millimolar [ATP] were degraded to adenosine,
leading to neuroprotection via the activation of adenosine receptors. Furthermore, these
studies only investigated death 24‐48 h following P2X7 activation, and did not investigate
SOD1 release, while the current study did not examine SOD1 release at time‐points past
20 min. Thus, it may be worthwhile to extend observations from 20 min to 24‐48 h and
investigate the short and long term effects of adenosine in future. Regardless, it is likely that
motor neurons exhibit different responses to P2X7 activation depending on the local
environment, P2X7 expression levels and stage of disease.
4.4.3.3 SOD1 release via vesicles
Real time imaging in the current study suggested that ATP induced some morphological
changes, characterised by membrane blebbing, which may have coincided with mSOD1
release via vesicles (such as microvesicles or exosomes). However, given that imaging was
conducted in one z‐plane, the existence of ATP‐induced vesicular release cannot be
concluded. In addition, approximately 20% of the ATP‐induced material released pelleted at
100,000 x g. Thus, it could suggest that ATP induced mSOD1 release via small vesicles such
as exosomes. However, the 100,000 x g fraction was not further purified, allowing for the
possibility of contamination with apoptotic blebs if cell death was induced.
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A role for P2X7 in vesicle release is well established (Dubyak, 2012). Furthermore, SOD1
release via vesicles, of both ER‐Golgi and endosomal origins, has been reported in a number
of studies. SOD1 is released from neuroblastoma cells via microvesicles, in a process
dependent on ATP (Mondola et al., 2003). Furthermore, mutant SOD1 is released from
neurosecretory vesicles by interaction of mutant SOD1 with chromogranins, components of
these vesicles (Urushitani et al., 2006). In NSC‐34 cells, both WT and mutant SOD1 can be
released via exosomes (Gomes et al., 2007; Grad et al., 2014). However, less mutant than
WT SOD1 is secreted (Gomes et al., 2007; Turner et al., 2005), suggesting that retention of
secretory mutant SOD1 may be an important component of ALS. Despite this, it may be that
mutant SOD1 is secreted during the early stages of the disease, possibly via the actions of
P2X7, where it may exert some of the inflammatory, non‐cell‐autonomous effects involved
in disease progression. At later stages of disease, protein trafficking pathways may then be
overloaded or damaged by the accumulation of misfolded proteins, resulting in SOD1
retention and cell‐autonomous damage.
4.4.3.4 A role for calcium influx in P2X7‐mediated SOD1 release
A role for Ca2+ influx in P2X7‐mediated mSOD1 release was indirectly suggested in the
current study, using the Ca2+ ionophore ionomycin. In contrast, high extracellular K+
concentrations, which prevent K+ efflux, had no effect on ATP‐induced mSOD1 release in the
current study. A role for Ca2+ in SOD1 release has been observed in other studies. In pituitary
cells, exocytosis of SOD1‐containing vesicles was dependent on Ca2+ influx, although this
Ca2+ influx was mediated by K+ depolarisation and voltage‐dependent Ca2+ channels, rather
than P2X7 activation (Santillo et al., 2007). Similar to SOD1, in a Parkinson's disease model,
α‐synuclein is secreted by exosomes in a manner dependent on Ca2+ influx (Emmanouilidou
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et al., 2010). In addition, ATP‐mediated Ca2+ influx is important for lysosome‐mediated
interleukin‐1β release from monocytes (Andrei et al., 2004), although it was not investigated
whether this response was mediated by P2X7. In addition to vesicular release, P2X7‐
mediated Ca2+ influx was also shown to be important in inducing neuronal death, via Ca2+
activation of neuronal nitric oxide synthase (Gandelman et al., 2013) and mobilisation of FAS
ligand‐containing intracellular vesicles (Franco et al., 2013). Collectively, this suggests that
changes in intracellular Ca2+ may be pathogenic in ALS, capable of inducing SOD1 release via
vesicles and/or cell death, with P2X7 activation being one way in which intracellular Ca2+
may be altered.
4.4.4 SOD1 uptake into naïve cells
A role for extracellular SOD1 in ALS progression has been suggested via interactions with
both the cell surface and those following internalisation (see Walker et al., 2009). In the
current study, mSOD1 released from conditioned media of mSOD1‐transfected NSC‐34 cells
associated with naïve microglia and motor neuron cells. This indirectly suggested that
mSOD1 was internalised by these cells, consistent with reports from others (Grad et al.,
2014; Meissner et al., 2010; Munch et al., 2011; Sundaramoorthy et al., 2013). The
percentage of cells containing fluorescently tagged SOD1 decreased between 2 and 24 h,
suggesting that cells were able to clear the toxic SOD1 protein. Alternatively, the SOD1‐
fusion proteins may have started to misfold and lose fluorescence, or enter endocytic
pathways and be quenched, or, cells with a high SOD1 load may have had slower rates of
division compared to those without, or selectively died. While SOD1 uptake in the current
study coincided with pro‐inflammatory responses, namely TNF‐α release and ER stress,
whether SOD1 itself was the causative toxic particle was not determined. However,
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immunolabelling and immunisation studies suggest that SOD1 is, or is a component of, the
toxic particle in ALS (Grad et al., 2014; Urushitani et al., 2007).
4.4.4.1 SOD1 uptake into microglia and TNF‐α release
Incubation of microglial cells with conditioned media from mSOD1‐transfected NSC‐34 cells
coincided with TNF‐α release. Similarly, extracellular mutant SOD1, derived from
conditioned media of mutant SOD1‐expressing neuronal cells, can be internalised by
microglia, coinciding with increased TNF‐α mRNA expression in these cells (Urushitani et al.,
2006). However, it was not investigated whether this corresponded with increased TNF‐α
release in this study. To confirm that extracellular SOD1 was the component of the neuronal
conditioned media responsible for this pro‐inflammatory response, this and other studies
have utilised recombinant SOD1 proteins (Oono et al., 2014; Roberts et al., 2013; Urushitani
et al., 2006; Zhao et al., 2010). In these studies, addition of recombinant mutant SOD1 to
microglia induced TNF‐α and interleukin‐1β release, and up‐regulated NOX2 and iNOS
mRNA in these cells. While recombinant proteins were not utilised in the current study,
these previous studies suggest that TNF‐α release in the current study may have been
mediated by mSOD1. However, conditioned media from EGFP‐transfected NSC‐34 cells also
induced TNF‐α release, albeit at lower levels. This suggests that at least one other factor is
released into the conditioned medium by stressed motor neurons, possibly EGFP, which is
also capable of stimulating TNF‐α release. Regardless, both mutant SOD1‐activated
microglia and conditioned media alone from these cells are toxic to co‐cultured motor
neurons (Roberts et al., 2013; Zhao et al., 2010). Furthermore, TNF‐α and nitric oxide are
able to synergistically induce apoptosis of naïve NSC‐34 motor neurons (Oono et al., 2014).
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Collectively, this suggests a role for microglia‐derived pro‐inflammatory factors in the non‐
cell‐autonomous nature of ALS progression.
4.4.4.2 SOD1 uptake in motor neurons and ER stress
The expression of mutant SOD1 in neuronal cells is well known to induce ER stress (see
Walker et al., 2009). In addition to cellular expression, in the current study, ER stress
coincided with the addition of mSOD1‐containing conditioned media and subsequent
mSOD1 association with naïve neuronal cells. However, only one measure of ER stress was
utilised in the current study. Other measures, such as the use of antibodies targeted against
downstream ER stress markers (see Oslowski and Urano, 2011), should be considered in
future to confirm these responses. Regardless, while it was not confirmed in the current
study whether mSOD1 in particular was the causative agent, the addition of recombinant
mutant SOD1 to naïve neuronal cells has previously been found to induce seeding of
aggregation of natively folded SOD1, and inhibit ER‐Golgi protein transport leading to ER
stress (Grad et al., 2014; Munch et al., 2011; Sundaramoorthy et al., 2013). Prolonged ER
stress induced by mutant and/or aggregated SOD1 is reported to induce apoptotic cell death
in SH‑SY5Y neuroblastoma, but not NSC‐34 motor neuron‐like cells (Sundaramoorthy et al.,
2013). NSC‐34 cell death was similarly not observed in the current study following ER stress.
Furthermore, other studies suggest that additional cell types are required, such as microglia,
which promote motor neuron death via production and release of pro‐inflammatory factors
including TNF‐α (Urushitani et al., 2006; Zhao et al., 2010). Neuronal cells undergoing ER
stress may be more susceptible to cell death induced by these pro‐inflammatory factors. In
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this way, defective protein trafficking pathways and the resulting ER stress may be involved
in disease progression.
4.4.5 Conclusion
In conclusion, this study represents the first report of P2X7 activation mediating SOD1
release from neuronal cells in an ALS context. While more work is required to determine the
exact mechanism of P2X7‐mediated SOD1 release, it is likely that multiple mechanisms
operate in vivo. Furthermore, in addition to P2X7‐mediated mechanisms, there are likely
other non‐P2X7‐mediated SOD1 release pathways occurring. In addition to neuronal cells,
there is evidence for SOD1 secretion from other CNS cells, including microglia and
astrocytes (see Kabashi et al., 2007), which would contribute to a toxic local environment
abundant in extracellular mutant and/ or misfolded SOD1. Thus, future studies investigating
whether P2X7 activation is involved in SOD1 secretion from these cells may be worthwhile.
Once present extracellularly, mutant SOD1 was internalised by both microglia and other
motor neuron cells, coinciding with TNF‐α release and ER stress, respectively. The
mechanisms by which motor neurons die in ALS are currently unknown, but may involve the
release of pro‐inflammatory factors from extracellular SOD1‐activated microglia acting on
motor neurons undergoing extracellular SOD1‐induced ER stress. In this way, extracellular
SOD1 may set off molecular cascades leading to motor neuron death (Figure 4.19). Indeed,
immunisation studies targeting misfolded extracellular SOD1 in ALS mice found an extension
in the lifespan of treated animals (Gros‐Louis et al., 2010). Collectively, together with
intracellular or "cell autonomous" SOD1‐mediated neuronal damage, this suggests that
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5.1

Background

5.1.1 Dogs as disease models
Dogs are receiving increasing attention as potential models of human diseases, as they
naturally suffer from a range of inherited disorders, most of which are relevant to humans
(Shearin and Ostrander, 2010; Switonski, 2014). One example is canine degenerative
myelopathy (CDM), a late‐onset progressive neurodegenerative disease which shares many
clinical and pathological characteristics of the human disease amyotrophic lateral sclerosis
(ALS) (Nardone et al., 2016). Similar to ALS, CDM is characterised by degeneration and death
of motor neurons in the spinal cord, leading to muscle atrophy and paralysis (Ogawa et al.,
2014; Shelton et al., 2012). Furthermore, CDM has also been linked to mutations in
superoxide dismutase 1 (SOD1), with the presence of cytoplasmic SOD1 aggregates a
feature of the disease (Awano et al., 2009; Crisp et al., 2013; Nakamae et al., 2015). Lastly,
similar to ALS, the precise mechanisms involved in disease progression are unknown. Given
these similarities, faster aging, shared environments with humans and high levels of health
care, dogs may represent good naturally occurring models of ALS and other diseases.
Although a role for P2X7 in CDM has yet to be reported, investigations of P2X7 in canines
suffering from CDM may also shed light on the roles of this receptor in ALS.
5.1.2 Canine P2X7 and single nucleotide polymorphisms
Functional P2X7 is present on canine erythrocytes, B cells, T cells and monocytes (Jalilian et
al., 2012a; Sluyter et al., 2007; Stevenson et al., 2009). Notably, P2X7 function varies
between individual dogs and breeds (Jalilian, 2011; Peranec, 2011; Spildrejorde, 2013).
Recently, a number of single nucleotide polymorphisms (SNPs) have been identified in the
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canine P2RX7 gene (Spildrejorde, 2013), which may be partially responsible for these
functional differences. However, these canine SNPs have not been characterised. In the
human P2RX7 gene there are at least twelve loss‐of‐function and three gain‐of‐function
SNPs, some of which are associated with human disease (see Sluyter and Stokes, 2011).
Moreover, a loss‐of‐function SNP, P451L, has also been identified and characterised in the
P2RX7 gene of some common mouse strains (Adriouch et al., 2002; Young et al., 2006). Of
note, the canine P2RX7 gene encodes a SNP at this equivalent position in canine P2X7
(P452S) (Jiang et al., 2013). Thus, characterisation of the recently identified canine P2RX7
SNPs may lead to further understanding of the potential role of P2X7 in canine biology and
disease. This has implications for the use of dogs as models of human disease.
P2X7 has recently been cloned from an English springer spaniel by our group (Jalilian, 2011).
The English springer spaniel P2X7 construct could be expressed heterologously as a
recombinant receptor in human embryonic kidney (HEK)‐293 cells (Spildrejorde, 2013).
Furthermore, pharmacological studies demonstrated that English springer spaniel P2X7‐
transfected HEK‐293 cells formed functional pores, which could be inhibited by pre‐
incubation with either one of five well‐known human and rodent P2X7 antagonists,
including AZ10606120 and Brilliant Blue G (BBG) (Spildrejorde, 2013).
5.1.3 Aims
This chapter aimed to introduce recently identified SNPs (Spildrejorde, 2013) into the cloned
English springer spaniel P2X7 plasmid (Jalilian, 2011) by site‐directed mutagenesis and
investigate their effects on canine P2X7 function and expression.
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5.2

Methods

5.2.1 Reagents and antibodies
DMEM/F12 and OPTI‐MEM reduced serum medium, GlutaMAX, Penicillin‐Streptomycin,
Lipofectamine 2000, probenecid, normal horse serum (NHS), YO‐PRO‐1 iodide solution and
SuperSignal West Pico Chemiluminescent Substrate were from ThermoFisher Scientific
(Waltham, MA). Foetal bovine serum (FBS) (heat‐inactivated before use) was from Bovogen
Biologicals (East Keilor, Australia). ATP, ethidium bromide, glycerol gelatin and
paraformaldehyde (PFA) were from Sigma‐Aldrich (St. Louis, MO). Diploma full‐cream milk
powder was from Fonterra (Mount Waverley, Australia). Protease inhibitor cocktail tablets
(complete, Mini, EDTA‐free) were from Roche Diagnostics (Penzberg, Germany). Phenyl‐
methyl‐sulfonyl‐fluoride (PMSF), n‐dodecyl β‐D‐maltoside, β‐mercaptoethanol and bovine
serum albumin (BSA) were from Amresco (Solon, OH). Glass coverslips (9 mm) were from
ProSciTech (Kirwan, Australia). P2X7 blocking peptide was from Alomone Labs (Jerusalem,
Israel). All other reagent grade chemicals and salts were from Sigma‐Aldrich or Amresco.
The antibodies (Abs) used and their respective companies are listed in Table 5.1.

Table 5.1 Antibodies used in Chapter 5 to investigate the effect of polymorphisms on canine P2X7 function

Antibody target1

Conjugate

P2X7, extracellular epitope
P2X7, COOH‐terminal epitope
Rabbit IgG
Rabbit IgG

‐
‐
Peroxidase
Cy3

Host species1
(clonality)
Rabbit (pAb)
Rabbit (pAb)
Goat (pAb)
Donkey (pAb)

Company2
(catalogue number)
Alomone Labs (APR‐008)
Alomone Labs (APR‐004)
Rockland (611‐103‐122)
Jackson (711‐165‐152)

1

Ig, immunoglobulin; pAb, polyclonal antibody. 2Alomone Labs, Jerusalem, Israel; Jackson ImmunoResearch,
West Grove, PA; Rockland Immunochemicals, Gilbertsville, PA.

210

Chapter 5 ‐ Effect of single nucleotide polymorphisms on canine P2X7 function

5.2.2 Cell lines
HEK‐293 and murine microglial EOC13 cells were from the American Type Culture Collection
(Manassas, VA). MDCK cells were from the European Collection of Cell Cultures (Porton
Down, UK). HEK‐293 and MDCK cells were maintained in DMEM/F12 medium supplemented
with 10% FBS, 2 mM GlutaMAX, 100 U/mL penicillin, and 100 μg/mL streptomycin
(complete culture medium) at 37°C/5% CO2. Murine microglial EOC13 cells were maintained
as described in Section 2.2.2.
5.2.3 Canine P2X7
Canine P2X7, cloned from peripheral blood mononuclear cells of an English springer spaniel
(pEnglish springer spaniel P2X7), was kindly provided by Iman Jalilian (University of
Wollongong, Wollongong, Australia) (Jalilian, 2011). Missense SNPs were introduced into
pEnglish springer spaniel P2X7 by Leanne Stokes (University of Sydney, Sydney, Australia),
using site‐directed mutagenesis as described (Stokes et al., 2010).
XL1‐Blue Escherichia coli transformed with P2X7‐containing plasmids were streaked onto
lysogeny broth (LB) agar plates containing 50 μg/mL kanamycin sulphate, and incubated at
37°C/5% CO2 overnight. The next day, overnight starter cultures derived from single
transformed bacterial colonies were prepared in sterile LB containing 50 μg/mL kanamycin
sulphate. Plasmid DNA was then purified from bacterial cells using the Wizard Plus SV
Miniprep DNA Purification System (Promega, Madison, WI), as per the manufacturer’s
instructions. The concentration and quality (260/280 ratio) of DNA within samples was
assessed using a NanoDrop 2000c dual‐mode UV‐Vis Spectrophotometer (ThermoFisher
Scientific).
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5.2.4 Cell transfections
HEK‐293 cells in complete culture medium (0.25 – 0.5 x 106 cells/mL) were incubated
overnight at 37°C/5% CO2. Cells were then incubated in complete culture medium
containing 4 μg plasmid DNA and Lipofectamine 2000 (diluted in OPTI‐MEM Reduced Serum
Medium) for 24 h at 37°C/5% CO2. The medium was then replaced, and the cells incubated
for a further 24 h at 37°C/5% CO2.
5.2.5 Immunoblotting
Whole lysates of HEK‐293 or EOC13 cells were prepared as described in Section 2.2.12.
Lysates (7.5 μg protein/lane) were separated under reducing conditions (5% β‐
mercaptoethanol) using Any kD Mini‐PROTEAN TGX Stain‐Free Gels (Bio‐Rad, Hercules, CA).
Before immunoblotting, equal protein loading was confirmed by visualising stain‐free gels
with a Bio‐Rad Criterion Stain Free Imager and Image Lab software. Proteins were then
transferred to nitrocellulose membranes using a Trans‐Blot Turbo Transfer System (all Bio‐
Rad). Membranes were blocked at room temperature for 1 h with Tris‐buffered saline
(250 mM NaCl and 50 mM Tris, pH 7.5) containing 0.2% Tween‐20 and 5% milk powder, and
then incubated at 4°C overnight with an anti‐P2X7 polyclonal antibody (pAb) (as described)
in Tris‐buffered saline containing 0.2% Tween‐20 and 5% milk powder. Membranes were
then washed three times over 30 min with Tris‐buffered saline containing 0.2% Tween‐20.
Membranes were incubated at room temperature for 1 h with peroxidise‐conjugated anti‐
IgG Ab (1:1000) in Tris‐buffered saline containing 0.2% Tween‐20 and 5% milk powder and
then washed as above. P2X7 was visualised as described in Section 2.2.12. Relative P2X7
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expression was measured with a Bio‐Rad GS‐800 Densitometer and ImageJ software
(Version 1.48) (National Institutes of Health, Bethesda, MD).
5.2.6 Fluorescent cation dye uptake assay
EOC13, MDCK, mock‐transfected HEK‐293 or canine P2X7‐transfected HEK‐293 cells (see
Section 5.2.4) were washed three times in NaCl medium (140 mM NaCl, 5 mM NaOH, 5 mM
KCl, 10 mM HEPES, and 5 mM glucose, pH 7.4), harvested by mechanical scraping, and
equilibrated in NaCl medium at 37°C for 5 min (5 × 104 cells/ 1 mL/ tube). Cells were then
incubated with 25 μM ethidium+ (or 1 μM YO‐PRO‐12+ where indicated) in the absence or
presence of the P2X7 agonist ATP (as indicated) for 5 min. In some experiments, cells were
pre‐incubated in the absence or presence of the gout drug probenecid (as indicated) for
15 min prior to cation dye and ATP addition. Incubations were stopped by the addition of an
equal volume of ice‐cold NaCl medium containing 20 mM MgCl2 (MgCl2 medium), followed
by centrifugation (300 x g for 5 min). Cells were washed once with NaCl medium and events
collected using a LSR II flow cytometer (BD Biosciences, San Diego, CA) (excitation 488 nm,
emission collected with 575/26 and 515/20 band‐pass filters for ethidium+ and YO‐PRO‐12+,
respectively). The mean fluorescence intensity (MFI) of relative cation uptake was
determined using FlowJo software (Tree Star, Ashland, OR).
5.2.7 Electrophysiology
P2X7 channel activity in canine P2X7‐transfected HEK‐293 cells was kindly assessed by
Leanne Stokes, using electrophysiological measurements of ATP‐induced currents as
described (Bhaskaracharya et al., 2014). Briefly, whole cell patch‐clamp recordings were
performed at room temperature using an EPC10 amplifier and Patchmaster acquisition
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software (HEKA, Lambrecht, Germany). ATP (1 mM) was delivered using the RSC‐160 fast‐
flow system (Bio‐Logic Science Instruments, Claix, France), with membrane potential
clamped at ‐60 mV. External solution was 145 mM NaCl, 5 mM KCl, 0.2 mM CaCl2, 1 mM
MgCl2, 13 mM glucose and 10 mM HEPES (pH 7.3; 295‐310 mOsm/L). Internal solution was
145 mM NaCl, 10 mM HEPES and 10 mM EGTA (pH 7.3; 295‐310 mOsm/L).
5.2.8 Immunocytochemistry
HEK‐293 cells were plated into 24‐well plates containing sterile 9 mm glass coverslips
(0.4 mL/ well) and then transfected with canine P2X7 as per Section 5.2.4. Canine P2X7‐
transfected cells were fixed with 4% PFA in PBS at room temperature for 15 min and then
washed three times with PBS over 10 min. Cells were then blocked with 20% NHS in PBS at
room temperature for 20 min. Cells were incubated at 4°C overnight with rabbit anti‐P2X7
pAb (1.6 μg/ 200 μL/ well) (pre‐incubated in the absence or presence of blocking peptide for
1 h as per the manufacturer’s instruction) in PBS containing 1% BSA, 0.2% NHS and 0.05%
NaN3. The next day, cells were washed as above, and incubated for 1 h at room temperature
with Cy3‐conjugated donkey anti‐rabbit IgG Ab (3 μg/ 200 μL) in PBS containing 0.2% NHS.
Cells were washed as above and then the coverslips mounted onto slides with 50% (v/v)
glycerol gelatin in PBS. Coverslips were sealed with nail varnish. Cells were visualised using a
DM IBRE inverted microscope and TCS SP confocal imaging system (Leica, Mannheim,
Germany) (excitation 561 nm, emission collected at 575‐630 nm). Images were captured
using Leica Confocal Software.
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5.2.9 Data presentation and statistical analyses
Data is presented as the mean ± SD. Differences between multiple treatments were
compared by ANOVA paired with Tukey’s HSD post‐tests. The software package Prism 5 for
Windows (Version 5.01) (GraphPad Software, San Diego, CA) was used for these statistical
analyses, with differences considered significant for P < 0.05. Inhibition curves were fitted
using Prism 5 and assuming a variable slope, with normalised response curves selected to
obtain the best fit. Estimates of half maximal inhibitory concentration (IC50) values were
obtained from individual fits of these plots.
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5.3

Results

5.3.1 Canine P2X7 cloned from an English springer spaniel forms functional receptors
To confirm if the cloned English springer spaniel P2X7 could be expressed heterologously as
a recombinant receptor in mammalian cells, whole lysates of canine P2X7‐ or mock‐
transfected HEK‐293 cells were examined by immunoblotting. Murine EOC13 microglia,
known to express functional P2X7 (Chapter 2; Bartlett, 2011), were used as a positive
control. Immunoblotting using Abs against either an extracellular or COOH‐terminal epitope
of P2X7 detected a major band at 75 kDa, the predicted size of glycosylated P2X7, in EOC13
and English springer spaniel P2X7‐transfected HEK‐293 cells, but not mock‐transfected
HEK‐293 cells (Figure 5.1a). Minor bands at 60 and 45 kDa were also detected in P2X7‐
transfected HEK‐293 cells, but not the other cell types (Figure 5.1a).
Next, to confirm if the cloned English springer spaniel P2X7 was functional, ATP‐induced
ethidium+ uptake (P2X7 function) into canine P2X7‐ or mock‐transfected HEK‐293 cells was
assessed by flow cytometry. ATP failed to induce ethidium+ uptake into mock‐transfected
HEK‐293 cells (Figure 5.1b). In contrast, ATP induced robust ethidium+ uptake into HEK‐293
cells transfected with English springer spaniel P2X7 compared with corresponding cells
incubated in the absence of ATP (Figure 5.1b).
Our group has previously shown that cloned English springer spaniel P2X7 can be blocked by
four antagonists of human P2X7, including AZ10606120 and BBG (Spildrejorde, 2013).
Moreover, our group has recently shown that the Food and Drug Administration‐approved
gout drug probenecid inhibits human P2X7, but shows minimal inhibition of rat or murine
P2X7 (Bhaskaracharya et al., 2014). Therefore, the ability of this drug to inhibit the cloned
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English springer spaniel P2X7 was investigated, using ATP at 250 μM, approximate to the
half maximal effective concentration for canine P2X7 (Spildrejorde, 2013). Previously
obtained concentration response curves for AZ10606120 and BBG (Spildrejorde, 2013) are
shown as a comparison. Probenecid impaired ATP‐induced ethidium+ uptake in a
concentration‐dependent manner, with an IC50 value of 200 µM (Figure 5.1c). This IC50 was
greater than that previously observed for AZ10606120 and BBG (9 nM and 1 µM,
respectively) (Spildrejorde, 2013) (Figure 5.1c).

Figure 5.1 Canine P2X7 cloned from an English springer spaniel is functional when expressed in HEK‐293
cells. (a) Whole lysates of EOC13 cells, HEK‐293 cells transfected with English springer spaniel P2X7 plasmid
DNA, or mock‐transfected HEK‐293 cells were separated by SDS‐PAGE under reducing conditions, transferred
to nitrocellulose membranes and incubated with anti‐P2X7 pAbs directed against either the extracellular
epitope (left) or COOH‐terminal epitope (right) of P2X7. Results show one experiment. Suspended HEK‐293
cells, (b and c) transfected with English springer spaniel P2X7 plasmid DNA or (b) mock‐transfected in NaCl
medium were incubated in the absence (basal) or presence of (b) 1 mM or (c) 250 μM ATP at 37°C for 5 min in
the presence of 25 μM ethidium+ and ATP. (c) Cells were also pre‐incubated for 15 min in the absence or
presence of AZ10606120, Brilliant Blue G (BBG) or probenecid (as indicated), prior to addition of ethidium+. (b
and c) Incubations were stopped by the addition of MgCl2 medium. Mean fluorescence intensities (MFI) of
ethidium+ uptake (pore formation) were determined by flow cytometry (b) Results shown as means ± SD, n = 3;
∗∗∗P < 0.001 compared to corresponding basal. (c) The curves are presented as a percentage of the maximal
ethidium+ uptake in the absence of antagonist and expressed as the mean ± SD, n = 3. The AZ10606120 and
BBG concentration response curves (Spildrejorde, 2013) are included as a comparison.
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5.3.2 The R270C polymorphism results in a loss of canine P2X7 function
5.3.2.1 The R270C polymorphism results in a loss of canine P2X7 pore formation
The relative function of P2X7 in peripheral blood monocytes from a number of dogs has
previously been assessed and found to vary between individuals and breeds (Spildrejorde,
2013). Analysis of the 13 exons of the P2RX7 gene from dogs with either low or high P2X7
function identified the presence of a number of SNPs (Spildrejorde, 2013) (Figure 5.2a). This
included the previously reported missense SNPs rs23314713 and rs23315462, coding for the
amino acid substitutions F103L and P452S, respectively. Novel missense SNPs coding for the
amino acid substitutions R270C and R365Q were also reported (Spildrejorde, 2013). Finally,
a missense SNP coding for the amino acid substitution L440F was present in P2X7 cloned
from an English springer spaniel (Spildrejorde, 2013).
To see if any of the reported mutations in canine P2X7 altered P2X7 function, site‐directed
mutagenesis was carried out on the cloned English springer spaniel P2X7. First, the plasmid
containing the cloned English springer spaniel P2X7 (which possessed 440F and 452S SNPs
compared to the wild type (WT) NCBI Reference Sequence NM_001113456.1, now termed
440F/452S mutant) was changed to WT at position 440 (termed 452S mutant) by mutating
the phenylalanine residue to leucine. Next, the plasmid containing only the 452S SNP was
either changed to WT P2X7 (termed WT P2X7) by mutating the serine residue at position
452 to proline, or changed to a double mutant (termed 270C/452S mutant) by mutating the
arginine residue at position 270 to cysteine. Finally, the WT P2X7 plasmid was mutated to
contain either the 103L or 365Q SNPs (termed 103L and 365Q mutant, respectively), by
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mutating the phenylalanine at position 103 to leucine, or arginine at position 365 to
glutamine.

Figure 5.2 The R270C single nucleotide polymorphism results in loss of function of canine P2X7. (a) Sequence
analysis of canine P2X7 has previously identified F103L, R270C, R365Q, L440F and P452S polymorphisms as
shown. Boxes represent P2RX7 exons (not all 13 exons are represented). (b‐d) HEK‐293 cells, transfected with
wild type (WT) or mutant canine P2X7 (as indicated), suspended in NaCl medium were incubated in the
absence (basal) or presence of 1 mM ATP at 37°C for 5 min in the presence of 25 μM ethidium+. Incubations
were stopped by the addition of MgCl2 medium. Mean fluorescence intensities (MFI) of ethidium+ uptake (pore
formation) were determined by flow cytometry and results shown as means ± SD, n = 3‐4; ∗∗∗P < 0.001 or ∗∗P <
0.01 compared to corresponding basal; †††P < 0.001, ††P < 0.01 or †P < 0.05 compared to (b) 440F/452S ATP or
(c and d) WT ATP. (e‐g) Whole lysates of HEK‐293 cells transfected with WT or mutant canine P2X7 (as
indicated) were separated by SDS‐PAGE under reducing conditions, transferred to nitrocellulose membranes
and incubated with anti‐P2X7 pAb directed against the extracellular epitope of P2X7. Results show one
experiment. Density values (x 1000) are indicated below blots.
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Using the above plasmids, the effects of each SNP on canine P2X7 function were assessed by
measurements of ATP‐induced ethidium+ uptake into transfected HEK‐293 cells. ATP‐
induced ethidium+ uptake was 24% less in cells expressing 452S mutant P2X7 compared to
cells expressing 440F/452S mutant P2X7 (Figure 5.2b). ATP‐induced ethidium+ uptake into
cells expressing 452S mutant P2X7 was similar to that of cells expressing WT P2X7 (Figure
5.2c). In contrast, ATP‐induced ethidium uptake was almost completely abolished in cells
expressing 270C/452S mutant P2X7 compared with cells expressing either WT or 452S
mutant P2X7 (Figure 5.2c). Lastly, ATP‐induced ethidium+ uptake was 46 and 37% less in
cells expressing either 103L or 365Q mutant P2X7, respectively, compared with cells
expressing WT P2X7 (Figure 5.2d).
To determine whether the differences in ATP‐induced ethidium+ uptake related to total
P2X7 expression, whole lysates of HEK‐293 cells transfected with WT or mutant P2X7 were
examined by immunoblotting, and the relative amount of P2X7 quantified. Again (Figure
5.1a), a major band at 75 kDa was detected in lysates of HEK‐293 cells expressing either WT
or mutant P2X7 (Figure 5.2e‐g). The amount of P2X7 was 29% less in cells expressing the
452S mutant compared with cells expressing 440F/452S mutant P2X7 (Figure 5.2e). In
addition, the amount of P2X7 was 22, 30, 48 and 32% less in cells expressing either 452S,
270C/452S, 103L or 365Q mutant P2X7, respectively, compared with cells expressing WT
P2X7 (Figure 5.2f,g).
5.3.2.2 The R270C polymorphism results in a loss of canine P2X7 channel activity
The above data indicates that the R270C SNP has a major functional impact on canine P2X7.
Thus, the R270C SNP was further characterised in HEK‐293 cells expressing either WT, 452S,
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or 270C/452S mutant P2X7. First, P2X7 channel activity was assessed by electrophysiology.
Patch‐clamp measurements revealed that ATP induced similar robust inward currents in
HEK‐293 cells expressing WT or 452S mutant P2X7, with mean current densities of 49 ± 19
and 39 ± 24 pA/pF, respectively (P > 0.05, n = 6‐7) (Figure 5.3a). In contrast, ATP‐induced
inward currents in HEK‐293 cells expressing 270C/452S mutant P2X7 were significantly
smaller (mean current density of 3 ± 1 pA/pF) than those observed in HEK‐293 cells
expressing WT or 452S mutant P2X7 (P < 0.01 and P < 0.05, respectively, n = 5) (Figure 5.3a).
In addition, multiple applications of ATP saw WT and 452S mutant P2X7 display facilitation
of responses over 5 min, whereas 270C/452S mutant P2X7 responses did not display
facilitation and remained small (Figure 5.3b).

Figure 5.3 The R270C single nucleotide polymorphism results in loss of canine P2X7 channel activity. HEK‐293
cells, transfected with (left) wild type (WT), (middle) 452S mutant or (right) 270C/452S mutant P2X7, were
clamped at ‐60 mV at room temperature. ATP (1 mM) in low divalent solution was applied by a fast‐flow
delivery system, and whole cell currents were recorded. Results shown as inward current to (a) first exposure
to ATP and (b) repeated exposures to ATP every 60 s. Black bars indicate ATP exposure (5 s). Traces are
representative of 5‐7 cells.
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5.3.2.3 Canine P2X7 containing the R270C polymorphism is expressed on the surface of
transfected HEK‐293 cells
Finally, to determine whether canine P2X7 containing the R270C polymorphism is trafficked
to the cell surface, HEK‐293 cells expressing either WT, 452S, or 270C/452S mutant P2X7
were immunolabelled with an Ab specific for the extracellular loop of P2X7, and analysed by
confocal microscopy. Cell‐surface expression of P2X7 was evident on HEK‐293 cells
expressing WT, 452S, or 270C/452S mutant P2X7 (Figure 5.4a). Pre‐incubation of the anti‐
P2X7 Ab with blocking peptide abrogated the detection of P2X7 in both WT or mutant P2X7‐
expressing HEK‐293 cells (Figure 5.4b).

Figure 5.4 Canine P2X7 containing the R270C single nucleotide polymorphism is expressed on the cell
surface of transfected HEK‐293 cells. HEK‐293 cells, transfected with (left) wild type (WT), (middle) 452S
mutant or (right) 270C/452S mutant P2X7, were fixed with 4% paraformaldehyde and labelled with anti‐P2X7
pAb (directed against the extracellular epitope of P2X7) pre‐incubated in the (a) absence or (b) presence of
blocking peptide, followed by incubation with Cy3‐conjugated anti‐IgG. Slides were analysed by confocal
microscopy. Bars represent 100 µm. Results are representative of three experiments.
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5.3.2.4 MDCK cells, homozygous for the R270C polymorphism, have negligible P2X7
function
The MDCK cell line expresses negligible amounts of P2X7, with only low amounts of this
receptor detected by immunoblotting and by an ATP‐induced ethidium+ uptake assay
(Jalilian et al., 2012b). Subsequent sequencing of the P2RX7 gene of these cells identified
the presence of R270C SNP in homozygous dosage (Spildrejorde, 2013). To confirm that
MDCK cells express negligible amounts of functional P2X7, consistent with the presence of
the R270C P2X7 polymorphism, YO‐PRO‐12+ uptake into this cell line was investigated using
murine EOC13 microglia as a positive control. Incubation with ATP induced significant YO‐
PRO‐12+ uptake (pore formation) into EOC13 cells compared to cells incubated in the
absence of ATP (Figure 5.5). In contrast, incubation with ATP did not induce YO‐PRO‐12+
uptake into MDCK cells, with similar MFIs obtained in the absence or presence of ATP
(Figure 5.5). This confirms that the function of P2X7 is negligible in this cell line.

Figure 5.5 Five minute ATP incubation fails to induce pore formation in MDCK cells, homozygous for the
R270C polymorphism. EOC13 and MDCK cells suspended in NaCl medium were incubated in the absence
(basal) or presence of 1 mM ATP at 37°C for 5 min in the presence of 1 μM YO‐PRO‐12+. Incubations were
stopped by the addition of MgCl2 medium. Mean fluorescence intensities (MFI) of YO‐PRO‐12+ uptake (pore
formation) were determined by flow cytometry and results shown as means ± SD, n = 3; ∗∗P < 0.01 compared to
corresponding basal; ††P < 0.01 compared to EOC13 ATP.
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5.3.3 P452S and P452L polymorphisms have no effect on canine P2X7 pore formation
The murine P451L P2X7 polymorphism is a well‐known loss‐of‐function mutation (Adriouch
et al., 2002), which has been correlated with reduced neuropathic pain (Sorge et al., 2012)
and altered bone phenotype (Syberg et al., 2012). To see if the same mutation of the
corresponding residue (residue 452) in canine P2X7 also conferred a loss of P2X7 function,
further site‐directed mutagenesis was carried out on the 452S mutant P2X7 plasmid
generated above (Section 5.3.2.1). This was carried out by mutating the serine residue at
position 452 to leucine.
Using the WT P2X7, 452S mutant and 452L mutant plasmids, the effects of residue 452 SNPs
on canine P2X7 function were assessed by measurements of ATP‐induced ethidium+ uptake
into transfected HEK‐293 cells. ATP induced ethidium+ uptake into cells expressing 452L or
452S mutant P2X7 in a similar manner to cells expressing WT P2X7 (Figure 5.6a). To confirm
that the similarities in ATP‐induced ethidium+ uptake correlated with total P2X7 expression,
whole lysates of HEK‐293 cells transfected with WT or mutant P2X7 were examined by
immunoblotting, and the relative amount of P2X7 quantified. As above (Figure 5.1a and
Figure 5.2e‐g), a major band at 75 kDa was detected in lysates of HEK‐293 cells expressing
either WT or mutant P2X7 (Figure 5.6b). The amount of P2X7 was 12 and 32% less in cells
expressing the 452L and 452S mutants, respectively, compared with cells expressing WT
P2X7 (Figure 5.6b).
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Figure 5.6 P452S and P452L single nucleotide polymorphisms have no effect on the function of canine P2X7.
(a) HEK‐293 cells, transfected with wild type (WT) or mutant canine P2X7 (as indicated), suspended in NaCl
medium were incubated in the absence (basal) or presence of 1 mM ATP at 37°C for 5 min in the presence of
25 μM ethidium+. Incubations were stopped by the addition of MgCl2 medium. Mean fluorescence intensities
(MFI) of ethidium+ uptake (pore formation) were determined by flow cytometry and results shown as means ±
SD, n = 3; ∗∗∗P < 0.001 compared to corresponding basal. (b) Whole lysates of HEK‐293 cells transfected with
WT or mutant canine P2X7 (as indicated) were separated by SDS‐PAGE under reducing conditions, transferred
to nitrocellulose membranes and incubated with anti‐P2X7 pAb directed against the extracellular epitope of
P2X7. Results show one experiment. Density values (x 1000) are indicated below blot.
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5.4

Discussion

5.4.1 Summary of results
The current study confirmed that the previously cloned English springer spaniel P2X7 was
functional when expressed in HEK‐293 cells. Recently identified SNPs in the canine P2RX7
gene, F103L, R270C, R365Q, L440F and P452S (Spildrejorde, 2013), were then successfully
introduced into this sequence by site‐directed mutagenesis. Of these, the R270C SNP was
determined to be a loss‐of‐function mutation, with minimal pore‐forming and channel
activities despite cell‐surface expression. Similarly, 5 min ATP incubation failed to induce
pore formation in MDCK cells, which naturally contain the R270C SNP in homozygous
dosage. In contrast, P452S and P452L SNPs had no effect on canine P2X7 function, while
F103L and R365Q may be partial loss‐of‐function mutations. Lastly, the L440F SNP may be a
partial gain‐of‐function mutation. The identification and characterisation of canine P2X7
SNPs will be important if dogs are to be used as models of diseases in which P2X7 is
implicated, including ALS.
5.4.2 R270C single nucleotide polymorphism
The R270C SNP (rs851148233) was characterised in the current study and determined to be
a loss of function SNP, impairing both P2X7 channel activity and pore formation. In a study
of 52 dogs, only one animal (a cocker spaniel cross) was found to possess this SNP, which
was present in heterozygous dosage (Spildrejorde, 2013). Similar to the current study, this
cocker spaniel cross had low P2X7 function (approximately one third of the mean of the
dogs WT at position 270) (Spildrejorde, 2013). Moreover, a recent study has reported a
similar observation in a second cocker spaniel cross (Faulks, 2015). Furthermore, P2X7
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function is negligible in MDCK cells (Jalilian et al., 2012b; this study), which were originally
obtained from a cocker spaniel (Madin and Darby, 1958) and are homozogyous for the
R270C SNP (Spildrejorde, 2013). To the best of our knowledge, these studies represent the
only characterisation of this SNP to date. However, a SNP has also been reported at position
270 in the human P2RX7 gene (R270H, rs7958311). This SNP results in a partial loss of P2X7
function (Sorge et al., 2012; Stokes et al., 2010), supporting the notion that the canine
R270C SNP, which exchanges a positively charged residue for a polar, uncharged one, is a
loss‐of‐function mutation. In addition to the R270H SNP, a SNP at a neighbouring residue in
the human P2RX7 gene is also reported to result in a loss of P2X7 function (R276H;
rs7958316) (Stokes et al., 2010). Structural modelling of human P2X7 places both these
mutations in the extracellular loop of P2X7 (Figure 5.7), away from the ATP‐binding site
(Jiang et al., 2013). Thus, it has been proposed that these residues may be involved in
conformational changes associated with channel gating or receptor activation/deactivation
(Jiang et al., 2013). Given this, it is possible that the canine R270C SNP negatively affects
canine P2X7 function in a similar manner. Alternatively, the introduced cysteine residue at
position 270 may disrupt existing disulfide bonds, altering the structure of the subunit or
P2X7 trafficking to the cell surface (Jindrichova et al., 2012). However, the current study
showed cell surface expression of the R270C‐mutant P2X7 in HEK‐293 cells, suggesting that
this SNP does not impair P2X7 trafficking.
5.4.3 F103L, R365Q and L440F single nucleotide polymorphisms
The missense SNPs F103L (rs23314713) and R365Q (rs850760787) characterised in the
current study may be partial loss‐of‐function SNPs. However, total P2X7 expression was also
reduced by similar amounts in F103L‐mutant and R365Q‐mutant P2X7‐expressing HEK‐293
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cells compared to those expressing WT P2X7. Thus, further characterisation will be required
to determine if the reduced P2X7 function of these mutants is due to reduced P2X7 protein
synthesis or half‐life, or plasmid transfection efficiency. In addition to the current study,
these SNPs have also been characterised in monocytes derived from dogs (Spildrejorde,
2013). In this study, there was no significant difference in P2X7 function between dogs WT
at position 103 (n = 24) or heterozygous for the F103L SNP (n = 9). However, similar to the
current study, dogs homozygous for this SNP (n = 13) had partially reduced P2X7 function
compared to WT animals. In addition, of the 52 dogs previously investigated, three were
found to possess the R365Q SNP, although only in heterozygous dosage (Spildrejorde,
2013). Similar to the current study, these dogs tended to have lower P2X7 function.
However, due to the limited sample size, the significance of this functional difference could
not be confirmed. Furthermore, the relative amount of P2X7 protein in monocytes was not
investigated in this previous study for either mutant.
The F103L SNP is located in the extracellular loop of P2X7 (Figure 5.7). Thus, this SNP may
affect agonist or antagonist binding. However, given that both phenylananine and leucine
are non‐polar amino acids, the effects of this SNP may be limited. In comparison, the R365Q
SNP is located in the COOH‐terminal domain of P2X7 (Figure 5.7), and exchanges a positively
charged residue for a polar, uncharged one. Thus, this SNP may affect pore formation. In
fact, a SNP in a nearby residue of human P2X7 (T357S; rs2230911) is reported to result in
decreased P2X7 channel and pore formation (Shemon et al., 2006). Thus, together with the
current study, this indirectly supports the notion that the R365Q SNP in canine P2X7 is a
partial loss‐of‐function mutation. Regardless, further studies will be required to confirm
whether these P2X7 SNPs indeed result in a partial loss‐of‐function.
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In contrast to F103L and R365Q, L440F had a minor gain‐of‐function effect on canine P2X7.
However, total P2X7 expression was increased by similar amounts in L440F‐mutant‐
expressing HEK‐293 cells compared to those expressing the 452S mutant alone. Thus, the
increased P2X7 function of this mutant may be due to increased P2X7 protein synthesis or
half‐life, or plasmid transfection efficiency. The L440F SNP was originally identified in the
cloned English springer spaniel P2X7 (Jalilian, 2011), and was not observed in any other dog
for which exon 13 was sequenced (Spildrejorde, 2013). Furthermore, this SNP is not
reported in the NCBI SNP database (accessed March 5, 2016). Whether this variant
represents a SNP in English springer spaniels or was introduced as a result of the cloning
process remains unknown.
5.4.4 P452S single nucleotide polymorphism
Unlike the other missense mutations in the canine P2RX7 gene characterised in the current
study, the P452S SNP (rs23315462) was not found to have any effect on P2X7 function.
Similarly, there were no significant differences in P2X7 function observed between
monocytes derived from dogs WT at position 452 (n = 18), or heterozygous (n = 23) or
homozygous (n = 10) for the P452S SNP in another study (Spildrejorde, 2013). While there
are no other reports characterising this SNP, it is located at the equivalent position to that of
the P451L partial loss‐of‐function SNP in murine P2X7 (Adriouch et al., 2002). This SNP,
which is present in some but not all mouse strains, is located in the COOH‐terminal domain
of P2X7 (Figure 5.7), and impairs pore formation and re‐organisation of the plasma
membrane (Adriouch et al., 2002; Young et al., 2006). Thus, it is proposed that these
residues are important for P2X7‐mediated apoptosis and cytokine secretion (Adriouch et al.,
2002). The difference in effect between canine P452S and murine P451L are unknown.
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reports (Spildrejorde, 2013), the cloned canine P2X7 could be expressed as a functional
recombinant receptor in HEK‐293 cells. Furthermore, probenecid was found to impair pore
formation in these cells. Probenecid is a well‐established drug for the treatment of the auto‐
inflammatory arthritic disease gout in humans, and is largely thought to be beneficial via
inhibition of pannexin‐1 channels (Silverman et al., 2008). However, a recent study found
that probenecid was able to directly block human P2X7, and it was hence suggested that the
efficacy of probenecid in the treatment of gout was at least partially due to off‐target
effects on P2X7 (Bhaskaracharya et al., 2014). In the current study, the potency of
probenecid at inhibiting recombinant canine P2X7 (IC50 of 200 μM) was comparable to that
of recombinant human P2X7 (IC50 of 203 μM) (Bhaskaracharya et al., 2014). In comparison,
probenecid had minimal inhibitory effects on rat and mouse P2X7 (Bhaskaracharya et al.,
2014). Dogs naturally suffer from a gout‐like disease. Given the similar potencies of
probenecid at human and canine P2X7, this drug may also have beneficial off‐target effects
in canine gout via inhibition of P2X7. However, use of probenecid in dogs is limited and
almost exclusively used to extend the half‐life of certain antibiotics due to its inhibitory
effect on renal excretion (The Merck Veterinary Manual; http://www.merckvetmanual.com,
accessed March 18, 2016).
5.4.6

Canine degenerative myelopathy: a model of amyotrophic lateral sclerosis?

The development of large animal models of ALS may provide data that is more relevant to
human ALS. Unlike mouse models, which are transgenically modified to over‐express
mutant forms of SOD1, CDM in dogs is linked to naturally occurring spontaneous SOD1
mutations. This includes the missense mutations G118A and A52T, which are present at
homozygous dosage in the majority of CDM cases (Awano et al., 2009; Wininger et al., 2011;
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Zeng et al., 2014). While CDM has been reported in a number of dog breeds, it is most
frequently reported in the German shepherd, Pembroke Welsh Corgi and boxer (Nardone et
al., 2016), suggesting a breed‐specific disposition to disease. Similarly, in a recent study of
52 dogs, some breeds had a higher incidence of P2X7 SNPs (Spildrejorde, 2013). For
example, the R270C SNP was only found in cocker spaniel or cocker spaniel crosses, while
the R365Q SNP was only observed in Labrador retrievers or Labrador retriever crosses.
However, this study had no German shepherd, Pembroke Welsh Corgi or boxer dog
subjects. Thus, it is currently unknown whether these breeds have higher incidences of
specific P2X7 SNPs, or whether P2X7 has an impact on CDM progression in these breeds.
Given that P2X7 may have a role in ALS progression, it will be important to consider P2X7
SNPs in future studies investigating CDM as a model of ALS.
5.4.7 Conclusion
In conclusion, the current study identified the missense R270C SNP as a loss‐of‐function
mutation of canine P2X7. In comparison, the P452S and P452L SNPs had no effect on canine
P2X7 function, while F103L and R365Q were identified as potential partial loss‐of‐function
mutations, and L440F as a potential gain‐of‐function mutation. This study represents the
first description of SNPs that alter canine P2X7 function, and identify the R270C SNP as a
major loss‐of‐function allele in the canine P2RX7 gene. Following on from this, it will be
important to determine the effects of this SNP on P2X7‐mediated physiological processes,
such as ATP‐mediated ROS formation, and the frequency of this SNP amongst different dog
breeds. Moreover, given that SNPs in the human P2RX7 gene have been associated with
various diseases (Fernando et al., 2007; Gartland et al., 2012; Gidlof et al., 2012; Lester et
al., 2013), it may be worth investigating whether the R270C and other canine P2X7 SNPs are
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associated with diseases in dogs. Lastly, if dogs are to be utilised as naturally occurring
models of human diseases, an awareness of these SNPs and their effects on P2X7 function
will be essential to avoid confounding effects. This will be particularly relevant to diseases in
which P2X7 is thought to play a role, such as ALS.
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6.1

Overview

Amyotrophic lateral sclerosis (ALS) is a devastating disease for which there is currently no
effective therapeutics. ALS is generally characterised by a focal onset of motor neuron
degeneration, followed by a regional spread of pathology (see Section 1.2.1). However, the
aetiology and pathogenic mechanisms underlying disease progression are not fully
understood, appearing to be complex and potentially involve multiple cellular pathways,
such as glial activation, neuroinflammation and aberrant secretion and uptake of toxic
proteins (see Section 1.3). P2X7, a receptor expressed in a range of central nervous system
(CNS) cells, is involved in inflammatory signalling pathways and is up‐regulated during ALS
(see Sections 1.4 and 1.5). Thus, this thesis set out to investigate whether P2X7 plays a role
in ALS progression, and therefore represents a potential therapeutic target.
6.2

Conclusions and significance

Microglia activation and neuroinflammation are implicated in ALS progression (see Section
1.3.6.2). Activated microglia are capable of inducing motor neuron death through the
production of neurotoxic factors, and these microglial effects may be mediated in part by
P2X7 activation. In Chapter 2, the expression of functional P2X7 on primary murine
microglia was confirmed. Furthermore, Chapter 2 demonstrated that P2X7 activation in
murine EOC13 microglia induced reactive oxygen species (ROS) formation, nitric oxide (NO)
formation and cell death. This is consistent with prior reports in various cell types (see
Section 1.4.5), and with studies using superoxide dismutase 1 (SOD1)G93A microglia. In these
latter studies, P2X7 activation on these cells led to increased production of tumour necrosis
factor (TNF)‐α, cyclooxygenase‐2 (COX‐2), ROS and inflammatory microRNAs (Apolloni et al.,
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2013b; D'Ambrosi et al., 2009; Parisi et al., 2013; Parisi et al., 2016). Although ATP‐induced
TNF‐α release was not investigated in the current study, increased TNF‐α release was
observed from EOC13 microglia that had been incubated with SOD1G93A‐containing
conditioned media (Chapter 4). However, it is unknown whether this effect was mediated by
SOD1G93A or another component of the conditioned media. It is possible that this material
stimulated autocrine or paracrine ATP release pathways, leading to P2X7‐mediated TNF‐α
release. Use of the ATP‐degrading enzyme apyrase would help to elucidate the possible
involvement of ATP/P2X7 in this response. It is also possible that SOD1G93A internalisation by
EOC13 cells altered P2X7 cell‐surface expression and/or function to potentiate ATP‐induced
TNF‐α release. This would be consistent with P2X7 up‐regulation on SOD1G93A microglia
compared to WT microglia (Casanovas et al., 2008; D'Ambrosi et al., 2009). Future studies
should investigate the ability of SOD1 internalisation to potentiate P2X7‐mediated
neuroinflammatory pathways, including TNF‐α release.
Incubation of neuronal cells with P2X7‐activated WT or SOD1G93A microglia, or conditioned
media from these cells, has been shown to induce neuronal cell death (D'Ambrosi et al.,
2009; Parisi et al., 2016; Parvathenani et al., 2003; Skaper et al., 2006). However, the
neurotoxic factor/s responsible for this toxicity is unknown. Given this, it will be interesting
to determine if P2X7‐activated EOC13 microglia similarly induce death of neuronal cell lines
and, if so, identify the neurotoxic factors responsible.
In addition to releasing neurotoxic factors to directly mediate neuronal cell death, microglia
may also indirectly mediate neuronal death by secreting mutant SOD1 into the extracellular
space. In Chapter 4, extracellular SOD1G93A, which was present in conditioned media, was
shown to be internalised by murine NSC‐34 motor neurons, coinciding with endoplasmic
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reticulum (ER) stress. ER stress is similarly observed in neuronal cells expressing mutant
SOD1 and, when prolonged, can promote pro‐apoptotic pathways (see Section 1.3.4),
suggesting an alternative mechanism by which microglia may mediate neuronal death.
Evidence of SOD1 release from microglia is limited. However, the release of WT and mutant
SOD1 from microglia has been reported in one study (Polazzi et al., 2013). In this study, the
authors found that ATP potentiated SOD1 release, and suggested a role for secretory
lysosomes. Although Polazzi and co‐workers did not investigate whether P2X7 was involved
in this process, P2X7 has been shown to mediate interleukin (IL)‐1β release from secretory
lysosomes (Dubyak, 2012). In addition to secretory lysosomes, P2X7 activation may mediate
SOD1 release from microglia via ATP‐induced cell death (which is observed in Chapter 2;
Bartlett, 2011), or via an alternate ATP‐induced mechanism (as observed for motor neurons
in Chapter 4). Given the above, it may be worth investigating whether P2X7 can mediate
SOD1 release from EOC13 microglia, in addition to NSC‐34 motor neurons (Chapter 4), and
whether secretory lysosomes or another mechanism is involved. Furthermore, it may also
be of value to investigate whether P2X7 mediates SOD1 release from other CNS cells, such
as astrocytes, and the relative contributions of astrocytes, microglia and motor neurons to
the extracellular SOD1 pool.
In EOC13 microglia, short (5‐15 min) incubations with 2 mM ATP induced ROS and NO
formation (Chapter 2). In comparison, in NSC‐34 motor neurons, short (20 min) incubation
with higher ATP concentrations (3‐5 mM) were required to induce SOD1 release (Chapter 4).
These differences may reflect higher P2X7 expression and function on EOC13 compared to
NSC‐34 cells. This is consistent with higher amounts of 75 kDa P2X7 protein (by
immunoblotting) and ATP‐induced pore formation (by ethidium+ uptake) on EOC13
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compared to NSC‐34 cells (Chapter 2 and Chapter 4). However, caution should be exercised
when comparing relative amounts of P2X7 between cell lines as the techniques used do not
take into account differences in cell size, the relative amounts of P2X7 expressed per cell
(surface area) or the intracellular nucleic acid content to which the ethidium+ binds.
In addition to differences in the amount of P2X7 protein, the differences in ATP
requirements between EOC13 and NSC‐34 cells may have reflected cell type‐specific P2X7‐
mediated signalling pathways. In this regard, Ca2+ influx appeared to be important for SOD1
release (Chapter 4), while it was not required for P2X7‐mediated ROS formation (Chapter 2).
In contrast, K+ efflux was not required for either P2X7‐mediated SOD1 release or ROS
formation, while it is reported to be important for P2X7‐mediated IL‐1β release (Muñoz‐
Planillo et al., 2013).
Differences in P2X7 responses between EOC13 and NSC‐34 cells may also be due to the
presence of P2X7 single nucleotide polymorphisms (SNPs) or splice variants. The EOC13 cell
line was originally obtained from C3H/HeJ mice (Walker et al., 1995), while the NSC‐34 cell
line was originally made by fusing spinal cord cells from CD1 outbred mice with
neuroblastoma from A/J mice (Cashman et al., 1992). P2X7 SNPs, which alter receptor
function between mouse breeds, are known to exist. For example, the loss‐of‐function SNP
P451L, which results in a reduced sensitivity to ATP‐induced pore formation (Adriouch et al.,
2002; Young et al., 2006). Paradoxically, this SNP is present in C3H/He mice, but not A/J
mice (Sorge et al., 2012), suggesting that differences in P2X7 responses between EOC13 and
NSC‐34 cells are not due to variations in the 451 allele. However, to the best of our
knowledge, the entire P2X7 sequence of C3H/HeJ, CD1 outbred or A/J mice have not been
reported. Therefore, the possibility remains that other SNPs, in regions known to be
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important for receptor trafficking and function, exist in these cell lines. Alternatively, the
presence of additional P2X7 bands on EOC13 and NSC‐34 immunoblots (Chapter 4) may
indicate the presence of splice variants. The presence of such variants could also alter P2X7
function, as previously observed in cultured murine astrocytes (Kido et al., 2014).
Despite P2X7 activation mediating inflammatory and potentially ALS‐related processes
in vitro (Chapter 2 and Chapter 4), in Chapter 3, pharmacological inhibition of P2X7 using
Brilliant Blue G (BBG) had limited beneficial effects in a mouse model of ALS. P2X7 SNPs may
have potentially influenced this outcome. In Chapter 3, the SOD1 mice used were raised on
a C57Bl/6J background, which is known to possess the P451L loss‐of‐function SNP. Similarly,
both previous studies investigating BBG efficacy in mouse models of ALS used strains
possessing this mutation (C57Bl/6J and C57Bl/6J x SJL/J hybrid) (Apolloni et al., 2014;
Cervetto et al., 2013). Although these two studies reported more beneficial outcomes at
molecular and phenotypic levels, neither reported an extension in life span. Given the
presence of the 451L allele in these strains, it may be worth investigating P2X7 antagonism
in SOD1 mice on a background wild type (WT) at position 451, such as BALB/c. This may be
especially relevant given that SOD1G93A mice backcrossed onto BALB/c backgrounds have
earlier onset of symptoms and endpoints compared to those backcrossed onto C57BL/6J
backgrounds (Acevedo‐Arozena et al., 2011). In addition to P2X7 SNPs, it may also be worth
investigating alternatively spliced variants of P2X7 at a cell‐type level (Masin et al., 2012;
Nicke et al., 2009), particularly in the CNS with ALS progression. This may further shed light
on the role of this receptor in ALS.
P2X7 SNPs which impair P2X7 function have also been identified in canines. In Chapter 5, a
number of previously identified canine SNPs were characterised, including F103L, R270C,
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R365Q, L440F and P452S. Of these, the R270C SNP was identified as a loss‐of‐function
mutation. Given that dogs naturally suffer from an ALS‐like disease (canine degenerative
myelopathy; CDM) (Nardone et al., 2016), it may be worth investigating the relationship
between P2X7 genotype and disease progression in dogs. In particular, to determine
whether dogs suffering from CDM and possessing P2X7 loss‐of‐function mutations, such as
R270C, have extended lifespans compared to those WT for P2X7, similar to that observed
for BALB/c (451P) compared to C57BL/6J (451L) mice (Acevedo‐Arozena et al., 2011).
Recently, a cytokine‐based protocol was developed to generate monocyte‐derived microglia
from human peripheral blood (Etemad et al., 2012). In future, a similar protocol could be
utilised to generate canine microglia from the blood of canines with or without CDM or the
R270C SNP, to identify differences in P2X7‐mediated responses between these cells.
In vitro, 10 μM AZ10606120 completely inhibited 160 μM ATP‐induced pore formation in
primary microglia (Chapter 2), 2 mM ATP‐induced ROS formation, NO formation (Chapter 2)
and death (Bartlett, 2011) in EOC13 microglia, and 5 mM ATP‐induced pore formation and
SOD1 release in NSC‐34 motor neurons (Chapter 4). In comparison, 30 μM BBG inhibited
1 mM ATP‐induced pore formation in EOC13 microglia by only 80% (Chapter 3). In vivo, BBG
reduced the rate of body weight loss and prolonged survival in female SOD1 mice, but had
no effect on a number of other parameters, including clinical scores, motor coordination,
motor neuron loss or microgliosis (Chapter 3). This, together with a lack of observable blue
colouring in the CNS, may suggest that BBG never crossed the blood brain barrier in
pathologically effective levels. Given that AZ10606120 is more effective at inhibiting P2X7 at
lower concentrations in vitro, it may be worth investigating the efficacy of this more
selective P2X7 antagonist in ALS mice. However, similar to the lack of effect of BBG on
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microgliosis in SOD1G93A mice at end‐stage (Chapter 3), AZ10606120, at the same
concentration as used to inhibit other P2X7‐mediated responses (10 μM), had no effect on
EOC13 microglia proliferation (Chapter 2). Furthermore, to the best of our knowledge, the
CNS‐permeability of AZ10606120 has not been reported. Therefore, it may also be worth
utilising recently available (Bhattacharya et al., 2013), or developing new, CNS‐permeable
P2X7 antagonists in ALS models.
To date, all studies investigating purinergic signalling in ALS have used models consisting of
a SOD1G93A mutation. Although this is one of the more common SOD1 mutations and is
widely used to model familial ALS, this represents a major limitation in the current
literature. Thus, future work should take into account the wide range of SOD1 mutations
and other protein mutations, such as transactivation response DNA‐binding protein, that
have been implicated in ALS. Such work would be important for determining whether
increased P2X7 expression in microglia carrying mutations is restricted to the SOD1G93A
mutant, or also modulated by other mutant forms of SOD1 or other mutant proteins
associated with ALS. In addition, given the importance of metal state to the stability and
function of SOD1 (Hilton et al., 2015), it may be worth investigating the potential role of
metal binding in disease propagation, specifically, in the release and internalisation of SOD1.
The majority of studies investigating purinergic signalling in ALS have used rodent models of
ALS, which are widely available and largely informative. However, due to differences
between rodents and humans, and the unnatural nature of the rodent ALS‐like disease,
other models should also be utilised to strengthen the conclusions drawn from these
models. In the last few years, humanised models of ALS have been generated. These models
are characterised by the reprogramming of somatic cells from sporadic and familial ALS
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patients (at various disease stages) into patient‐specific induced pluripotent stem cells
(iPSCs) (see Hedges et al., 2016; Lee and Huang, 2015). These iPSCs can be differentiated
into disease‐relevant cell types, and used to study mechanisms contributing to disease
pathogenesis and drug development. In future, this humanised model could be utilised to
investigate P2X7 responses in ALS. In particular, P2X7 expression and function profiles
(including P2X7 genotypes) in glia and motor neurons derived from ALS patients compared
to those from healthy controls. In addition to humanised models, it may also be worth
investigating the role of P2X7 in other animals, such as dogs.
Many studies investigating purinergic signalling in ALS have relied predominantly on the use
of BzATP and BBG to substantiate a role for P2X7 in neuronal cell death. Although BzATP is
the most potent P2X7 agonist (Donnelly‐Roberts et al., 2009), it can also activate other P2X
receptors and thus should not be considered a specific P2X7 agonist (Jarvis and Khakh,
2009). Similarly, in addition to P2X7, BBG can also inhibit P2X5 and to a lesser extent P2X4
(Cotrina and Nedergaard, 2009; Jiang et al., 2000). Furthermore, the selectivity of BBG has
not been investigated for all P2X or any P2Y receptors. BBG is commonly used as a protein
dye, and thus is potentially capable of binding a range of molecules and modulating their
function. Despite these limitations, BBG was included in the current study (Chapter 3) as this
antagonist is relatively inexpensive and has been widely used to inhibit P2X7 in in vivo
models of neurodegenerative disease (Diaz‐Hernandez et al., 2009; Matute et al., 2007;
Peng et al., 2009). Regardless, future studies investigating the role of P2X7 in ALS should
predominantly employ more selective P2X7 antagonists and cells isolated from P2X7
knockout mice.
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6.3

Final remarks

Overall, this thesis demonstrated that EOC13 microglia and NSC‐34 motor neurons express
functional P2X7, and that P2X7 activation on these cells induced responses that could
potentially mediate neuroinflammation and disease progression in ALS. ATP activation of
P2X7 on EOC13 microglia led to ROS and NO formation, which could potentially contribute
to motor neuron death. Furthermore, 30 min incubation with ATP induced death of EOC13
microglia after 24 h, which could contribute to the extracellular pools of SOD1 and ATP.
However, P2X7 activation did not appear to promote proliferation in this cell line, despite
evidence for this P2X7‐mediated response in primary and other immortalised microglial cells
(Bianco et al., 2006; Monif et al., 2009; Rigato et al., 2012; Zou et al., 2012). In NSC‐34 motor
neurons, ATP activation of P2X7 led to SOD1 release, via a mechanism independent of cell
death. Internalisation of this released SOD1 into microglia and motor neurons coincided
with TNF‐α release and ER stress, respectively.
Thus, in ALS, ATP, potentially released from dying motor neurons in the early stages of
disease, may activate P2X7 on surrounding microglia and motor neurons, leading to the
release of SOD1 from these cells. In addition, P2X7 activation on microglia may result in
microglial proliferation and activation, and the release of pro‐inflammatory and neurotoxic
factors from these cells, potentially in concert with SOD1 internalisation. Extracellular SOD1
may also be internalised by surrounding motor neurons, leading to cellular stress, and these
motor neurons may be more susceptible to cell damage and/or death induced by microglia‐
derived pro‐inflammatory factors. Newly damaged/dead motor neurons may then continue
to propagate disease in a similar way (Figure 6.1). In this manner, P2X7 may play a role in
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the regional propagation of ALS. While not investigated in this thesis, it should be noted that
other P2X7‐expressing CNS cells, such as astrocytes, may also contribute to this cycle.
Despite the above, inhibition of P2X7 using BBG was found to have limited beneficial effects
in a mouse model of ALS. This is consistent with the known complex, multi‐systemic and
multi‐factorial nature of this disease. Thus, while P2X7 signalling alone is unlikely to mediate
ALS progression, evidence suggests that it may be one of many mechanisms operating in
concert to mediate motor neuron degeneration. Furthermore, many of these mechanisms
are likely to have overlapping or redundant features. Given this, it is reasonable to speculate
that any successful ALS therapeutics will need multiple drug targets, one of which could
potentially be P2X7. However, P2X7 may be neuroprotective in the early stages of disease,
and thus P2X7‐targeted drug development will need to consider the timing of treatment
onset. In addition, the tissue specificity and the balance between the normal physiological
and cytotoxic actions of P2X7 will need to be considered.
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